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ABSTRACT
Maintaining skeletal muscle mass has a well-documented role in health and quality of life.
Two members of IL-6 family of cytokines, IL-6 and LIF, and have a paradoxical role in
skeletal muscle mass regulation: short term elevation of IL-6 and LIF plays a key role in
mechanical stimuli induced muscle growth and muscle hypertrophy, while the long term
elevated IL-6 and LIF regulate muscle wasting during cancer cachexia by disrupting
muscle protein turnover regulation. The regulation of muscle protein synthesis is an
important determinant of mechanical stimuli induced muscle hypertrophy and muscle
wasting during cancer cachexia. IL-6 family of cytokines can induce intracellular signaling
pathways involved in muscle mass regulation, including STAT3, ERK1/2, PI3K/Akt and
AMPK via their functional receptor complex containing gp130. However, it is still
unknown whether physiologically and pathologically elevated IL-6 or LIF can regulate
basal mechanical stimuli induced muscle protein synthesis. The overall purpose of this
dissertation was to determine if physiological short term or pathological long term exposure
of IL-6 and LIF would regulate basal protein synthesis or protein synthesis induction by
mechanical stimuli in cultured myotubes and skeletal muscles. Specific aim 1 investigated
if physiological short term exposure of IL-6 or LIF would activate myotube protein
synthesis by activating gp130-Akt-mTOR signaling cascade. Short term IL-6 and LIF
iv

exposure increased myotube protein synthesis, which was associated with the induction of
gp130-Akt signaling pathway. Either gp130 siRNA knock-down or Akt signaling inhibition
blocked IL-6/LIF induction of myotube protein synthesis, Interestingly, mTORC1 or
STAT3 signaling inhibition did not completed blocked IL-6/LIF induction of myotube
protein synthesis. Specific aim 2 investigated if pathological long term IL-6 or LIF
exposure would suppress myotube protein synthesis by activating AMPK signaling. We
reported long term exposure of IL-6 and LIF suppressed myotube mTORC1 signaling and
protein synthesis, which was rescued by the pharmaceutical inhibition of AMPK signaling
during IL-6/LIF exposure. However, long term AMPK signaling resulted suppression of
basal myotube protein synthesis. Specific aim 3 investigated if short term or long term IL6/LIF exposure would regulate stretch induction of protein synthesis in myotubes and
eccentric contraction induction of protein synthesis in skeletal muscles, respectively. We
reported that both short term and long term IL-6/LIF disrupted stretch induction of myotube
protein synthesis in vitro, but in vivo IL-6 overexpression had no effect on muscle protein
synthesis induction by eccentric contractions. Taken together, our results demonstrate that
short term IL-6 or LIF exposure can stimulate protein synthesis in myotubes by activating
gp130-Akt signaling, but is not dependent on mTOR signaling. Long term pathological
exposure of IL-6 or LIF suppressed myotube protein synthesis though the activation of
AMPK signaling. However, the IL-6/LIF regulation of mechanical stimulus induction of
protein synthesis is dependent on different mechanical stimuli models. These findings

v

provide new insight of the IL-6/LIF role in skeletal muscle mass regulation under
physiological and pathological conditions.
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CHAPTER 1
INTRODUCTION

1

Skeletal muscle provides a fundamental basis for human function, including
locomotion, respiration and homeostasis of metabolism. Maintaining skeletal muscle mass
is critical for physical activity level, quality of life and decreased mortality. The skeletal
muscle mass is sensitive to multiple systematic changes related to nutritional status,
physical activity level, inflammatory cytokines and muscle wasting diseases. The
regulation of skeletal muscle mass involves the balance between protein synthesis and
degradation, which is termed protein turnover (1). However, significant gaps remain in our
understanding of skeletal muscle protein turnover regulation by hypertrophic or atrophic
stimuli in health and disease.

The Interleukin-6 (IL-6) family of cytokines regulate many physiological and
pathological processes including immune system regulation, inflammation, wound healing
and cell survival (2). Skeletal muscle serves as both a biological target and source of the
IL-6 family of cytokines. IL-6 family of cytokines induce intracellular signaling pathways
via their trans-membrane receptor complex containing glycoprotein 130 (gp130). gp130 is
signal-transducing receptor that forms part of the receptor complex for IL-6 family of
cytokines (3). Formation of functional ligand-receptor complex results in gp130 activation
of multiple downstream signaling pathways, including STAT3, ERK1/2 and PI3K-Akt (4).
Two members of IL-6 family of cytokines, IL-6 and Leukemia Inhibitory Factor (LIF),
have recognized roles in skeletal muscle mass regulation (5). Repeated contractions or
overload IL-6 and LIF can induce a short the plasma elevation and muscle expression of
IL-6 and LIF (6), which is thought to initiate important autocrine and paracrine signaling
that contributes to metabolic adaptations and muscle hypertrophy through, at least in part,
2

the activation of satellite cell proliferation and fusion to myofibers (7, 8). However, longlasting elevated systemic levels of IL-6 family of cytokines is associated with the
pathological inflammatory conditions in some types of cancer and other chronic disease
states. Long term elevation of IL-6 has been demonstrated as a key mediator of different
muscle wasting diseases such as rheumatoid arthritis, chronic kidney disease and cancer
cachexia (9-11). Currently, there is no clear understanding of this complex dichotomy
involving the effects LIF and IL-6 on muscle mass regulation.

The muscle protein synthesis regulation is a key determinant of muscle mass (12).
The integration of muscle protein synthesis through mTORC1 is an acknowledged control
point of skeletal muscle mass (12). Activation of mTOR signaling plays a central role in
muscle hypertrophic response to multiple hypertrophic stimulus, including growth factors,
hormones, nutrition and mechanical stimuli (16), while the muscle mTOR signaling and
protein synthesis suppression is associated with muscle wasting (17-19). Once activated,
mTOR can induce muscle protein synthesis through the phosphorylation of the p70S6K
and 4E-BP1 (13). Multiple upstream signaling pathways, including PI3K-Akt, ERK1/2 and
AMPK, regulate mTORC1 by phosphorylating different sites of tuberous sclerosis 1/2
(TSC1/2). TSC2 phosphorylation by PI3K-Akt or ERK1/2 can relieve TSC1/2 suppression
on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTOR signaling
(14-16), while AMPK suppress mTOR signaling by phosphorylation of TSC2 and
subsequent enhancement of the inhibition of TSC1/2 on mTOR (17).
Although short term physiological and long term pathological elevation of IL-6
and LIF is involved in both muscle hypertrophy and atrophy respectively, the
3

potential gp130 signaling regulation of muscle protein synthesis in physiological or
pathological conditions still needs to be determined. gp130 induction can activate
PI3K/Akt and ERK1/2 signaling, two upstream stimulator of mTOR, through JAK and Ras
dependent mechanisms, respectively (3). Short term IL-6 or LIF exposure induces gp130
activation of Akt-mTOR signaling in cardiomyocytes, which is a key mechanism of IL-6
and LIF induced cardiac hypertrophy (18, 25). However, the specific interaction between
these cytokines and the PI3K/Akt-mTORC1 or gp130-ERK1/2-mTORC1 signaling axis
within skeletal muscle fibers needs further investigation. Unlike the potential anabolic
effects of short term IL-6/gp130 signaling action, pathological long term activation of IL6-gp130 dependent signaling is associated with suppression of muscle protein synthesis
(18, 19). Chronic in vivo systemic IL-6 overexpression or in vitro IL-6 administration can
decrease mTOR and p70S6K phosphorylation in skeletal muscles or cultured myotubes
(20). The induction of AMPK signaling is a potential mediator of IL-6 suppression of
muscle mTOR signaling (20), but the mechanisms of IL-6 induction of muscle AMPK
signaling is not well understood.

Mechanical stimuli such as loading, stretch or muscle contractions can induce skeletal
muscle hypertrophy by stimulating muscle protein synthesis (21, 22), that is important for
the maintenance of mass and function (23). The induction of mTOR signaling through
TSC2 dependent mechanisms plays a key role (24), but the biochemical events connecting
the mechanical stimuli and mTOR activation still need to be determined. Physiological
elevation of IL-6 family of cytokines during exercise or overload have a documented role
in muscle metabolic adaptations and muscle hypertrophy (4-6). Pathological induction of
4

muscle inflammatory or stress signaling pathways has the potential to inhibit muscle
anabolic signaling induced by mechanical stimuli. Muscle contraction-induced mTOR
signaling is attenuated in severely cachectic ApcMin/+ mice, which is associated with
muscle STAT3 and NF-κB signaling activation (25). AMPK activation is also sufficient to
prevent mTOR induction by electrically-stimulated muscle contractions (26). However, the
role of physiological or pathological IL-6/gp130 signaling in mechanical stimuli induced
muscle protein synthesis have not been investigated.

The overall goal of this dissertation is to examine gp130 regulation of anabolic
signaling in skeletal muscle during physiological and pathological conditions.
Specifically, we will investigate the role of gp130 signaling in basal muscle protein
synthesis regulation during either physiological short term or pathological long term
exposure to inflammatory cytokines. Additionally, we will investigate if physiological or
pathological gp130 signaling regulates the induction of protein synthesis by mechanical
stimuli. We hypothesize that physiological, short term inflammatory cytokine exposure will
induce basal muscle protein synthesis through gp130 activation of Akt-mTOR signaling,
while pathological, long term cytokine exposure will suppress basal muscle protein
synthesis through gp130 activation of AMPK signaling. Furthermore, physiological or
pathological cytokine exposure will either amplify or suppress mechanical regulation of
muscle protein synthesis, respectively.

In this study, we propose to address the following specific aims.
Aim. 1: Determine if physiological, short term exposure of inflammatory
5

cytokines IL-6 or LIF can stimulate muscle protein synthesis through gp130
regulation of Akt-mTOR signaling.
Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress
muscle protein synthesis through AMPK signaling.
Aim 3: Determine if physiological or pathological administration of IL-6 or LIF
cytokines can regulate the induction of protein synthesis by mechanical stimuli.

Overall working model:
IL-6/LIF
(Short Term)

IL-6/LIF
(Long Term)

gp130

150

100

AMPK

Akt
50

TSC1/2

Stretch/ECC

1

0

mTOR

Protein Synthesis

Figure 1.1 Working Model: IL-6 and LIF are able to activate or
suppress skeletal muscle mTOR signaling and protein synthesis,
which is determined by the duration of cytokine exposure. Short term
IL-6 or LIF can induce mTOR signaling and subsequent protein
synthesis through gp130-PI3K/Akt signaling axis under physiological
conditions, while pathological long term IL-6 or LIF exposure can
suppress muscle mTOR signaling and protein synthesis, which is
dependent on gp130 and AMPK signaling. Furthermore, short term or
long term IL-6/LIF exposure can potentiate or suppress muscle protein
synthesis induction by mechanical stimuli, including stretch and
eccentric contractions.
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CHAPTER 2
LITERATURE REVIEW

7

2.1 Introduction
Skeletal muscle composes ~50% of total body mass, and is fundamental for basic
functions of human bodies. Maintaining skeletal muscle mass and function is critical for
disease prevention, mobility and quality of life, and whole-body metabolism. Increasing
skeletal muscle mass is desired by many types of athletes to enhance athletic performance,
increase body size, and improve aesthetic appearance. More importantly, reduction in
skeletal muscle mass occurs in aging people and patients of many chronic diseases.
Maintenance of skeletal muscle mass contributes significantly to disease prevention and is
associated with improved quality of life. Skeletal muscle mass and muscle fiber size are
sensitive to various physiological and pathological conditions. An increase in muscle mass
and fiber size, or muscle growth or hypertrophy, occurs during development and in
response to mechanical overload or anabolic hormonal stimulation. While a decrease in
muscle mass and fiber size, or muscle atrophy, results from aging, starvation, cancer,
diabetes, bed rest, loss of neural input or catabolic hormonal stimulation. As skeletal muscle
consists of the largest pool of proteins in the whole organism, the regulation of muscle mass
and fiber size is largely determined by protein turnover, which is the balance between
protein synthesis and degradation within the muscle fibers. An increase in skeletal muscle
mass can occur when protein synthesis exceeds protein degradation. Hyper-activation of
protein degradation pathways, on the other hand, causes muscle atrophy involves the
shrinkage of myofibers due to a net loss of proteins, organelles and cytoplasm, which
occurs in many pathological conditions. In addition to protein turnover regulation, skeletal
muscle mass may also be affected by cell or nuclear turnover, i.e. addition of new
myonuclei, due to fusion of satellite cells, or loss of myonuclei, due to nuclear apoptosis.
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Increases in the number of individual myofibers within a muscle, termed hyperplasia, is
another potential mechanism contributing to muscle growth.

Mechanical stimuli is a potent stimulator of skeletal muscle mass. Increase in
mechanical loading results in muscle hypertrophy and a decrease in mechanical loading
results in muscle atrophy (27). It has also been demonstrated that mechanical stimuli
induced changes in muscle mass are highly associated with changes in the rate of protein
synthesis. Muscle hypertrophy induced by increased mechanical is accompanied by an
increase in the rate of protein synthesis, while muscle atrophy induced by a decrease in
mechanical stimuli is accompanied by a decrease in the rate of protein synthesis (28-30).
Thus, muscle protein synthesis regulation appears to play a fundamental role in the
mechanical regulation of muscle mass. However, the molecular mechanisms through which
mechanical stimuli regulate changes in the rate of protein synthesis, and ultimately muscle
mass, have only been vaguely defined.

Cachexia, derived from the Greek word ‘kachexia’ (kakos = bad; hexis = state), is a
typical muscle wasting disease. It is defined as a malnourished, wasting state observed
during the later stages of many chronic diseases including cancer, AIDS, COPD (31). The
typical symptoms of cachexia includes an ongoing loss of skeletal muscle mass, a loss of
fat mass, leading to progressive functional impairment (32). Cachexia is prevalent in many
cancer types, with the highest rates found for cancers of the lung and upper gastrointestinal
tract, where over half of all patients are affected at diagnosis (32, 33). Cachexia is
responsible for the death of about 20% of cancer patients, which is 2 million worldwide
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every year (34). Loss of skeletal muscle mass, or skeletal muscle atrophy, is common
symptom in all cachexia patients (32). Functional consequences of muscle mass loss in
cachexia include exercise intolerance, reduced muscle function, reduced exercise capacity,
and physical inactivity, all of which impact adversely on a patient's quality of life, level of
independence and survival (35). However, no therapeutic interventions are established to
successfully treat muscle wasting in cachexia. Mechanical stimuli have been demonstrated
to stimulate muscle mass increase. Therefore, it represents a promising intervention that
has the potential to attenuate or even reverse the process of muscle wasting. As such, a
better understanding of the mechanisms contributing to muscle mass regulation by
mechanical stimuli and cachexia is critical for clinical applications of mechanical stimuli
on muscle mass preservation of cachexia patients.

gp130 is a ubiquitously expressed transmembrane receptor protein, which mediate
signaling transduction of IL-6 family of cytokines. Interestingly, the gp130 ligands and
downstream signaling pathways are involved in both muscle hypertrophy response by
mechanical stimuli and atrophic response in cachexia. IL-6 cytokine family has pleiotropic
functions in different tissues and organs, including skeletal muscles. Circulation level and
IL-6 cytokine family are tightly associated with both muscle hypertrophy and atrophy.
Several members of IL-6 cytokine family, including IL-6 and LIF, are produced by the
working skeletal muscle by mechanical stimuli and act on to myofibers or other kinds of
muscle cells, eg. satellite cells and myoblasts, through autocrine/paracrine manner (7, 8).
IL-6 signaling is associated with stimulation of hypertrophic muscle growth and
myogenesis through regulation of the proliferation, differentiation and fusion of muscle
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stem cells (36, 37). Paradoxically, deleterious actions for IL-6 family of cytokines have
also been proposed, such as promotion of atrophy and muscle wasting in cachexia (9).
Elevation of IL-6 and its downstream signaling STAT3, are directly associated with muscle
mass loss in both cachexia patients and animal models (38, 39). However, there is no clear
explanation of the apparently paradoxical role of gp130 ligands and gp130 dependent
signaling pathways in muscle mass regulation.

Changes in muscle protein synthesis play a fundamental role in the regulation of
muscle mass by mechanical stimuli and cachexia. gp130 cytokines and gp130 downstream
pathways have a documented role in muscle hypertrophy induced by mechanical stimuli
and muscle atrophy in cachexia, but its role in mechanical stimuli and cachexia regulation
in muscle protein synthesis still need to be determined. This review will focus on 4 major
topics: 1) Muscle protein synthesis regulation, 2) Mechanical stimuli induction of muscle
protein synthesis and hypertrophy, 3) Muscle protein synthesis regulation in cachexia, 4)
Role of gp130 dependent signaling in muscle mass regulation.
2.2 Muscle protein synthesis regulation
Regulation of Protein Translation
The efficiency of translation process in ribosomes is the key determinant of protein
synthesis. mRNA translation process occurs through a series of molecular events that can
be functionally divided into three phases: initiation, elongation, and termination (40). The
majority of mechanisms known to regulate mRNA translation and protein synthesis involve
the initiation phase, with many fewer occurring at elongation or termination (40). Therefore,
we will briefly go over the important molecular events and regulatory sites of protein
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synthesis initiation.

The first steps in translation initiation is the formation of a ternary complex consisting
of eukaryotic initiation factor eIF-2, GTP, and initiator methionyl-tRNA (Met- tRNAi) (40).
The ternary complex then associates with other initiation factors to form a multifactor
complex that subsequently binds to the 40S ribosomal subunit to form the 43S preinitiation
complex. The next step is the binding of mRNA to the 43S preinitiation complex. eIF4E
binds to the m7GTP cap structure at the 5’-end of the mRNA, and the eIF4E•mRNA
complex then interacts with eIF4G in association with eIF4A to form the eIF4F•mRNA
complex. eIF4B modulates the assembly of eIF4A into the eIF4F complex (41). eIF4B also
enhances the RNA helicase activity of eIF4A (42). As part of the eIF4F complex, eIF4G
subsequently interacts with eIF3 that is associated with the 43S pre-initiation complex to
form the 48S preinitiation complex. The 48S pre-initiation complex then scans along the
5’-untranslated region (5’-UTR) of the mRNA, and stops at the AUG start codon. The GTP
bound to eIF2 is then hydrolyzed and the eIF2•GDP complex along with most of the other
initiation factors are released from the 40S ribosomal subunit. The 60S ribosomal subunit
then joins, and the resulting 80S initiation complex is competent to proceed with peptide
chain elongation. The GDP bound to eIF2 must then be exchanged for GTP to permit
formation of the ternary complex and efficient recycling of eIF2, because the affinity of
Met-tRNAi for the eIF2•GDP complex is significantly lower compared to its affinity for
eIF2•GTP. The GDP-GTP exchange on eIF2 is mediated by the heteropentameric complex,
eIF2B (40).
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Regulatory Points of Protein Translation: There are three well-characterized
mechanisms for regulating translation initiation, which involve phosphorylation of eIF4B
protein complex (eIF2α and eIF2Bε subunits), release of 4E-BP1 from eIF4E and release
of programmed cell death 4 (PDCD4) from eIF4A, which modulate cap-dependent mRNA
translation. eIF2α phosphorylation on S51 indirectly inhibits translation initiation. The
phosphorylated eIF2α competitively binds to eIF2B and inhibit its GEF activity, which
results in accumulation of the eIF2•GDP complex that has limited affinity for Met-tRNAi,
and subsequent decrease in the amount of the active Met-tRNAi•eIF2•GTP complex
available to participate in assembly of the 43S pre-initiation complex (43). eIF2B GEF
activity is suppressed in response to phosphorylation of the catalytic eIF2Bε subunit.
Amino acid deprivation results in phosphorylation of eIF2Bε on S525 and repression of
eIF2B GEF activity (44). Phosphorylation of eIF2Bε on S540 by glycogen synthase kinase
3 (GSK-3) also leads to inhibition of eIF2B GEF activity (45).

Assemble of eIF4A, eIF4E, and eIF4G into the active eIF4F complex is the key process
of cap-dependent protein translation. The binding of eIF4E to eIF4G is predominantly
regulated by a family of eIF4E binding proteins (4E-BP) that bind to the same domain on
eIF4E as does eIF4G. Thus, the binding of 4E-BP to eIF4E prevents its association with
eIF4G, and therefore attenuates cap-dependent binding of mRNA to the 43S preinitiation
complex. The association of 4E-BPs with eIF4E is controlled by phosphorylation:
hyperphosphorylated forms of the 4EBP1 at T37/46 and S65 sites do not bind to eIF4E,
while none-phosphorylated or hypophosphorylated forms of 4EBP1 have high affinity to
eIF4E. Therefore, 4E-BP1 phosphorylation leads to the dissociation of 4E-BP1 from eIF4E,
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which allows eIF4G to bind to eIF4E and promotes an increase in cap-dependent
translation (46). Similar to the function of 4E-BP1 to inhibit assembly of the eIF4E•eIF4G
complex, PDCD4 interacts with eIF4A and prevents its association with eIF4G (47).
Phosphorylation

of

PDCD4

permits

eIF4E•eIF4G

complex.

Finally,

eIF4B

phosphorylation leads to the assembly of eIF4A into the eIF4F complex. The
phosphorylation of 4EBP1, PDCD4 and eIF4B are tightly regulated by mTOR-p70S6K
signaling pathway, which will be discussed later.

mTOR signaling pathway
mTOR: In 1965 it was discovered that a microorganism (Streptomyces hygroscopicus)
in the soil of Rapa Nui (Easter Island) produced a compound that possessed antibiotic
properties. This compound was subsequently given the name rapamycin (48). Subsequent
research showed rapamycin was able to inhibit the growth of a variety of eukaryotic
organisms (49). It was later determined that the growth regulatory effects of rapamycin
were a result of its ability to inhibit signaling by two closely related serine / threonine
kinases in yeast, which were designated the target of rapamycin (mTOR) (50). In vivo,
rapamycin forms a complex with the immunophilin FKBP12, and this complex has been
shown to bind to mTOR in a region termed the FRB domain. To date, numerous studies
have shown that mTOR plays a critical role in regulating protein synthesis and cell
growth/hypertrophy in skeletal muscle (14, 51-54). mTOR is a serine/threonine kinase of
the phosphatidylinositol kinase-related kinase family. mTOR signaling pathway has a wide
range of functions including regulation of protein synthesis, cell proliferation, apoptosis,
and autophagy (13).
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It has been well established that mTOR is the central component of a signaling network
that controls cellular growth and a large number of studies focus on understanding how
mTOR signaling is regulated. In mammalian cells, mTOR protein functions in two distinct
multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2),
only mTORC1 is inhibited by the FKBP12-rapamycin complex (13). mTORC1 is a protein
complex comprised of mTOR, regulatory associated protein of mTOR (Raptor), and G
protein β-subunit-like (Gβl/also known as mLST8). The primary role of mTORC1 is
regulating protein synthesis, this protein complex also mediates autophagy, lysosome
biogenesis, and lipid biosynthesis, thereby broadly integrating and regulating cellular
energy metabolism (13). The mTORC2 complex is comprised of mTOR, rapamycininsensitive companion of mTOR (Rictor), stress-activated-protein-kinase-interacting
protein 1 (SIN1), and Gβl. The role of mTOR complex 2 (mTORC2) is less well understood
but includes effects on cytoskeletal organization as well as growth, differentiation, and
survival (13).

Because of the major role of mTORC1 in mTOR regulation of muscle

protein synthesis, we will focus on mTORC1 effectors and regulation in this review.

mTOR downstream effectors: mTORC1 activation leads to increased protein synthesis
increase through different mechanisms, which include both protein translation efficiency
and capacity increase. Two of the most studied mTORC1 targets are the eukaryotic
initiation factor 4E binding protein (4E-BP1) and the ribosomal S6 kinase (p70S6K1),
which play an important role in protein translation initiation and elongation (14). Protein
translation initiation factor, eIF4E, which binds to the 7-methyl-guanosine ‘cap’ (on the 5’15

end of all cellular mRNAs), is inhibited from binding to eIF4G by 4E-BP1, thus
suppressing cap-dependent translation initiation. 4E-BP1 phosphorylation by mTORC1
results in the dissociation of 4E-BP1 from eIF4E, which allows eIF4G to bind to eIF4E and
promotes an increase in cap-dependent translation (46). The phosphorylation of p70S6K
on Thr 389 by mTORC1 allows p70S6K phosphorylates several downstream targets
involved in protein translation initiation, including two proteins that modulate capdependent mRNA translation, eIF4B and PDCD4, which are key modulators of capdependent mRNA translation. Another downstream phosphorylation target of p70S6K is
S6 ribosomal protein (S6RP) phosphorylation. S6 phosphorylation selectively increases the
translation of mRNA transcripts containing a tract of pyrimidine (TOP) motif. These TOPcontaining mRNAs often code for ribosomal proteins and other translational regulators,
therefore S6RP phosphorylation by p70S6K leads to the increased translational capacity
(55). p70S6K also increases eEF2 activity through the phosphorylation and inhibition of
eEF2K, a upstream suppressor of eEF2 (55).

Upstream regulator of mTOR
TSC1/TSC2: Signaling through mTOR is modulated through changes in activation of
multiple upstream pathways, many of which converge on the tuberous sclerosis complex
(TSC) proteins TSC1 and TSC2 (56, 57). Together, TSC1 and TSC2 function to promote
GTP hydrolysis by the small GTPase referred to as Ras homolog enriched in brain (Rheb).
When it is associated with GTP, but not GDP, Rheb can activate mTORC1. By stimulating
the GTPase activity of Rheb, the TSC complex converts Rheb from a GTP-bound to a
GDP-bound form, thereby inhibiting mTORC1 activity (57). The GTPase-activating
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function of the TSC complex is repressed through phosphorylation of TSC2 by Akt and
ERK, and activated through phosphorylation by AMPK (57).

IGF-1/PI3K/Akt: The most well-defined pathway regulating mTORC1 activity in
skeletal muscle is the IGF-1/insulin pathway (54). Binding of the growth factor IGF-1
induces a conformational change in the IGF-1 receptor tyrosine kinase, resulting in its
trans-phosphorylation and the subsequent phosphorylation of insulin receptor substrate 1
(IRS-1). In turn, this results in the activation of PI3K. Activation of PI3K results in the
production of phosphatidylinositol-3,4,5-trisphosphate, which provides a membranebinding site for the serine/threonine kinase Akt. After translocating to cell membrane, Akt
is phosphorylated on threonine 308 site and subsequently activated. Activated Akt then
stimulates mTOR signaling through regulation of the TSC1/2 complex. Akt directly
phosphorylates TSC2 on multiple residues, including Ser939 and Thr1462 (15).

This

phosphorylation of TSC2 by Akt/PKB inhibits its GAP activity, allowing Rheb to
accumulate in its active GTP-bound form and stimulate mTOR signaling (15). This leads
to the well-established growth factor associated signaling cascade through PI3K-Akt/PKBTSC1/2-Rheb-mTOR seen in muscle as well as other cell types.

Amino Acids: In addition to growth factors, mTOR can also be regulated by amino
acids availability (58-61). Among the amino acids, changes in leucine levels alone are
sufficient to regulate the phosphorylation state and activity of the mTOR pathway (60).
Several studies have shown that ingestion of essential amino acids (specifically leucine)
leads to increased protein synthesis in skeletal muscle primarily through activation of
17

mTOR signaling (62-64). However, precise mechanisms of amino acids regulation on
mTOR signaling remains poorly understood. It has been demonstrated that hVps34, a class
III PI3K, is implicated in the amino acid-induced activation of mTOR signaling (65), which
is independent of Akt/PKB-TSC-Rheb pathway (66, 67), but more work is still required to
determine the detailed mechanisms.

Mechanical Stimulation: One of the important variables contributing to the
hypertrophy and growth response in skeletal muscle is the application of mechanical
stimuli, from resistance exercise, high-force contraction or overload. Induction of mTOR
signaling was critical for mechanical overload-induced skeletal muscle hypertrophy (14).
Many studies have further confirmed the association between mechanical loading and
activation of mTOR signaling in mammalian muscle. While the effect of resistance
exercise/contraction on muscle mass has long been recognized, the mechanisms underlying
the link between mechanical stimuli and muscle protein synthesis increase is not fully
understood. The potential biochemical events that link the mechanical loading of a
muscle/muscle fiber to mTOR signaling will be discussed in section 3.

Energy Status and AMPK: AMPK is an intracellular sensor of energy stress that
negatively regulates muscle protein synthesis in response to energy deficiency or catabolic
cytokines in cachexia. AMPK is a protein complex contains three subunits: α, β and γ. The
phosphorylation of AMPKα subunit at T172 increases activity of AMPK protein complex.
Decreased intracellular ATP/ADP ratio and AMP build up, which is a marker of energy
deficiency, results in a conformational change of AMPK γ subunit, which allows the
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phosphorylation of AMPKα subunit at Thr172 by AMPK upstream activator, LKB1.
Phosphorylation of AMPKα results in the activation of AMPK complex activity. AMPK is
also pathologically activated in muscle catabolic diseases, including cachexia (18, 19).
Activated AMPK phosphorylates TSC2 on Thr1227 and Ser1345 residues (56).
Phosphorylation of TSC2 on Ser1387 by AMPK also results in further phosphorylation of
TSC2 by GSK-3 on multiple residues (56). TSC2 phsophorylation by AMPK and GSK-3
enhances its inhibitory function on mTOR activity (56). AMPK can also directly
phosphorylate the Raptor protein on two serine residues (Ser722/Ser792), which is required
to inhibit mTOR activity through cellular energy stress-induced AMPK activation (17).
Consistent with these observations, many in vivo and in vitro experiments demonstrated
that AMPK activation results in decreased protein synthesis and a repression of mTORmediated signaling in skeletal muscle (68-70).

REDD1/2: REgulated in Development and DNA damage responses 1 (REDD1) and
REDD2 were firstly identified as negative regulators of the Drosophila TOR pathway (71).
REDD1 is ubiquitously expressed in all cell types while expression of REDD2 is
significantly enriched in human and mouse skeletal muscle. REDD1 and REDD2 can
inhibit mTOR kinase activity downstream of Akt/PKB but upstream of TSC2 (72-75). The
upregulation of REDD1/2 is a potential mediator of mTOR signaling and protein synthesis
inhibition in many muscle catabolic conditions, including hindlimb unloading (76),
dexamethasone administration and alcohol intoxication (75, 77), while the rapid
degradation of REDD1 in muscle was associated with enhanced mTOR signaling (78).
These observations suggest REDD1 and REDD2 are stress responsive negative regulators
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of mTOR signaling and implicate skeletal muscle size regulation.
2.3 Mechanical stimuli induction of muscle hypertrophy
Mechanical stimuli can initiate muscle hypertrophy through a multifaceted series of
events contributing to mechanical stimuli induced muscle hypertrophy. Induction of protein
translation and synthesis drives protein accretion, while satellite cells activation and
incorporation of satellite cells facilitates the addition of newly formed myofibrils to the
contractile machinery. The molecular mechanisms converting the mechanical stimulus into
intracellular biochemical responses are known as mechanotransduction. Work by Bodine
et al. firstly established that mechanical overload-induced signaling through mTOR was
necessary for skeletal muscle hypertrophy (79). Since then, many studies have confirmed
the association between mechanical loading and activation of mTOR signaling and
subsequent

protein

synthesis

induction

in

mammalian muscle,

although the

mechanotransduction signaling pathways inducing muscle mTOR still remain poorly
understood. In this section, we will 1) describe the research models of mechanical stimuli
induced muscle hypertrophy; 2) summarize our current knowledge of the potential
mechanisms involved in the mechanical activation of mTOR signaling and protein
synthesis; 3) review other mechanisms contributing muscle hypertrophy by mechanical
stimuli.

Research models of muscle mass regulation by mechanical stimuli
In vitro model for stretch-induced hypertrophy of skeletal muscle cells was firstly
established in 1979 (80), Their models included both static stretch and stretch oscillations
on embryonic chicken skeletal myotubes, and resulted in several biomechanical changes
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related to muscle hypertrophy, including amino acid accumulation, increased protein
synthesis, total protein level and myosin heavy chain level. Since then, a large variety of
muscle cell stretch models have been developed, which differs in direction (radial stretch
or one-axial stretch), type (cyclic stretch or chronic constant stretch), frequency and
duration. Many of them have been demonstrated to induce anabolic signaling pathways,
protein accumulation or hypertrophy in cultured muscle cells (81, 82). However, a widely
accepted in vitro stretch model has not been fully established. It is difficult to compare
results from different research because the variability in stretch parameters. In fact, the
effect of cyclic stretch on protein synthesis in cultured myotubes can be influenced by
stretch type, duration and frequency (83). It was also reported cyclic stretch may also have
the potential to decrease myotube protein synthesis, despite the activation of anabolic
signaling in L6 cells (84). Recently, another in vitro mechanical stimuli system is developed,
in which mouse C2C12 myotubes underwent electric pulse stimulation to induce
spontaneous contractions, and mimic the electric stimulation induced muscle concentric
contraction (85). But its effect on myotube hypertrophic response, including protein
synthesis induction, still needs to be determined.

To complement the in vivo studies, several labs have employed both in vivo animal
models and ex vivo tissue models to evaluate the contribution of mechanical stimuli on
protein synthesis. Carson et al. applied passive stretch on anterior latissimus dorsi muscle
of quail by attaching weigh onto their upper hindlimbs, which has been demonstrated to
induce satellite cell activation, myofiber growth, myosin expression and muscle
hypertrophy in 30 days (86-88). Because of their clear genetic background and feasibility
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to conduct genetic manipulations, mouse and rat are more widely used in mechanistic
investigations of mechanical signaling pathways. A widely-used model of mechanical
stimuli induced muscle hypertrophy in adult mice or rats is compensatory hypertrophy
induced by ablation of synergist muscles: for example, hypertrophy of the plantaris or
soleus muscle after removal of the gastrocnemius, or hypertrophy of the extensor digitorum
longus after removal of the tibialis anterior muscle. This model of acute functional overload
causes induction of muscle protein synthesis, immediate satellite cell proliferation and
fusion to myofibers (16, 89). A similarly dramatic increase in mechanical load may be
induced in human skeletal muscle by high-intensity eccentric contractions, which also
cause activation of muscle protein synthesis, proliferation of satellite cells and, when
repeated, are known to induce muscle hypertrophy (90). Muscle concentric contraction
induced by low frequency electrical stimulation also demonstrated its ability to induce
mTOR signaling in mouse muscle (25). More recently, Hornberger et al. (52) used an ex
vivo system to test the contribution of mechanical strain oscillations on the regulation of
protein synthesis in mammalian muscle. Mouse extensor digitorum longus (EDL) muscles
were incubated in an organ bath and passively stretched 15% of resting length for up to 90
min. The results of these experiments found that passive stretch was sufficient to induce
increases in protein synthesis.

Mechanical Stimuli induction of Muscle mTOR signaling and Protein Synthesis
Due to the importance of protein synthesis exceeding breakdown over an extended
period of time, the degree of muscle hypertrophic response by mechanical stimuli is
strongly associated with the phosphorylation of p70S6K, a major controller of protein
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translation machinery (90). Until now, mTOR (or more specificly, mTORC1) is the only
molecular pathway that has repeatedly been identified to be necessary for growth of
skeletal muscle induced by various mechanically stimuli. However, the molecular events
connecting mechanical stimuli to mTOR activation is poorly understood. Numerous
investigations have been aimed at defining how mechanical stimuli activate mTOR
signaling.

PI3K/Akt signaling: The most widely discussed model is that mechanical stimuli
activate mTOR through a mechanism involving the IGF-1 and the PI3K-Akt-mTOR
signaling axis. Resistant exercise can induce muscle expression of growth factors which
can stimulate PI3K/Akt signaling, including insulin, IGF, MGF (91, 92). It has been
demonstrated that mTOR is liable of being activated by Akt dependent mechanisms in
synergist ablation induced hypertrophic muscles (79). Many studies carried out in humans
and animals also observed Akt activation under acute contractile stimuli (93-96). However,
exercise can also induce muscle mTOR/p70S6K signaling in the absence of Akt activation
(97-100). It is possible that different contraction patterns are capable of activating Akt in a
distinct manner, although the mechanisms are still not fully understood. Intermittent stretch
induced signaling through mTOR/p70S6K was not disrupted in the presence of PI3K
inhibitor wortmannin (101) or in muscles from Akt1-/- mice (52), suggesting the presence
of alternative pathways to activate mTOR signaling in response to acute contraction. It has
been demonstrated that at least acute activation of muscle mTOR signaling can be mediated
through Akt independent mechanisms (16). In conclusion, Akt contributes to acute
activation of mTOR/p70S6K by certain types of mechanical stimuli, and growth factors
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leading to PI3K/Akt/mTOR activation seem to be part of a late component of protein
synthesis activation in chronic muscle hypertrophy induced by exercise training.

Amino Acids: Amino acids have been implicated in the regulation of mTORC1
signaling through PI3K/PKB independent mechanisms. Mechanical stimuli have been
shown to induce an increase in amino acid uptake and hVps34 signaling activation (102,
103), which suggest amino acids may contribute to PI3K/PKB-independent mTOR
activation mechanism in response to mechanical stimuli. However, it has also been reported
that eccentric contractions induced mTOR activation precedes the increase in intracellular
amino acids (103). Ex vivo stretch of isolated muscle can also activate mTOR the absence
of exogenous amino acids (101). Thus, although amino acids signaling can contribute to
mechnical activation of mTOR, mechanical stimuli appear to activate mTOR signaling via
a mechanism that is distinct from amino acids.

ERK1/2: Extracellular signal-Regulated Kinases 1/2 (ERK1/2), act in a signaling
cascade that regulates various cellular processes such as proliferation, differentiation, and
cell cycle progression in response to a variety of extracellular signals, including mechanical
stimuli. Exercise caused a rapid and sustained activation of the MEK1/2-ERK1/2-p90RSK
pathway in skeletal muscles, resulting in increased phosphorylation of downstream targets
including eIF4E and the RPS6 (104). Another study showed MEK/ERK-dependent
pathway was activated at the early stage of overload (105). ERK1/2 can contribute to
induction of muscle mTOR signaling and protein synthesis through the phosphorylation of
TSC2 at S464 and subsequent suppression of GTPase activity of TSC1/2 complex, which
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is independent of Akt (105). However, ERK1/2 inhibitor did not influence the stretch
induction of p70S6K phosphorylation in cultured myotubes (83), which suggest ERK1/2
signaling activation is not the only mechanism mediating mTOR induction in some
mechanical stimuli models. At least, activation of ERK1/2 is contributes to acute induction
of muscle mTOR signaling by mechanical stimuli.

Phosphatidic acid: Phosphatidic acid (PA) is a well-known lipid based second
messenger which plays a role in several signaling systems, whose activation influences
mitogenesis, secretory processes and cytoskeleton reorganization. PA activation depends
on phospholipase D (PLD) enzyme activity, which hydrolyses phosphatidilcholine in PA
and choline (106). Once synthesized, PA binds to the FRB domain of mTOR protein, which
results in increased mTOR kinase activity and p70S6K phosphorylation (107). PA also
competes with the FKBP12-rapamycin complex for binding to the FRB domain (107, 108).
Hornberger et al. reported ex vivo stretch of mouse muscles induced PA accumulation and
p70S6K phosphorylation, while treating muscles with a PLD inhibitor neutralized the
stretching effects over p70S6K in a dose dependent manner (101). Incubating C2C12
myoblasts with exogenous PA is sufficient to induce a rapid induction of mTOR signaling
(101). These results clearly demonstrate that mechanical stimulation acutely activates
mTOR pathway through increments in intracellular concentration of PA. Although PA
increment also activates PI3K in cultured fibroblast cells (109), mechanical stimulation of
mTOR does not seem to be dependent on PI3K-Akt signaling activation (52, 101).
However, the precise mechanism underlying muscle contraction induced PA increments is
still not clear.
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Other Signaling pathways contributing mechanical stimuli induced muscle hypertrophy
Satellite cell activation and Myogenesis: Skeletal muscle satellite cells are quiescent
cells located adjacent to muscle fibers and beneath the fiber basal lamina, which can be
induced to divide during conditions of muscle damage or increased activation. Subsequent
fusion with an existing myofiber results in the addition of a myonucleus to the fiber
syncytium. The proposed role of the satellite cells in muscle hypertrophy revolves around
the concept of a myonuclear domain—a theoretical volume of cytoplasm associated with a
single myonucleus—and each myofiber being composed of many myonuclear domains
(110). Cytokines, such as IL-4 (111) and IL-6 (36) have been implicated in satellite cell
proliferation. However, the role of satellite cells in hypertrophy of adult skeletal muscle is
still under debate (112). For example, in satellite cell depletion experimental models,
overload induced skeletal muscle fiber hypertrophy is observed without obligatory satellite
cell incorporation, whereas regeneration from acute muscle injury is impaired, suggesting
that the role of satellite cells is markedly different between the two muscle growth
paradigms (113). However, synegist ablation induced functional overload produces supraphysiological gains in muscle size in a short time frame, and may not adequately represent
human adaptation (114).

SRF signaling pathway: Serum response factor (SRF) is a transcriptional factors
belonging to MADS superfamily. SRF binds to the serum response element (SRE) in the
promoter region of target genes and regulates the expression of genes participating in cell
cycle regulation, apoptosis, cell growth, and cell differentiation (115). SRF was found to
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be required for muscle hypertrophy induced by synergist elimination. In this model, the
effect of SRF activation by overload leads to myofiber release of IL-4 and IL-6, which act
in a paracrine manner to induce satellite cell proliferation and fusion, respectively (8).
Another study reported that SRF is able to activate the Akt pathway via a muscle-enriched
microRNA, miR-486, which targets the phosphatase and tensin homolog PTEN, a negative
regulator of PI3K–Akt signaling (116). However, the Akt phosphorylation is unchanged in
both control and SRF deficient muscles at during the synergist ablation induced
hypertrophic process, and future research is required to determine the role of SRF-miR486-PTEN-PI3K–Akt signaling axis in mechanical stimuli induced muscle hypertrophy.
Finally, SRF is known to control the transcription of several cytoskeletal and sarcomeric
protein genes, including α-actin, by binding to CArG box regulatory elements (117). It has
been demonstrated that both in vivo and in vitro stretch can induce SRF protein and
transcriptional activity, which is associated with increased α-actin transcription and muscle
hypertrophy.

2.4 Muscle Wasting in Cachexia
Muscle atrophy in cachexia is caused by the protein turnover balance shift to the
catabolic side, which involves increase in muscle protein breakdown and decrease in
muscle protein synthesis. Increased protein breakdown, in particular breakdown of the
myofibrillar proteins actin and myosin, is the most important mechanism of muscle wasting
(118). It has been demonstrated that the ubiquitin-proteasome signaling (UPS) pathway
plays an important role in the development of muscle wasting in cancer cachexia (119),
and protein synthesis suppression is another important contributor (120, 121).
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In this

section, we will go over the current research models of cachexia, major signaling pathways
involved in muscle wasting in cachexia. Because protein synthesis is the major outcome of
our proposed study, this section will focus of mechanisms involved in the impairment of
muscle protein synthesis associated with cachexia.

Research models of cachexia
Because of the difficulty to recruit patients and technical limitations to control
experiment conditions and variables in human, most mechanistic investigations of cachexia
are conducted in cell culture models and animal models. A highly simplified cachexia
model is cell culture, where C2C12 myotubes (from mouse), L3 myotubes (from rat) or
primary cultured myotubes are exposed to conditioned media of cancer cells or specific
molecules which have the potential to mediate muscle wasting in cachexia. The cell culture
model allows investigator easily manipulating signaling pathways, and is a strong tool to
investigate mechanisms driving muscle protein turnover disruption in cachexia. It is also
useful to rapidly screen compounds for their anti-cachectic activity, prior to their use in
vivo. In terms of multicellular organisms, murine models (rats and mice) are widely used
to reproduce clinical features of cachexia patients. Injection of cancer cell lines in
syngeneic animals have been used to set up in vivo experimental cachexia models,
including C-26, Walker 256, MAC16, AH-130, LLC and B16 melanoma (122). The feature
of each of these tumor cell lines that induce cachexia is the release of humoral mediators
either from the cancer cells or by the host, therefore mimicking the etiology of cachexia in
humans. Injecting cancer cells derived from patients that exhibited cancer cachexia into
immune-deficient mice is also a cachexia animal model, although these experiments are
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not very common (123). Among these cell lines, C-26 and LLC cells are most widely used.
C-26 tumor was originally chemically induced in BALB/c mice (124). LLC cells were
isolated from a spontaneous tumor in a C57BL/6 mouse (by Margaret Lewis at the Wistar
Institute in 1951). Both C-26 and LLC models are easy to manage and cancer cells can be
maintained and expanded either in vitro with standard adherent cell culture conditions or
in vivo by means of mouse-to-mouse transplantation. Subcutaneously injection of C26 into
Balb/C mice or IP-injection of LLC in C57BL/6 mice can induce several typical symptoms
of cachexia within one month, including loss of body weight (~15%), muscle mass, grip
strength and elevation of serum inflammatory cytokines (124). Moreover, the LLC model
is often used to model cachexia in transgenic or knockout mice since the most frequent
background used for producing transgenic animals is the C57BL/6 strain, which is
syngeneic to LLC cells.

The major limitations of tumor cell injection models are their 'acute' cachexia
progression, which is not the natural history of the tumor and prevent us to investigate the
early alterations that drive the onset of cachexia. Using the genetic engineered mouse
models, which is characterized by the spontaneous tumor growth can, partially at least,
circumvent these drawbacks. The best characterized genetic engineered model of cachexia
is the ApcMin/+ mouse, which was introduced by the Carson's laboratory (18, 125). The
acronym specifies that these mice bear a heterozygous mutation in the APC gene, which is
sufficient to determine the appearance of intestinal polyps as soon as 4 weeks after birth.
Cachexia has an average onset 10 weeks, which makes this model suitable for intervention
studies. At least 18 papers support the use of the model (125). Similar to C-26 model,
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cachexia progression in ApcMin/+ mouse is highly associated with IL-6, which is a
promising therapeutic target of cachexia (125).

Important mediators of cachexia induced muscle wasting.
Disruption of muscle protein turnover caused by hyperactivation of proteolysis and
suppression of protein synthesis plays a key role in muscle wasting during cachexia. The
role of protein degradation during cancer cachexia has been well established. The major
proteolytic pathway responsible for skeletal muscle protein degradation is ubiquitinproteasome pathway (UPS) (126). Several inflammatory signaling pathways appear to be
a potent mediator of cachexia-induced muscle proteolysis. Here, we will briefly review the
mechanisms of UPS mediated proteolysis and important signaling pathways mediating
UPS activation in cachexia. The mechanism of cachexia suppression of muscle protein
synthesis will be detailed reviewed in next section.

Induction of ubiquitin-proteasome system: In the ubiquitin-proteasome system,
proteins are targeted for degradation by the 26S proteasome through covalent attachment
of a chain of ubiquitin molecules. Ubiquitinated proteins are then recognized and degraded
by the large proteolytic 26S proteasome though a highly complicated process (127).
Different classes of enzymes, named E1, E2 and E3, are involved in protein ubiquitination.
The ubiquitin ligase enzyme, or E3, binds the protein substrate and catalyzes the movement
of the ubiquitin from the E2 enzyme to the substrate, which is the rate-limiting step of the
ubiquitination process. Once the protein is ubiquitinated, it is docked to the proteasome for
degradation. Different E2-E3 pairs function in the degradation of different proteins, and
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the specificity of the E3s for specific groups of proteins provides exquisite selectivity to
this degradation process. Different E2 and E3 proteins are involved in the precise regulation
of different cellular processes.

In muscles, there are two specific E3 ubiquitin ligases, atrogin-1 (also known as
MAFbx or FBXO32) and muscle RING finger-1 (MuRF1, also known as E3 ubiquitinprotein ligase TRIM63), which are considered the main markers of muscle atrophy because
they are strongly upregulated in different types of muscular atrophy (127-129). MuRF1 and
Atrogin-1 mediate ubiquitination and degradation of their specific proteins. MuRF1 is
localized to the sarcomere, and induces muscle atrophy by directly attacking the thick
filament of the sarcomere and causing the proteolysis of myosin proteins including
ubiquitinate myosin heavy chain (MyHC), myosin light chain and myosin binding protein
C. Large myofibrillar protein titin is also a potential substrate for MuRF. Identified
substrates of atrogin-1 include MyoD (130, 131) and calcineurin (132). Atrogin-1 also
mediates the ubiquitin degradation of eIF3-f, a protein initiation factor, which suggests that
Atrogin-1 can result in muscle atrophy through the downregulation of protein synthesis
(133, 134). Expression of Atrogin-1 and MuRF1 requires the FOXO family of transcription
factors, which locates in nucleus when they are not phosphorylated (135, 136). Activation
of Akt can in turn inhibit the transcriptional upregulation of Atrogin-1 and MuRF1 through
phosphorylating FOXOs, and making them translocate to cytoplasm and induce expression
of their target genes (137).

TNF-α/ NF-κB and TNF-α/ p38 MAPK Signaling pathways: IL-1 and TNF-α levels
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are elevated in the circulations of patients with cancer cachexia, contributing to negative
nitrogen balance (138). TNF-α can induce muscle expression of genes involved in the UPS
proteolysis pathway, and was believed to have a crucial role in the weight loss observed in
tumour-bearing mice (139, 140). TNF-α and IL-1 are involved in two established pathways,
the NF-κB pathway and the p38 MAPK pathway, both of which have a documented role in
cachexia induced muscle wasting. Another TNF-α family cytokine TWEAK, induces
MuRF1 upregulation via NF-κB, resulting in MyHC loss (141). Many studies demonstrated
NF-κB signaling is necessary and sufficient to induce proteolysis and muscle atrophy in
cachexia. Muscle specific activation of NF-κB signaling by the over-expression of either
constitutively active IKKβ or a dominant inhibitory form of IκBα can directly induce
expression of MURF1. Overexpression of IκBα could block loss of myosin in TNF-α
treated C2C12 myotube (142). In vivo inhibition of classical NF-κB

signaling also

significantly decreased tumor-induced muscle loss, at least in part, by inhibiting the
upregulation of MuRF1 (143, 144). Another TNF-α downstream pathway, p38 MAPK, can
also upregulate atrogin-1 expression in skeletal muscle via p38 MAPK-mediated C/EBPβ
phosphorylation (145, 146).

In addition to proteolysis, NF-κB signaling also mediates

cachexia factors induced Pax7 dysregulation, which contributes to an impaired
regenerative capacity of myogenic cells in cachexia (147).

IL-6/STAT3: Circulation level of IL-6 is upregulated in cachexia, and IL-6 levels
correlate with weight and muscle loss in certain human cancers (38, 148-150). IL-6 for
inducing muscle mass loss has been confirmed by many studies. The overexpression of IL6 in transgenic mice induced skeletal muscle atrophy (151). Administration of IL-6 to
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C2C12 myotubes increases atrogin-1 protein expression (20). Moreover, cachexia can be
ameliorated in mice treated with IL-6-targeted antibodies (39). IL-6 induces intracelluar
STAT3 signaling through binding to the receptor complex consisting IL-6r and gp130. IL6 is also associated with AMPK and NF-κB activation indirectly.

It has been

demonstrated IL-6-gp130-STAT3 signaling axis plays is a central regulator of in muscle
wasting in several cachexia animal models, which will be reviewed in detail in section 2.

Myostatin: Myostatin is a member of the transforming growth factor-β (TGF-β)
superfamily that acts as a negative regulator of muscle growth (152-154). Once bounding
to its type I [Activin Receptor II A or B (ActRIIA or B)] and type II [Activin-Like Kinase4 or 5 (ALK-4 or 5)] receptors, myostatin activates intracellular signaling via the
phosphorylation and activation of the transcription factors Smad 2 and 3, which translocate
to the nucleus and activate target genes (155). Myostatin is involved in skeletal muscle
wasting in different catabolic conditions, including cancer (156). Inactivation of myostatin
and other TGF-β family proteins by treatment with a soluble form of ACTRIIB (sACTRIIB)
ablates the muscle wasting and other symptoms of cancer cachexia in LLC tumor bearing
mice (157, 158). It has been demonstrated myotatin is a strong catabolic regulator of muscle
protein turnover. Myostatin induces muscle wasting by activating the ubiquitin proteolytic
system through an NF-κB-independent, FoxO1-dependent mechanism (159). Myostatin
also negatively regulates Akt signaling, an upstream stimulator of muscle protein synthesis
(160).

Suppression of Muscle Protein Synthesis in cachexia
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Rates of muscle protein synthesis are significantly reduced in patients with cancer
cachexia (161) and muscle of cachectic patients is resistant anabolic stimulation (162). The
suppression of muscle protein synthesis contributes to muscle wasting in cachexia (118),
but the understanding of muscle protein synthesis suppression in cachexia falls behind our
understanding of protein degradation. Due to the difficult nature of studying muscle protein
synthesis regulation in cachexia patients, most of our mechanistic understanding have been
delineated using mouse models. The ApcMin/+ mouse, which is characterized by slow
progression of cachexia, shows significantly decreased rates of myofibrillar protein
synthesis (18). The dysregulation of protein synthesis in early stage of cachexia is
associated with suppression mTOR signaling as assessed by decreased phosphorylation of
both 4E-BP1 and p70S6K1. However, no change in phosphorylation of Akt, mTOR, or
AMPK is observed, suggesting that mTORC1 signaling might be regulated by another
upstream regulator(s) (18). A further decline in the rate of myofibrillar protein synthesis,
beyond that seen in early cachexia, occurs in advanced cachexia, suggesting mechanisms
which regulate protein synthesis at more advanced stages may occur through mechanisms
distinct from those in early cachexia. Interestingly, AMPK phosphorylation and AMPK
activity increase significantly during late stages of cachexia (18). Moreover, late stage of
cachexia manifests repressed phosphorylation of mTOR and phosphorylation of mTOR
substrates, p70S6K and 4EBP1, show further declines compared to early cachexia, despite
the paradoxically increased phosphorylation of the upstream mTORC1 regulator, Akt (18).
In LLC tumor bearing mice, another sever cachexia model, muscle mTOR signaling,
including phosphorylation of p70S6K, S6RP, 4EBP1, and protein synthesis were also
suppressed, which is accompanied with increased AMPK phosphorylation (19). LLC
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released factors also induce myotube protein synthesis suppression and AMPK activation,
although Akt phosphorylation is increased (19). The apparent disconnect that occurs
between Akt and mTOR signaling during advanced cachexia may be related to activation
of AMPK because AMPK activation in muscle overcomes insulin-induced activation of
mTOR with no effect on insulin-induced phosphorylation of Akt (163). The cachexiaassociated activation of AMPK could be caused by mitochondrial dysfunction. Muscle
mitochondrial size is significantly reduced in Apcmin/+ mice which is prior to the onset of
cachexia (164). The protein level of mitofusin 1 and 2 which promote mitochondrial fusion
and maintain metabolic function (165, 166) are also decreased during early stage of
cachexia (18, 164). The protein expression of Fis1, which promotes fragmenting of
mitochondria (167), is increased during late stage of cachexia, which coincides with AMPK
activation (164). These results suggest that mitochondrial dysfunction may results in
energy deficiency and further AMPK signaling activation during later stages of cachexia
leading to further reductions in mTOR signaling and the rates of protein synthesis.

Down-regulation of insulin/IGF-1 signaling is another potential mechanism
underlying the muscle protein synthesis suppression in cachexia. IGF-1 mRNA expression
is significantly reduced upon the initiation of cachexia (18). IGF-1 administration can
attenuate loss of body weight in rats inoculated with AH-130 cancer cells (168). However,
serum IGF-1 does not change in cachexia patients (169). A possible explanation for this
dichotomy may be that the cachexia-induced decrease in muscle IGF-1 mRNA expression
in animal models results in reduced intramuscular concentrations of the hormone, leading
to repressed autocrine/paracrine function, while circulating IGF-1 is not affected. It is also
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possible that wasting muscles in cachexia have disrupted Akt-mTORC1 signaling axis and
reduced sensitivity to insulin/IGF-1. There is evidence of skeletal muscle insulin resistance
in human cancer patients (170) and increased plasma insulin concentrations in cachexia
patients (169). Furthermore, plasma insulin levels as well as the phosphorylation of Akt are
significantly cachectic mice despite reduced protein synthesis (18, 171). As mentioned
above, this dissociation may be a consequence of chronic AMPK signaling activation.

Muscle anabolic Resistance in cachexia
In additional to suppression of basal protein synthesis in muscle, cachexia can also
prevent muscle protein synthesis induction by anabolic stimuli, which is known as anabolic
resistance (162). Some evidence suggests that the muscle anabolic resistance in cachexia
is associated with induction of inflammatory signaling pathways and muscle proteolysis.
For example, TNF-α can inactivate PI3K/Akt signaling pathway (172) and attenuates
insulin-stimulated protein synthesis (173). TNF-α leads to serine phosphorylation of IRS1, inhibiting its recruitment to the insulin/IGF-1 receptor. TNF-α can also impinge on the
insulin/IGF-1 signaling via direct interaction between the IKK complexes and IRS-1. TNFα induced activation of JNK may also play a role, because TNF-α does not downregulation
of the IGF-1-dependent signaling in the presence of a JNK inhibitor (174). TNF-α
downstream NF-κB signaling activation is associated with anabolic resistance to amino
acids and resistance exercise in muscle wasting conditions, such as sarcopenia or sepsis
(175). Muscle contraction-induced mTOR signaling is attenuated in severely cachectic
ApcMin/+ mice (25). Interestingly, administration of PDTC, a NF-κB and STAT3 inhibitor,
to these cachectic mice can rescue contraction-induced mTOR activation (25). These
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results suggest cachexia induced inflammatory environment can interact with and impinge
anabolic signaling pathways leading to protein synthesis in skeletal muscle.

Activation of UPS dependent proteolysis in wasting muscles induced cachexia also
has strong potential to block protein synthesis induction by anabolic stimuli. Many
signaling molecules contributing to muscle protein synthesis induction by anabolic stimuli
can be targeted by E3 ubiquitin ligase. For example, Atrogin-1, whose expression is
strongly induced by cachexia, can mediate the ubiquitinization of protein translation factor
eIF3f (134), which block the stimulation of protein synthesis by mTOR/p70S6K signaling
pathway (176, 177). Other E3 ligases include Fbx-containing protein Fbxo40 and cullinRING E3 ubiquitin ligase 7 (CRL7), can ubiquitinize and degrade IRS1, preventing
signaling transduction from IGF-1 to Akt (178, 179). The UPS-dependent IRS1
degradation is a negative feedback mechanism preventing hyperactivation of Akt signaling
under physiological condition, but its role in cachexia induced muscle anabolic resistance
still needs to be determined.
2.5 Role of gp130 signaling in muscle mass regulation
gp130 signaling is involved in both muscle hypertrophy and atrophy. gp130 cytokines,
IL-6 and LIF, are known as ‘myokines’, which means they are produced and released from
skeletal muscles during exercise and are involved muscle adaptation to exercise in
autocrine/paracrine manner. Both IL-6 and LIF have demonstrated their role in overload
induced muscle hypertrophy. Further research showed that IL-6 and LIF can stimulate
satellite cell proliferation which contribute to muscle hypertrophy. However, chronic
elevation of gp130 cytokines and/or activation of gp130 downstream signaling pathways
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in skeletal muscles, are key mediators of muscle wasting in cancer cachexia. In this section,
we will review (1) major gp130 ligands and gp130 downstream signaling pathways, (2)
role of gp130 cytokines and downstream signaling pathways in muscle hypertrophy and
myogenesis and (3) role of gp130 cytokines and downstream signaling pathways in muscle
wasting.

gp130 ligands and downstream pathways.
Glycoprotein 130 kDa (gp130) is a ubiquitously expressed trans-membrane protein. It
serves as the signal transduction unit of a family of cytokines: the IL-6 family. The
members of this family are IL-6, IL-11, IL-27, IL-30, IL-31, oncostatin M (OSM),
leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC)
and ciliary neurotrophic factor (CNTF) (2). These cytokines utilize type I cytokine
receptors which consist of a ligand binding α-receptor subunit and a signal transducing βreceptor subunit containing a cytoplasmic signaling domain. Each gp130 cytokine is
characterized by a certain profile of receptor recruitment but all cases involve at least one
molecule of gp130. IL-6, IL-11 and CNTF first bind specifically to their respective αreceptor subunits. Once bound to the α-receptor, the complex then binds to two β-receptors
to form a dimer. The remaining gp130 cytokines do not bind to an α-receptor, but bind to
their respective β-receptor directly and signal via heterodimers of either gp130 and the
LIFR (LIF, CNTF, CT-1 and CLC) or gp130 and the OSMR (OSM). Regardless of different
binding pattern, this ligand-receptor protein complex then activates constitutively bound
Janus family kinases, JAK1, JAK2 or Tyk2, which then phosphorylates tyrosine residues
in the distal cytoplasmic domains of gp130. Phosphorylated gp130 can act as a docking
38

site for SH2 domains of Signal Transducer and Activator of Transcription (STAT) family
of transcription factors (STAT1, 3 and 5). Subsequent phosphorylation of STATs by gp130
then induces STAT dimerization and translocation to the nucleus where they induce gene
transcription. Thus, JAK/STAT activation is a classical hallmark of gp130 dependent
cytokine signaling. Dimerization of gp130 cytokine receptors also leads to the induction of
the MAPK cascade, including ERK1/2, JNK1/2 and p38 MAPK. gp130 activation of
MAPKs is primary mediated through the recruitment of the protein tyrosine phosphatase
SHP2 to the gp130 phosphorylation site. Phosphorylation of Tyr759 on gp130 results in
the recruitment of SHP-2 (Src homology domain-containing protein tyrosine phosphatase2), allowing its phosphorylation by JAK. Phosphorylated SHP-2 then interacts with Grb2
(growth-factor receptor bound protein 2), which leads to the activation of the Ras-RafERK1/2 cascade (2). gp130 cytokines can also activate the stress-activated members of the
MAPK family: p38 and JNK (180, 181), but the signal transduction pathways resulting in
their activation remain poorly understood.

gp130 cytokines can also lead to the activation signaling cascades involving PI3K.
This enzyme modifies certain phosphatidylinositides, so that the serine/threonine Akt is
recruited to the plasma membrane, where it becomes activated through phosphorylation by
PDK1 (phosphoinositide-dependent kinase-1).

can induce the activation of mTOR

signaling IL-6-induced activation of the PI3K/Akt pathway is involved in protection
against apoptosis, as well as in enhanced proliferation in multiple myeloma cells (182-184),
cardiac myocytes (185, 186) and basal carcinoma cells (187). The molecular mechanism
linking gp130 engagement to the activation of the PI3K/Akt pathway is not well understood.
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Some evidence exist suggesting that IRS-1 and its adaptor protein Gab1 are involved in
gp130 activation of PI3K (188, 189). Notably, PI3K activation upon gp130 cytokines is
observed in a cell-type specific manner. For example, no significant Akt activation could
be observed in IL-6 treated HepG2 hepatoma cells (190). Whether gp130 cytokines can
induce PI3K/Akt signaling activation in skeletal muscle cells has not been examined.

Activation of gp130/STAT3 signaling is transient in most biological systems because
of the efficient inhibition mechanisms for STAT inactivation. This inhibition mechanisms
of

gp130/STAT

signaling

pathway

can

inhibit

the

constant

activation

of

JAK1/STAT1/STAT3 pathway. Three families of regulators of JAK/STAT signaling are
known: the SOCS family of proteins, the protein inhibitor of activated STAT (PIAS) family
of proteins and the SH2-containing phosphatase family of proteins (191). These proteins
target to distinct members of the gp130/STAT signaling pathway: SOCS1 and SOCS3
target JAK1 and gp130, respectively, near the plasma membrane to prevent cytoplasmic
STATs from being activated, whereas PIAS1 principally targets activated STAT proteins in
the cell nucleus and prevents it from binding to DNA (191). SOCS proteins transcription
is induced by IL-6 and LIF and since they inhibit tyrosine phosphorylation of gp130,
STAT1 and STAT3. SOCS proteins contain a SH2 domain and was shown to directly
interact with the kinase domain of JAK2, resulting in a reduced tyrosine kinase activity of
JAK2. Thus SOCS is a JAK inhibitor that is induced by the STAT3 activation and
eventually leads to feedback regulation of gp130/STAT3

Role of gp130 signaling in muscle hypertrophy
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IL-6 and LIF are induced in overloaded muscles during the process of hypertrophy in
rodents (7). LIF and IL-6 expression is also significantly induced by resistance exercise in
human muscle and in electrically stimulated cultured human myotubes (192). Both LIF and
IL-6 knockout mice were shown to have an impaired hypertrophic response to overloading,
which confirms the role of these cytokines in muscle hypertrophy (7, 8). Overload induced
protein synthesis induction was not attenuated by IL-6 knock-out mice. It was believed that
impaired hypertrophic muscle growth is ascribed to blunted accretion of myonuclei, which
is caused by the defective proliferation and migration capacities of satellite cells in the
absence of IL-6 (8). Indeed, IL-6 can activate murine satellite cell proliferation via
regulation of cyclin D1 and c-myc (193). Similarly, exogenous LIF can induce human
myoblast proliferation via induction of the cell proliferation associated factors c-Myc and
JunB (192). The overload induced myofiber hypertrophy also requires IL-4, which
promotes myoblast fusion without affecting their proliferative capacity. Similar to IL-6, IL4 is expressed in skeletal muscles in response to overload and exercise (8, 194). The
expression of both cytokines has been shown to depend on the transcription factor serum
response factor (8). Thus, serum response factor can be used by the myofibers to translate
mechanical cues into paracrine growth-promoting signals that impact positively on satellite
cell proliferation and fusion. Collectively, these results demonstrate that gp130 family of
cytokines contribute to myogenesis in vitro and muscle regeneration and growth in vivo,
acting at distinct stages of these processes in a timely and regulated fashion, through
distinct signaling pathways and effectors.

Consistent with the functions of IL-6 and LIF in myogenesis, the gp130 downstream
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JAK/STAT signaling pathway is also associated with muscle growth and hypertrophy
through the promotion of myoblast proliferation. Proliferating satellite cells in regenerating
muscle showed activated STAT3 (195). STAT3 signaling directly associates with MyoD
expression and overexpression of d.n.STAT3 in C2C12 myoblast can inhibit its myogenic
activities (196). JAK1, STAT1 and STAT3 signaling pathways are activated in early stage
of muscle regeneration which is characterized by rapid proliferation of satellite cells (197).
Consistent with this, the JAK1/STAT1/STAT3 pathway was shown to be necessary for
myoblast proliferation in vitro, based on its capacity to regulate the expression of cell cycle
associated genes. STAT1/STAT3 complex is also necessary for LIF stimulation of myoblast
proliferation (197), which is consistent with the delayed muscle regeneration of LIF knockout mice, which can be rescued by delivery of exogenous LIF (7). However, activation of
the JAK1/STAT1/STAT3 pathway can also prevent premature differentiation of myoblasts
by blocking the expression of genes critical for myoblast differentiation and fusion, such
as MyoD, MEF2 and myogenin, while knockdown of JAK1 or STAT1 reduces myoblast
proliferation and leads to premature differentiation (197). These results suggest that the
JAK1/STAT1/STAT3 pathway serves as a differentiation checkpoint, ensuring that
differentiation commences only when a sufficient number of myoblast cell progeny have
been generated during the proliferative phase. SOCS dependent negative feedback is
important to inhibit JAK1/STAT signaling, which allows the cessation of myoblast
proliferation and commencement of differentiation. Kinase activity of JAK1 is reduced
upon differentiation, which is associated with increased expression of SOCS1 and SOCS2
(195). In conclusion, LIF and IL-6 induction of JAK1/STAT1/STAT3 pathway plays dual
role in proliferating myoblasts, that is, promote their proliferation and also inhibit their
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precocious differentiation.

In addition to JAK/STAT3 signaling pathway, several intracellular signaling pathways
downstream gp130 are known to regulate myogenesis. The p38 MAPK, PI3K/AKT,
calcium/calmodulin activated protein kinase, and calcineurin positively regulate myogenic
differentiation (198), while ERK1/2 pathway activates myoblast proliferation and inhibits
differentiation at the early stage of differentiation, but promotes myocyte fusion at the late
stages of differentiation (199, 200). Similarly, NF-ĸB also promotes myoblast proliferation,
while also favoring differentiation at later stages by acting as a downstream mediator of
p38 MAPK signaling (201).

Role of gp130 cytokines in muscle atrophy
Since early 1990’s, it has been recognized that elevated circulating IL-6, as well as
complex underlying cytokine network, could participate in cachexia development (118).
IL-6/gp130 signaling has been demonstrated to play a key role in several cancer cachexia
animal models. Inhibiting IL-6 signaling by neutralizing antibodies showed a protective
effect on body weight loss in C26 tumor bearing mice (39). The IL-6 dependent muscle
mass loss has also been demonstrated in ApcMin/+ and C26 tumor-implanted mice (125,
202, 203). Recently, LIF has also been demonstrated to play a key role in C26 induced
muscle wasting (204). However, whether IL-6/gp130 signaling is sufficient and/or has a
direct role in the induction of muscle atrophy remains controversial. Further research is
still required to determine the mechanisms underlying IL-6 /gp130 signaling in cachexia
induced muscle wasting.
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Whether IL-6 induces muscle protein degradation is still under debate. In fact, different
in vivo and in vitro studies got controversial results. Several early studies showed protein
degradation rate in isolated rat muscles exposed to recombinant IL-6 (205), or after
injection of IL-6 into wild type mice (206, 207), was unaltered. Similarly, exogenous IL-6
administration showed no effect on the proteolytic rate of rat and murine myotubes (208).
These results are also supported by the fact that infusion of a single dose of IL-6 to rats did
not induce ubiquitin gene upregulation in muscle (209). In contrast to these negative results,
increased muscle proteolysis was observed after high doses or long-term administration of
IL-6 in rats or mice (210). IL-6 transgenic mice showed elevated circulating levels IL-6
and displayed severe muscle atrophy by the age of 10 weeks, together with the activation
of the proteolysis in muscles (211). The inhibition of IL-6 signaling by sustained
administration of mouse IL-6R antibody completely reversed the muscle wasting in IL-6
overexpressing mice (212) and C26 tumor bearing wild type mice (151). These results
demonstrate that IL-6 at least has a permissive role in the development of skeletal muscle
proteolysis and muscle wasting when other cachectic factors are also present. Some
evidence suggest IL-6 may synergize with other cytokines to induce muscular atrophy in
some disease states. For example, activation of the rennin-angiotensin system can cause
severe muscle wasting, which is commonly found in congestive heart failure or chronic
kidney disease (213).

Consistent with IL-6 and LIF role, the role of STAT3 signaling in cachexia induced
muscle wasting has been well established. Increased muscle STAT3 phosphorylation has
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been observed in several cachexia models. Overexpression of constitutively active STAT3
in normal mouse muscle by plasmid transfection induced a significant reduction of
myofiber cross sectional area (202, 214). Transfection of dominant negative STAT3
mutants, or STAT3 short hairpin, prevented the atrophy induced by injection of Chinese
hamster ovary cells overexpressing IL-6 in athymic nude mice and in the C26
adenocarcinoma mouse model (202). A recent study further demonstrates STAT3 signaling
activation contributes to muscle wasting in C26 and LLC cachexia model by inhibiting
muscle protein synthesis, as well as stimulating caspase-3, myostatin, and the ubiquitinproteasome system (215). The disruption of SOCS3 dependent negative feedback loop may
contribute to constant muscle STAT3 signaling activation in cachexia. Indeed, augmented
SOCS3 mRNA expression was reported in cachexia induced wasting muscle undergoing
an exacerbated proteolysis. Interestingly, the SOCS3 protein level was unchanged or even
reduced in this model, despite SOCS3 mRNA upregulation. This discrepancy can be
interpreted as a JAK/STAT-driven increase in proteolytic degradation of SOCS3 protein
(202). Taken together, these results strongly suggest STAT3 activation is the major
mediator of IL-6 dependent muscle wasting in cachexia.

The role of STAT3 activation in cachexia induced muscle protein synthesis suppression
still needs to be examined. Some evidence support IL-6 may indirectly suppress muscle
protein synthesis though its interference with the growth hormone/IGF-1 axis. Suppressed
serum IGF-1 and muscle IGF-1/Akt signaling was observed in ApcMin/+ mice, an IL-6
dependent cachexia model (18). Short term IL-6 administration to wild type mice and
humans reduced circulating IGF-1 levels. Transgenic mouse models overexpressing IL-6
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showed reduced growth, which is accompanied with high serum IL-6 level, low serum IGF1 levels and enhanced muscle SOCS3 mRNA expression (216). Neutralization of IL-6
activities in IL-6 transgenic mice rescued the circulating IGF1 levels and fully restored
growth, reinforcing the casual relationship between high IL-6 and low IGF1 levels in
plasma (216). Some existing evidence also suggests that AMPK signaling activation is
involved in IL-6 suppression of muscle protein synthesis. Late stage of cachectic ApcMin/+
showed increased muscle AMPK phosphorylation (18). Systemic IL-6 overexpression in
ApcMin/+ mice produced a dose-dependent suppression of mTOR signaling which
correspond to AMPK phosphorylation, and chronic IL-6 administration was enough to
induce AMPK phosphorylation in cultured myotubes (20). IL-6 suppression of myotube
mTOR activity was rescued by AMPK inhibition (20). However, induction of muscle and
myotube AMPK phosphorylation by LLC, which is another gp130 dependent cachexia
model, was not attenuated by IL-6 or gp130 signaling inhibition (19), which indicates IL6/gp130 signaling is not the only inducer of muscle AMPK signaling in cachexia.

2.6 Conclusion
Taken together, the current literature has many gaps in understanding the gp130
signaling regulation of muscle protein synthesis during mechanical stimuli induction of
hypertrophy and cachexia induced atrophy. gp130 cytokines IL-6 and LIF are necessary
for overload induction of muscle hypertrophy. A wide body of literature shows
gp130/STAT3 signaling in muscle hypertrophy has documented this role in satellite cell
proliferation and myogenesis, suggesting that IL-6 and LIF may induce muscle
hypertrophy through stimulating satellite cell proliferation during overload induced
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hypertrophic process. But the role of satellite cell’s role in mechanical stimuli induction of
muscle hypertrophy is questionable. Induction of mTOR signaling dependent protein
synthesis plays a central role in mechanical stimuli induction of muscle hypertrophy, but
the role gp130 signaling in muscle protein synthesis regulation by mechanical stimuli still
needs to be determined. Cancer cachexia induced muscle gp130/STAT3 signaling
activation is a key mediator of increased proteolysis and muscle mass loss. gp130 signaling
dependent cachexia models showed muscle AMPK signaling activation, and cachexia
activation of gp130 downstream signaling including STAT3 and NFκB can interact
mechanical signaling in skeletal muscles, which is associated with muscle protein synthesis
suppression and anabolic resistance in cachexia. But the potential interaction of gp130 with
anabolic signaling induced by mechanical stimuli in cachexia has not been determined.
Finally, the paradoxical role of gp130 signaling in muscle mass regulation has not been
clearly explained. The current proposal aims to the gp130 signaling regulation muscle
protein synthesis during mechanical stimuli induced hypertrophy and cachexia induced
atrophy process, and if gp130 cytokine regulation can differentially regulate protein
synthesis in cultured myotubes in a time and dose dependent manner through differentially
inducing upstream stimulator and suppressor of mTOR signaling.
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CHAPTER 3
SHORT TERM REGULATION OF MYOTUBE PROTEIN
SYNTHESIS BY IL-6 RELATED CYTOKINES

Song Gao and James A. Carson. To be submitted to American Journal of Physiology – Cell
Physiology
48

3.1 Abstract
IL-6 and LIF are members of the IL-6 family of cytokines that have recognized
paradoxical regulatory roles in skeletal muscle mass. Short term muscle production of IL6 and LIF are necessary for overload induced muscle hypertrophy, but the cellular
mechanisms involved in this regulation have not been completely identified. mTOR
signaling is a key controller of muscle protein synthesis, which is a driver of muscle mass
regulation. IL-6 family of cytokines regulates upstream activators of mTORC1 including
PI3K/Akt and ERK1/2, but the muscle mTOR signaling regulation of by the IL-6 family
of cytokines remains poorly understood. Therefore, we investigated the short term effects
of IL-6 and LIF induced cellular signaling on the regulation of C2C12 myotube mTORC1
signaling and protein synthesis. C2C12 myotubes were subjected to short term IL-6 or LIF
adminsitration. Signaling through the gp130 receptor and downstream effectors including
PI3K/Akt, STAT3 and ERK1/2 were investigated by administration of specific siRNA or
pharmaceutical inhibitors. Short term IL-6 or LIF administration increased myotube
protein synthesis and activated STAT3 and Akt-mTOR signaling pathways. The induction
of mTOR signaling and protein synthesis by IL-6 or LIF was attenuated by either gp130
siRNA knock-down or Akt signaling inhibition. Inhibition of STAT3 and mTOR signaling
did not block the IL-6/LIF induction of myotube protein synthesis. These results
demonstrate that short term IL-6 and LIF exposure can induce protein synthesis in culture
myotubes through the activation of gp130-Akt signaling pathway, and IL-6/LIF induced
Akt signaling can activate protein synthesis via mTOR independent mechanisms.

Keywords: IL-6, LIF, gp130, Akt, STAT3, protein synthesis
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3.2 Introduction
Skeletal muscle mass has a well-documented role in health and quality of life. To this
end, our knowledge of processes governing skeletal muscle mass, which involves the
balance between protein synthesis and degradation, have been rapidly expanding (1).
However, significant gaps remain in our understanding of skeletal muscle regulation of
protein turnover by systemic changes related to nutritional status, physical activity level,
inflammation and underlying disease. The effectors of these systemic conditions targeting
skeletal muscle protein turnover include mechanical stimuli, cytokines, growth factors, and
hormones (1, 217). The Interleukin-6 (IL-6) family of cytokines regulate many
physiological and pathological processes including immune system regulation,
inflammation, wound healing, and cell survival (2). Skeletal muscle serves as both a
biological target and source of the IL-6 family of cytokines. Two members of IL-6 family
of cytokines, IL-6 and Leukemia Inhibitory Factor (LIF), have recognized roles in both
skeletal muscle hypertrophy and atrophy (5, 218). Under physiological conditions, repeated
contractions during exercise, overload or muscle injury can induce plasma elevation and
muscle production of IL-6 and LIF (192, 219), which is thought to initiate important
autocrine and paracrine signaling that contributes to muscle hypertrophy by stimulate
myocyte proliferation and differentiation (7, 8, 192). Notably, the systematic IL-6 release
in response to exercise is in a temporal manner, increasing rapidly and remaining elevated
for a few hours (36, 220). Unlike the beneficial effects of short term actions of IL-6 and
LIF under physiological conditions, long term, pathological elevation of circulating IL-6
and LIF are tightly associated with muscle wasting (9, 118, 204, 221, 222). Currently, the
duration of IL-6 family of cytokines exposure is the plausible explanation of their
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differential effects on muscle mass regulation (5), but further research is still needed to
understand this complex dichotomy.

IL-6 and LIF can induce multiple intracellular signaling pathways via type I cytokine
receptors. These receptors contain a ligand binding α-receptor subunit and two signal
transducing β-receptor subunits, which contain a cytoplasmic signaling transducing
domain (2, 223). Glycoprotein 130 (gp130), a transmembrane protein, functions as the βreceptor subunits for the IL-6 and LIF. The ligand-receptor protein complex activates
constitutively bound Janus family kinases 2 (JAK2), which phosphorylates tyrosine
residues in the cytoplasmic domains of gp130 (2, 223). Phosphorylated gp130 can
phosphorylate and activate STAT3, leading to STAT3 dimerization and nuclear
translocation to induce target gene transcription. Notably, activated STAT3 signaling
induces SOCS3 expression. SOCS3 can suppress gp130 dependent signaling through direct
interaction with the kinase domain of JAK2 (2, 224), which forms a feedback inhibition
mechanisms that prevents constant induction of gp130 dependent signaling pathways under
physiological conditions (224). Phosphorylated gp130 also induces ERK1/2 signaling
through the recruitment of protein tyrosine phosphatase SHP-2 (Src homology domaincontaining protein tyrosine phosphatase 2), allowing SHP2 phosphorylation by JAK2.
Phosphorylated SHP2 then interacts with Grb2 (growth-factor receptor bound protein 2),
leading to the activation of the Ras-Raf-ERK1/2 cascade (2). Finally, IL-6 family of
cytokines can induce the phospho-inositide-3-kinase (PI3K)/Akt signaling axis (2), but the
molecular events mediating this regulation are not well understood. PI3K-Akt and ERK1/2
signaling induction by the IL-6 also demonstrates cell-type specific regulation. For
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example, PI3K/Akt activation could be observed in IL-6 treated multiple myeloma cells
(182-184), cardiac myocytes (185, 186) and basal carcinoma cells (187), but not HepG2
hepatoma cells (190).

Despite a growing body of evidence for cytokine induced gp130

signaling in cells, additional work is needed to better define the specific regulatory role of
this signaling pathway in skeletal muscle fibers.

The induction of protein synthesis has a well-documented role in skeletal muscle
hypertrophy (1). The mammalian target of rapamycin (mTOR), which functions in the
multi-protein complex, mTORC1, plays an essential role in the regulation of protein
synthesis and skeletal muscle mass (14). Activated mTORC1 can induce muscle protein
synthesis through the phosphorylation of the p70 ribosomal S6 kinase (p70S6K) and
eukaryotic initiation factor 4E binding protein (4E-BP1), leading to increased ribosomal
biogenesis and cap-dependent protein translation initiation (13). Many muscle
hypertrophic factors, such as growth factors like insulin-like growth factor 1 (IGF-1) and
mechanical stimuli, can stimulate muscle mTOR signaling and protein synthesis through
signaling pathways which converge on the phosphorylation of mTORC1 suppressor,
tuberous sclerosis 1/2 (TSC1/2). IGF-1 can activate PI3K-Akt signaling, which further
relieves TSC1/2 suppression on Ras homolog enriched in brain (Rheb) by phosphorylation
of TSC2, allowing Rheb to stimulate mTORC1 (14, 15). Induction of Extracellular signalRegulated Kinases 1/2 (ERK1/2) signaling by mechanical overload also phosphorylates
and inhibits TSC2, which contributes to early activation of muscle mTORC1 (16). Muscle
produced of IL-6 and LIF also plays a key role in muscle overload induced muscle
hypertrophy. However, whether they can stimulate mTOR signaling and subsequent protein
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synthesis still need to be investigated.

gp130 signaling induction by IL-6 family of cytokines have the potential to induce
upstream stimulators of mTOR, including Akt and ERK1/2 signaling pathways, leading to
the increased protein synthesis. In cardiomyocytes, induction of gp130 by IL-6 or LIF leads
to PI3K/Akt signaling activation and subsequent protein synthesis increase, which is a key
mechanism of IL-6 and LIF induction of cardiac hypertrophy (186, 225). IL-6 induction of
ERK1/2 signaling in cardiomyocytes has also been demonstrated to be necessary and
sufficient for its cardioprotection effect (186). However, the specific interaction between
gp130 and the PI3K/Akt-mTORC1 or ERK1/2-mTORC1 signaling axis within muscle
cells requires further investigation. The purpose of this study is to investigate if short term
administration of IL-6 family of cytokines, IL-6 or LIF will regulate myotube protein
synthesis by activating gp130 dependent signaling pathways. We hypothesized that short
term IL-6 or LIF will induce mTOR signaling and protein synthesis in cultured myotubes
by activation the gp130-Akt-mTOR signaling axis. The role of gp130 and its potential
downstream effectors, including PI3K-Akt-mTOR, STAT3, ERK1/2 signaling pathways
were investigated with the siRNA knock-down or the administration of their specific
pharmaceutical inhibitors.

3.3 Methods
Cell culture
C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin.
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To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4
days after they reached ∼95% confluence.

Cytokine treatment
Differentiated C2C12 myotubes were treated with different doses (5, 10, 20 or
100ng/ml) of IL-6 (Sigma-Aldrich, St. Louis, MO) or LIF (Thermo Scientific, Waltham,
MA) for different time periods (30min, 1h, 2h or 4h). To exclude the potential effects of
cytokines in serum, myotubes were maintained in serum-free condition during cytokine
treatment.

RNA interference
Three days after the onset of differentiation, C2C12 myotubes were transfected with
scramble siRNA (GE Dharmacon, Lafayette, CO, USA) or siRNA targeting to gp130,
STAT3, SOCS3 or AMPK (Santa Cruz Biotech, Santa Cruz, CA, USA) using Dharmafect
3 transfection reagent (GE Dharmacon) according to the manufacturer’s instructions.
Briefly, siRNA and transfection reagent were separately diluted in serum-free and
antibiotics-free DMEM and incubated at RT for 5min. The diluted transfection reagent was
then added to the siRNA mixture and allowed to complex with siRNA for 20 min. siRNAtransfection reagent complexes were then added to the antibiotics-free differentiation
medium, and myotubes were incubated for 24 h in the medium containing the transfection
mixture. The final concentration of siRNA was set at 100 nM.
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Intracellular signaling inhibition
To inhibit gp130 dependent STAT3, ERK1/2 and PI3K/Akt signaling pathways, and
Akt downstream target mTOR signaling pathway, STAT3 specific inhibitor LLL12 (1μM,
BioVision, Milpitas, CA, USA), ERK1/2 inhibitor PD98059 (20μM, Cell Signaling
Technology, Danvers, MA, USA), PI3K inhibitor specific wortmannin (2μM, Cell
Signaling Technology) or mTORC1 inhibitor rapamycin (20nM, Cell Signaling
Technology), was added to cell culture medium 1h before the IL-6 or LIF administration.
For each inhibitor, equal volume of DMSO was added into cell culture medium as vehicle
controls.

Western Blot
Western blot analysis was performed as previously described (226). Briefly, cells were
washed by ice-cold PBS and then scraped into ice-cold RIPA buffer [50 mM Tris, 150 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM NaF,
1 mM NaVO4, 1 mM β-glycerophosphate, and 1% protease inhibitor cocktail (SigmaAldrich)]. Cell lysates were homogenized on ice and centrifuged at 4°C, and supernatants
were collected. Protein concentrations were determined by the Bradford reagent (Bio-Rad)
following the manufacturer’s instructions. Protein were fractionated in SDSpolyacrylamide gels and transferred to polyvinylidene fluoride membranes. After the
membranes were blocked, antibodies for phosphorylated/total ERK1/2, STAT3, NF-κB p65,
Akt, p70S6K, 4EBP1, GAPDH (Cell Signaling Technology), gp130 (Santa Cruz
Biotechnology), and puromycin (Millipore, Billerica, MA) were incubated at dilutions
from 1:2,000 to 1:8,000 overnight at 4°C in 2% Tris-buffered saline-Tween 20 milk. Anti55

rabbit or anti-mouse IgG-conjugated secondary antibodies (Cell Signaling Technology)
were incubated with the membranes at 1:2,000 to 1:5,000 dilutions for 2 h in 2% Trisbuffered saline-Tween 20 milk. Enhanced chemiluminescence (Advansta, Menlo Park, CA)
developed by autoradiography was used to visualize the antibody-antigen interactions.
Blots were analyzed by measuring the integrated optical density (IOD) of each band with
ImageJ software (National Institutes of Health, Bethesda, MD).

Protein synthesis measurement
The myotube protein synthesis was determined by puromycin incorporation as
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was
added into cell culture media (1 μM final concentration) 30 min before protein collection.
The amount of puromycin incorporated into newly synthesized protein was determined by
Western blots. The protein samples from myotubes without puromycin labelling were used
as negative control.

RNA isolation, cDNA synthesis, and real-time PCR
RNA isolation was performed using Trizol Reagent (Thermo scientific) according to
the manufacturer’s instructions. cDNA synthesis, and real-time PCR were performed as
previously described, using reagents from Applied Biosystems (Foster City, CA, USA).
Quantitative real-time PCR analysis was carried out in 20-ul reactions consisting of 2 ×
SYBR Green PCR buffer (AmpliTaq Gold DNA Polymerase, Buffer, dNTP mix, AmpErase
UNG, MgCl2), 0.1ul of cDNA, RNase-free water, and 60 nM of each primer. The
sequences of SOCS3 primers set are5’-TGCAGGAGAGCTGATTCTAC-3’ (forward) and
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5’-TGACGCTCAACGTGAAGAAG (reverse). The sequence of GAPDH primers were
published elsewhere (19). Data were analyzed by ABI software using the cycle threshold
(CT), which is the cycle number at which the fluorescence emission is midway between
detection and saturation of the reaction. The SOCS3 data of each sample was normalized
by its GAPDH results.

Statistical Analysis
Student's t-test, one-way ANOVA, and two-way ANOVA (indicated in figure legends)
were used to examine the effects of stretch and culture conditions. Post hoc analyses were
performed with Student-Newman-Keuls method. For all comparisons, six replicates from
two independent experiments were included. P values < 0.05 were considered significant.

3.4 Results
Regulation of myotubes protein synthesis and mTOR signaling by different doses of
cytokines
To determine the effect of short term administration of IL-6 family of cytokines, IL-6
and LIF, on myotube protein synthesis and mTOR signaling, myotubes were treated with
different doses (5ng/ml, 10ng/ml, 20ng/ml and 100ng/ml) of IL-6 or LIF for 2h. IL-6
induced myotube protein synthesis in a dose dependent manner from 5ng/ml to 20ng/ml,
and 100ng/ml IL-6 showed no further induction (Fig. 1A and B). All doses of LIF
significantly increased myotube protein synthesis (Fig. 1A and B). Interestingly, 10ng/ml
LIF demonstrated the maximal induction of protein synthesis (Fig. 1 A and B). Unlike the
effects of IL-6 or LIF, TNF-α, which is not the member of IL-6 family of cytokines, did
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not change myotube protein synthesis at low doses (5ng/ml and 10ng/ml), and decreased
myotube protein synthesis at 20ng/ml. All doses of TNF-α increased phosphorylation of
NF-κB, the direct downstream target of TNF-α (Fig. 1C), which demonstrated the action
of TNF-α on myotubes. As mTORC1 signaling is the central regulator of protein synthesis,
phosphorylation was also measured using two downstream targets of mTORC1, p70S6K
and 4EBP1, in myotubes treated with different doses of IL-6 or LIF. Administration of low
dosage of IL-6 (5ng/ml, 10ng/ml and 20ng/ml) and LIF (5ng/ml and 10ng/ml) significantly
increased p70S6K phosphorylation (Fig. 1D), while high doses of IL-6 or LIF did not
change (100ng/ml IL-6 and 20ng/ml LIF) or even decreased (100ng/ml LIF) p70S6K
phosphorylation (Fig. 1D). However, either IL-6 or LIF administration did not change
4EBP1 phosphorylation (Fig. 1D). These results demonstrate short term IL-6 related
cytokines, IL-6 and LIF, are able to induce myotube protein synthesis and mTOR signaling
in a dose sensitive manner.

IL-6 family of cytokines can control the satellite cells expansion and myogenic
differentiation process by regulating cyclin D1 expression (36, 228, 229). Interestingly,
activation of mTOR signaling is also necessary for satellite cell proliferating and
myogenssis (230). To exclude the possibility that IL-6 or LIF regulates mTOR signaling
and protein synthesis only in the residual myoblasts in C2C12 myotube culture, we
measured the expression of cyclin D1, a molecular marker of proliferating myoblasts, and
myogenin, a molecular marker of differentiated myotubes. The cyclin D1 protein was
expressed in proliferating C2C12 myoblasts, but not in 4 days differentiated myotubes (Fig.
3.8A), and short term (2h) IL-6 or LIF administration did not induce cyclin D1 expression
58

in myotubes (Fig. 3.8A). Unlike cyclin D1, myogenin is only expressed in differentiated
myotubes, but not myoblasts (Fig. 3.8B). To exclude the residual myoblasts in myotube
culture, we differentiated myotubes for 8 days (Fig. 3.8C) or pretreated myotubes with
50μM cell cycle inhibitor Ara-C for 24h (Fig. 3.8C). Short term (2h) administration of IL6 or LIF increased protein synthesis in both 8 days differentiated myotubes (Fig. 3.8C) and
Ara-C pretreated myotubes (Fig. 3.8D). These results demonstrate that the protein synthesis
regulation by IL-6 or LIF happens in differentiated myotubes.

gp130 knock-down attenuated myotube protein synthesis induction by IL-6 or LIF
The IL-6 family of cytokines regulate intracellular signal transducers through the
interaction with their specific cytokine receptors and the gp130 transmembrane protein. To
determine whether gp130 is necessary for myotube protein synthesis induction by IL-6 or
LIF, we transfected myotubes with gp130 siRNA to inhibit gp130 dependent signaling
pathways. gp130 siRNA transfections significantly decreased myotube gp130 protein
expression, while IL-6 or LIF administration did not change gp130 protein level in either
control or gp130 siRNA transfected myotubes (Fig. 2A). Short term IL-6 and LIF exposure
increased protein synthesis in control siRNA transfected myotubes (Fig. 2B). However, IL6 or LIF did not significantly increase protein synthesis in gp130 siRNA transfected
myotubes (Fig 2B). Consistent with the changes in protein synthesis, short term IL-6 or
LIF significantly increased p70S6K phosphorylation in control siRNA, transfected
myotubes, but not in gp130 siRNA transfected myotubes (Fig. 2C). These results
demonstrate gp130 is necessary for IL-6 or LIF regulation of myotube mTOR signaling
and protein synthesis.
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Time course regulation of IL-6 and LIF on myotube gp130 dependent signaling pathways
and protein synthesis.
gp130 signaling induction results in the activation of multiple intracellular signaling
pathways, including STAT3, ERK1/2 and PI3K/Akt. STAT3 signaling activation then
induces expression of SOCS3, forming a negative feedback loop to prevent long term
gp130 signaling induction under physiological conditions. As we have demonstrated gp130
is necessary for myotube protein synthesis induction by IL-6 or LIF, we then investigated
the regulation of gp130 dependent signaling pathways by IL-6 and LIF. Myotubes were
treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 30min, 1h, 2h and 4h. The dosages of IL6 and LIF chosen here have demonstrated the maximal protein synthesis induction (Fig.
1A and B). The phosphorylation of STAT3 was induced as early as 30min after addition of
either IL-6 or LIF (Fig. 3A). The elevation of STAT3 phosphorylation lasted for 2h under
IL-6 exposure and for 1h under LIF exposure (Fig. 3A). Long term IL-6/LIF exposure (4h
for IL-6 and more than 2h for LIF) did not increase the STAT3 phosphorylation (Fig. 3A).
30min LIF administration elevated ERK1/2 phosphorylation, but ERK1/2 phosphorylation
did not maintain elevated after 1h, 2h or 4h LIF exposure (Fig. 3A). Neither time period of
IL-6 exposure was able to induce ERK1/2 phosphorylation. The Akt phosphorylation was
induced as early as 1h after the addition of either IL-6 or LIF which remained elevated after
1h to 4h IL-6 or LIF exposure (Fig. 3A).

Role of PI3K-Akt-mTOR signaling in IL-6/LIF regulation of myotube protein synthesis
Because both IL-6 and LIF were able to induce Akt phosphorylation, we use
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wortmannin, a PI3K/Akt signaling inhibitor, to examine the role of PI3K/Akt signaling in
IL-6 or LIF induction of myotube protein synthesis. Myotubes were pretreated with
wortmannin (1μM) for 1h before the addition of IL-6 or LIF. As expected, wortmannin
administration blocked the induction of myotube Akt phosphorylation by either IL-6 or LIF
(Fig. 4A). Furthermore, the wortmannin decreased basal phosphorylation of p70S6K, and
prevented IL-6 or LIF induction of p70S6K phosphorylation (Fig. 4B). Both IL-6 and LIF
increased protein synthesis in control (DMSO) condition (Fig. 4C). However, Wortmannin
decreased basal protein synthesis, and blocked protein synthesis induction by IL-6 or LIF
(Fig. 4C). These results demonstrate that PI3K/Akt signaling is necessary for myotube
mTORC1 signaling and protein synthesis induction by either IL-6 or LIF.

Akt signaling is well established and can induce muscle protein synthesis though the
activation of mTORC1. To examine the role of mTORC1 in myotube protein synthesis
induction by IL-6 and LIF, we pretreated myotubes with mTORC1specific inhibitor
rapamycin before the addition of IL-6 or LIF. The presence of rapamycin decreased basal
p70S6K phosphorylation and blocked the induction of p70S6K phosphorylation by IL-6 or
LIF (Fig. 4D). Interestingly, although rapamycin decreased basal myotube protein
synthesis, both IL-6 and LIF were able to significantly increase the protein synthesis in the
presence of rapamycin (Fig. 4E). These results demonstrate that IL-6 and LIF can induce
myotube protein synthesis though the mTORC1 independent mechanisms.

Role of STAT3 in IL-6/LIF regulation of myotube protein synthesis
Induction of STAT3 phosphorylation is a classical hallmark of gp130 dependent
61

cytokine signaling, and we have observed a short term induction of STAT3 phosphorylation
by both IL-6 and LIF (Fig. 3A). To examine the role of STAT3 signaling in IL-6 and LIF
regulation of myotube protein synthesis, we use STAT3 specific inhibitor LLL12 to block
the STAT3 signaling induction by IL-6 and LIF. Pretreatment of LLL12 decreased basal
STAT3 phosphorylation, and blocked the induction of STAT3 phosphorylation by 2h IL-6
administration (Fig. 5A). 2h LIF administration alone or in the presence of LLL12 did not
change the STAT3 phosphorylation (Fig. 5B). Interestingly, LLL12 decreased basal
myotube protein synthesis, but both IL-6 and LIF administration significantly increased
protein synthesis in the presence of LLL12 (Fig. 5C). Consistent with the changes in protein
synthesis, LLL12 also decreased myotube p70S6K phosphorylation, but there was still a
slight induction of p70S6K phosphorylation by IL-6 or LIF (Fig. 5D). These results
demonstrate that STAT3 signaling is necessary for maintaining basal myotube protein
synthesis, but is not involved in IL-6 or LIF induction of myotube mTORC1 signaling and
protein synthesis.

Role of ERK1/2 in LIF regulation of myotube protein synthesis
LIF induced transient elevation of ERK1/2 phosphorylation was observed. ERK1/2
signaling has the potential to activate muscle mTORC1 though the phosphorylation of
TSC1/2 (16). Therefore, ERK1/2 specific inhibitor, PD98059 was used to examine the role
of ERK1/2 signaling in LIF induction of myotube protein synthesis. Pretreatment of
PD98059 inhibited the induction of ERK1/2 phosphorylation by 30min LIF administration
(Fig. 6A). Consistent with previous observations (Fig. 3A), 2h LIF administration showed
no induction of ERK1/2 phosphorylation (Fig. 6B). PD98059 pretreated myotubes showed
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decreased ERK1/2 phosphorylation, which was independent of LIF (Fig. 6B). 2h LIF
administration increased protein synthesis in control group (Fig. 6C). Interestingly,
PD98059 alone was able to induce protein synthesis (Fig. 6C). However, combination of
PD98059 and LIF showed no further induction of protein synthesis (Fig. 6C). These results
demonstrate ERK1/2 signaling is not involved in LIF induction myotube protein synthesis,
and suggest potential crosstalk between ERK1/2 signaling and protein synthesis regulation
in cultured myotubes.

Role of SOCS3 in IL-6/LIF time course regulation of myotube protein synthesis
We have observed that both IL-6 and LIF only induced short term increase in STAT3
phosphorylation, suggesting the induction of SOCS dependent feedback inhibition of
gp130 signaling. Therefore, we examined the IL-6/LIF time course regulation of SOCS3
expression. The mRNA expression of SOCS3 was induced by both IL-6 and LIF as early
as 30min exposure, and 1h IL-6 or LIF administration demonstrated the maximum
induction of SOCS3 expression (Fig. 7A), which demonstrated the induction of SOCS3
dependent feedback inhibition of gp130 signaling. Because we have demonstrated that
gp130 is necessary for IL-6/LIF induction of myotube protein synthesis, we further
examined the time course regulation of myotube protein synthesis by IL-6 or LIF. Both IL6 and LIF increased myotube protein synthesis as early as 1h, and 2h IL-6 or LIF exposure
resulted in further protein synthesis induction (Fig. 7B). Interestingly, 4h exposure of either
IL-6 or LIF did not further increase myotube protein synthesis, but showed less induction
compared with 2h IL-6/LIF exposure (Fig.7B). These results demonstrate that IL-6 and LIF
only results in short term induction of myotube protein synthesis, which coincide with the
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increased SOCS3 expression..

To determine whether IL-6 or LIF induced SOCS3 can block their activation of
myotube protein synthesis, we inhibited SOCS3 expression by siRNA transfection before
the short term IL-6 and LIF administration. SOCS3 siRNA transfected decreased basal
SOCS3 mRNA level and attenuated the IL-6/LIF induction of SOCS3 expression (Fig. 7C),
but SOCS3 siRNA did not fully block the IL-6/LIF induction of SOCS3 expression (Fig.
7C). We also compared the effect of 4h IL-6 or LIF administration on protein synthesis in
control or SOCS3 siRNA transfected myotubes. 4h administration of IL-6 and LIF resulted
a slight induction of protein synthesis (Fig. 7D). SOCS3 siRNA transfection also increased
basal myotube protein synthesis, IL-6 and LIF treatment resulted in further protein
synthesis increased in SOCS3 siRNA transfected myotubes (Fig. 7D). These results
demonstrate that SOCS3 is a suppressor of protein synthesis in myotubes and can prevent
the long term protein synthesis induction by IL-6 or LIF.

3.5 Discussion
IL-6 family of cytokines plays a paradoxical role in skeletal muscle mass regulations.
Under physiological conditions, skeletal muscle production of IL-6 family of cytokines,
including IL-6 and LIF, are important regulators of skeletal muscle hypertrophy. The
muscle protein synthesis regulation through Akt-mTOR signaling is an acknowledged
controller of skeletal muscle mass. However, the regulation of skeletal muscle protein
synthesis by IL-6 family of cytokines has not been fully investigated. In this study, we
report the important and novel finding that administration of myotubes with IL-6 family of
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cytokines, IL-6 or LIF, resulted in an induction of protein synthesis, which was blocked by
the inhibition on gp130 or its downstream PI3K-Akt signaling. Interestingly, inhibition of
Akt downstream target mTORC1 signaling only decreased basal myotube protein synthesis,
but did not blocked protein synthesis induction by IL-6 or LIF. While STAT3 signaling is
necessary for maintaining basal protein synthesis, we report that STAT3 signaling
inhibition did not block thr protein synthesis induction by IL-6 or LIF. Overall, these results
demonstrate that short term IL-6 family of cytokines, IL-6 or LIF, can transiently increase
myotube protein synthesis through the activation of gp130-Akt signaling. Both IL-6 and
LIF are able to induce protein synthesis through mTOR independent mechanisms.

Mechanical stimuli from overload or resistant exercise results in increased muscle
production of IL-6 and LIF, which can regulate muscle hypertrophic process though
autocrine/paracrine manner (7, 192, 231). Both LIF and IL-6 knockout mice demonstrated
an impaired hypertrophy to overloading, (7, 8). It has been well established that IL-6 and
LIF play a key role in satellite proliferation and differentiation, which is believed to be the
major mechanisms of IL-6 and LIF regulation of muscle hypertrophy. IL-6 activates murine
satellite cell proliferation via regulation of cyclin D1 and c-myc (193). The overload
induced muscle IL-6 expression also plays a key role in satellite cell differentiation when
cooperated with IL-4 (8, 228). Similarly, exogenous LIF can induce human myoblast
proliferation via induction of the cell proliferation associated factors c-Myc and JunB (192).
Although the induction of mTOR signaling plays a key role in satellite cell proliferation
(230), there is no compelling evidence demonstrating that IL-6 or LIF can regulate protein
synthesis in skeletal muscle cells. IL-6 and LIF can indirectly stimulate anabolic side
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muscle protein turnover regulation by sensitizing the insulin/IGF-1 action on Akt signaling
pathway (232-234), or facility glucose input through Akt-mTORC2 signaling (235, 236),
but it is still unknown whether IL-6 family of cytokines can regulate protein synthesis in
differentiated myofibers, thus contributes to the IL-6 and LIF regulation of muscle
hypertrophy. In the present study, we report both IL-6 and LIF are enough to alter protein
synthesis in cultured myotubes. The 4-days differentiated myotubes showed no expression
of myoblasts markers of Cyclin D1, and high expression of myotube marker, Myogenin.
Most importantly, unlike the upregulation of Cyclin D1 by IL-6 in myoblasts (228), short
term IL-6 or LIF expression did not induce Cyclin D1 expression in 4-days differentiated
myotubes, which exclude the possibility that IL-6 and LIF induce protein synthesis in
residual myoblasts in cell culture. Our results demonstrate that either IL-6 or LIF alone are
enough to induce protein synthesis in cultured myotubes, which provide another potential
mechanism underlying the mechanical stimuli regulation of muscle protein synthesis and
IL-6 family of cytokines regulation of muscle hypertrophy. Interestingly, the overload
induction of muscle protein synthesis was not attenuated in IL-6 deficient mice, which
demonstrate the direct protein synthesis induction by IL-6 is not the only mechanism (8).
Indeed, multiple biochemical events have been identified as mediators of protein synthesis
induction by mechanical stimulus. Further work is needed to determine whether regulation
of protein synthesis by IL-6 or LIF contributes to the mechanical stimuli induced muscle
hypertrophy.

The IL-6 family of cytokines regulate intracellular signal transducers through the
interaction with their specific cytokine receptors and the gp130 transmembrane protein.
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The binding of IL-6 family of cytokine on receptor complex containing its specific receptor
and gp130 causes the phosphorylation of gp130 intracellular tyrosine residues and STAT3
by Janus kinases, JAK1 and JAK2 (2). This active receptor complex also leads to activation
and the Ras-Raf-ERK /MAPK pathway and the PI3K/Akt pathway (2, 237). Intracellular
signaling pathways initiated by gp130 multiple cellular processes including growth,
differentiation, and apoptosis (238). However, relatively little is known about its role in
muscle protein synthesis regulation. Pathological activation of gp130 signaling is a key
regulator of muscle wasting during LLC induced cancer cachexia, but is not involved in
muscle protein synthesis suppression (19). Our previous work suggest that gp130 signaling
may plays an important role in mechanical stretch regulation of myotube protein synthesis,
even under LLC induced atrophic environment (226). Here, we report that gp130 knockdown blocked the IL-6/LIF induction of both mTOR signaling and protein synthesis in
cultured myotubes. This finding further demonstrates that gp130 is required for protein
synthesis induction by IL-6 and LIF, and further strengthens the anabolic role of gp130 in
protein synthesis regulation (226).

The PI3K-Akt is the most well defined hypertrophic signaling pathway which leads to
the anabolic shift of muscle protein turnover regulation (14, 54). Once activated, PI3K-Akt
signaling can phosphorylate TSC2, thus relieves suppression of TSC1/2 protein complex
on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTORC1 and
subsequent protein synthesis (14, 15). Activation of Akt also downregulate the expression
of MAFbx and MuRF1 by inhibiting the transcriptional activity of FOXO3, which in turn
suppress the ubiquitin-proteasome system induced muscle protein degradation muscle
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protein degradation (239). IL-6 family of cytokines have to potential to activate Akt
signaling, but this regulation seems to be cell-type specific and the mechanism is still
poorly understood (183-188, 240). We report that both IL-6 and LIF administration
increased Akt phosphorylation. Most importantly, inhibition of Akt signaling blocked
protein synthesis induction by IL-6 or LIF. These findings demonstrate that IL-6 family of
cytokines are able to activate Akt signaling, which plays an important role in IL-6/LIF
induction in skeletal muscle cells. Our results are similar with previous reports
demonstrating that Akt signaling is a central mediator of IL-6 and LIF regulation of cardiac
myocyte survival and hypertrophy (185, 186). Taken together, these results highlight the
importance of PI3K/Akt signaling activation by gp130 signaling in short term IL-6/LIF
activation of protein synthesis in culture myotubes. However, future work is still required
determine the role of gp130-Akt signaling in IL-6/LIF regulation of skeletal muscle
hypertrophy.

mTOR signaling is known to play a central role in regulating skeletal muscle protein
synthesis and essential for muscle hypertrophy response to growth factors. mTOR signaling
activation induces muscle protein synthesis though the phosphorylation of its two
downstream factors, p70S6K and 4EBP1 (241). Phosphorylation of S6K1 results in hyperphosphorylation of the ribosomal protein RPS6, which assists in the translation of mRNA
encoding proteins of translation apparatus (241, 242). The phosphorylation of 4EBP1
results its dissociation from eIF4E, allowing the formation of eIF4E-eIF4G protein
complex, a key step of cap-dependent protein translation initiation (243). Here, we showed
the induction of phosphorylation of p70S6K by IL-6 and LIF, which can be inhibited by
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gp130 knock-down or Akt signaling inhibition. These results clearly demonstrate that IL-6
family of cytokines is able to induce a gp130-PI3K-Akt-mTOR signaling axis in cultured
myotubes which has been shown in several studies in cardiac myocytes (185, 186).
Inhibition of mTOR signaling decreased the protein synthesis in both control and IL-6/LIF
treated myotubes, which further support the central role of mTOR signaling in protein
synthesis regulation. Surprisingly, mTOR signaling inhibition did not completely block the
protein synthesis induction by IL-6 or LIF, which highlights the role of mTOR independent
mechanisms in IL-6/LIF induction of myotube protein synthesis. Interestingly, the IL-6/LIF
induction of protein synthesis was completely blocked by PI3K inhibitor wortmannin,
suggesting this mTOR independent mechanisms is still under the control of PI3K/Akt
signaling. Previous studies have demonstrated that mTOR is not the only mediator of
muscle protein synthesis induction by nutritional supplementation, including glucose and
branched chain amino acids (244, 245). Administration of glucose or leucine to diabetic
rats resulted in the formation of eIF4E-eIF4G protein complex and increased protein
synthesis in skeletal muscles in the absence of increases in p70S6K or 4E-BP1
phosphorylation (244, 245), and rapamycin only partially inhibited leucine induced muscle
protein synthesis (62). A potential mechanism by which leucine stimulates protein
synthesis independent of mTOR activity is through direct phosphorylation of eIF4G (246,
247). Interestingly, both IL-6 and LIF can stimulate muscle glucose uptake, which involves
the activation of PI3K/Akt signaling (235, 236). Therefore, it is possible that the IL-6/LIF
stimulate myotube uptakeglucose uptake is a key mechanism of mTORC1 independent
protein synthesis induction. Finally, the ERK1/2 or p38 MAPK signaling cascade can
induce eIF4E phosphorylation, of rRNA transcription and ribosomal biogenesis
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independent of mTOR (248-250). However, the role of glucose translocation and MAPK
signaling in IL-6/LIF induced mTOR independent protein synthesis induction still need to
be investigated.

STAT3 signaling is a well-defined downstream target of IL-6-gp130 signaling (251).
Once activated, STAT3 proteins dimerize and translocate to nucleus, where it promotes the
transcription of downstream genes that are responsible for a variety of cellular functions
including proliferation, migration and the prevention of apoptosis (36, 252). STAT3 play a
critical role during development and its deletion lead to early embryonic lethality (253).
STAT3 activation is also required for hypertrophy under the action of IL-6 requires (36),
by regulating the transcription of myogenesis genes (229). However, to our knowledge, no
evidence exists demonstrating a direct regulation of STAT3 on mTOR signaling or protein
synthesis. Rather, we found that STAT3 inhibition did not block the myotube mTOR
signaling and protein synthesis induction by IL-6 or LIF, which demonstrate STAT3 is not
involved in IL-6/LIF regulation of myotube protein synthesis. Interestingly, STAT3
inhibition resulted in a suppression of mTOR signaling and protein synthesis in both control
and IL-6/LIF treated myotubes, which suggest that STAT3 is involved in maintaining basal
protein synthesis in myotubes. These results in conjunction with the previous report and
demonstrate that STAT3 signaling plays a permissive role in IL-6 induction of PI3K/Akt
signaling in primary cultured renal proximal tubule cells (254). Several other studies also
suggest that downregulation of STAT3 signaling may inhibit protein synthesis indirectly,
by disrupting the glucose metabolism. In cancer cells, STAT3 signaling induction is critical
for increased glucose uptake and aerobic glycolysis (255), which have been demonstrated
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a positive regulator mTOR signaling and protein synthesis (245, 256). However, the
potential cross talk between STAT3 signaling and protein synthesis in skeletal muscle needs
to be further defined.

ERK1/2 is another downstream effector of gp130 signaling. Previous work has
demonstrated ERK1/2 can induce muscle proteins synthesis in response to mechanical
stimulus, through both mTOR dependent and independent mechanisms (16, 257). ERK1/2
signaling induction is also necessary for LIF and mechanical stretch induced cardiac
muscle hypertrophy (258). However, our observations did not support that essential role of
ERK1/2 signaling in IL-6/LIF regulation of protein synthesis in myotubes. Only LIF
demonstrated a very short induction of ERK1/2 phosphorylation, while both IL-6 and LIF
were able to induce protein synthesis at the time points when LIF phosphorylation was on
basal level. Furthermore, ERK1/2 inhibitor had no effect on protein synthesis in LIF treated
myotubes. Interestingly, ERK1/2 inhibitor alone increased myotube protein synthesis.
These results suggest that potential crosstalk between ERK1/2 signaling and protein
synthesis exist, but ERK1/2 seems to be independent from IL-6/LIF regulation of protein
synthesis in myotubes.

SOCS3, whose expression is induced by STAT3 activation, can inhibit STAT3
signaling by binding the phosphotyrosines of JAK2, thus physically block binding of
STAT3 to JAK2 (2), thus prevented the long term induction of gp130 signaling. Several
previous studies suggest SOCS3 is a potential catabolic factors of skeletal muscle mass
regulation. Long term in vivo IL-6 overexpression results in muscle protein synthesis
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suppression and muscle wasting, which is associated with SOCS3 expression. Increased
SOCS3 expression is observed in wasting skeletal muscles during cancer cachexia and
sarcopenia (125, 214, 259). Further studies suggest that SOCS3 mays play an indirect role
in muscle protein synthesis regulation by interacting with IGF-1-PI3K-Akt signaling
pathways. For example, SOCS3 can target and degrade IRS-1 in inflammation-induced
insulin resistance possibly via the elongin BC ubiquitin-ligase (260). Consistent with
previous reports (204, 228), IL-6 and LIF induced a transient increase in STAT3
phosphorylation, which coincided with the induction of SOCS3 expression by both IL-6
and LIF. These results demonstrated that both IL-6 and LIF can activate the SOCS3
dependent negative feedback mechanisms of gp130 signaling. Interestingly, we found
similar time course regulation of IL-6 and LIF on myotube protein synthesis: it went to
peak 2h post the addition of IL-6 or LIF and showed a trend to go back to basal level after
longer IL-6 or LIF exposure. Most importantly, we report that SOCS3 siRNA known-down
increased basal myotube protein synthesis, and SOCS3 siRNA knock-down resulted in
longer term induction of IL-6 and LIF on myotube STAT3 phosphorylation and protein
synthesis. These results demonstrate that the IL-6/LIF induced SOCS3 expression is an
important negative regulator of myotube protein synthesis and further strengthen the
catabolic role of SOCS3 in muscle mass regulation. However, it is still unknown whether
SOCS3 can inhibit myotube protein synthesis through inhibiting gp130 signaling or IRS1/Akt signaling. More work is required to investigate the potential interplay of SOCS3 with
gp130 signaling and anabolic signaling pathways in skeletal muscles.

In summary, we examined the short term regulation of IL-6 family of cytokines, IL-6
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and LIF, on protein synthesis in cultured myotubes. Both IL-6 and LIF are able to activate
myotube mTOR signaling and protein synthesis in a time and dose sensitive manner. The
gp130 receptor and PI3K/Akt signaling pathway is critical for this protein synthesis
induction, as their inhibition blocked the IL-6 and LIF induction of protein synthesis.
Interestingly, although IL-6 and LIF induced gp130-Akt signaling axis activated mTORC1
signaling and can induce protein synthesis through mTORC1 independent mechanisms.
STAT3 signaling plays a regulatory role in maintaining basal myotube protein synthesis,
but STAT3 signaling is independent from the protein synthesis induction by IL-6 and LIF.
Finally, IL-6/LIF induced SOCS3 expression is an inhibitor of protein synthesis, thus
prevent long term protein synthesis activation by IL-6 or LIF. Our work provide a new
insights into the involvement of IL-6 family of cytokines in muscle mass regulation, and
further strengthen the anabolic role of physiological IL-6/gp130 signaling induction in
muscle mass regulation. Further work is necessary to determine the potential mTOR
independent mechanisms underlying IL-6/LIF induction of protein synthesis, and the role
of protein synthesis induction by IL-6 or LIF in muscle regeneration and muscle
hypertrophy.

3.6 Figure Legends
Figure 3.1: Myotube protein synthesis and mTOR signaling regulation by short term
exposure of different cytokines. C2C12 myotubes were treated with different doses (5,
10, 20, 100ng/ml) of IL-6, LIF and TNF-α for 2h. A. The protein synthesis was determined
by puromycin incorporation. Dash lines represent different positions on the same gel. B.
Quantified results of puromycin incorporation in A. *: p < 0.05 vs. control group, #: p <
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0.05 vs. 5ng/ml and 10ng/ml groups, $: p < 0.05 vs. all other groups, one-way ANOVA. C.
The phosphorylation of NF-κB in myotubes treated with different doses of TNF-α were
measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA. D. The
phosphorylation of p70S6K and 4EBP1 in myotubes treated with different doses of IL-6 or
LIF were measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA.

Figure 3.2: Role of gp130 in IL-6/LIF regulation of myotubes protein synthesis and
mTORC1 signaling. C2C12 myotubes were transfected with 100nM control or gp130
siRNA for 24h, which was followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml).
A. gp130 protein level in control or gp130 siRNA transfected myotubes treated
with/without IL-6/LIF. #: main effect of gp130 siRNA, two-way ANOVA. B. Protein
synthesis in control or gp130 siRNA transfected myotubes treated with/without IL-6/LIF
was determined by puromycin incorporation. *: p < 0.05 vs. all other groups, two-way
ANOVA. C. Phosphorylation of p70S6K in in control or gp130 siRNA transfected
myotubes treated with/without IL-6/LIF was measured by western blot. *: p < 0.05 vs. all
other groups, two-way ANOVA.

Figure 3.3: Time course regulation of IL-6 or LIF on myotube gp130 dependent
signaling pathways. C2C12 myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml)
for different time periods (30min, 1h, 2h or 4h). The phosphorylation of STAT3, ERK1/2
and Akt were measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA.

Figure 3.4: Role of Akt-mTORC1 signaling in short term IL-6/LIF regulation of
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myotube protein synthesis. C2C12 myotubes were pre-treated with PI3K/Akt signaling
inhibitor, wortmannin (1μM) or mTORC1 inhibitor, rapamycin (10nM) for 1h, which was
followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml). The equal volume of
DMSO was added into cell culture medium of control group. A-B. Phosphorylation of Akt
(A) and p70S6K (B) in myotubes treated with/without IL-6/LIF or wortmannin was
measured by western blots. Dash lines represent different positions on the same gel. *: p <
0.05 vs. all other groups, two-way ANOVA. C. The protein synthesis in myotubes treated
with/without IL-6/LIF or wortmannin was determined by puromycin incorporation. *: p <
0.05 vs. all other groups, two-way ANOVA. D. Phosphorylation of p70S6K in myotubes
treated with/without IL-6/LIF or rapamycin was measured by western blots. Dash lines
represent different positions on the same gel. *: p < 0.05 vs. all other groups, two-way
ANOVA. E. The protein synthesis in myotubes treated with/without IL-6/LIF or rapamycin
was determined by puromycin incorporation. #: main effect of rapamycin, $: main effect
of IL-6/LIF, two-way ANOVA.

Figure 3.5: Role of STAT3 signaling in IL-6/LIF regulation of myotube protein
synthesis. C2C12 myotubes were pre-treated with STAT3 signaling inhibitor, LLL12 (1μM)
for 1h, which was followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml). A.
Phosphorylation of STAT3 in myotubed treated with/without LLL12 or IL-6 for 2h. *: p <
0.05 vs. all other groups, two-way ANOVA. B. Phosphorylation of STAT3 in myotubed
treated with/without LLL12 or LIF for 2h. #: main effect of LLL12, two-way ANOVA. C.
Protein synthesis in myotubes treated with/without LLL12, IL-6 or LIF was determined by
puromycin incorporation. Dash lines represent different positions on the same gel. #: main
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effect of LLL12, $: main effect of IL-6/LIF, two-way ANOVA. D. Phosphorylation of
p70S6K in myotubes treated with/without LLL12, IL-6 or LIF. Dash lines represent
different positions on the same gel. #: main effect of LLL12, $: main effect of IL-6/LIF,
two-way ANOVA.

Figure 3.6: Role of ERK1/2 in LIF regulation of myotube protein synthesis. C2C12
myotubes were pre-treated with ERK1/2 signaling inhibitor, PD98059 (20μM) for 1h,
which was followed with 30 min (A) or 2h (B and C) exposure of LIF (10ng/ml). A. The
phosphorylation of ERK1/2 in myotube with/without 1h PD98059 pretreatment and 30min
LIF administration was determined by western blot. Dash lines represent different positions
on the same gel. *: p < 0.05 vs. control group, one-way ANOVA. B. The phosphorylation
of ERK1/2 in myotube with/without 1h PD98059 pretreatment and 2h LIF administration
was determined by western blot. Dash lines represent different positions on the same gel.
#: main effect of PD98059, two-way ANOVA. C. Protein synthesis was determined by
puromycin incorporation. Dash lines represent different positions on the same gel. *: p <
0.05 vs. control group, two-way ANOVA.

Figure 3.7: Role of SOCS3 in time course regulation of IL-6/LIF on myotube protein
synthesis. A. mRNA expression of SOCS3 in myotubes treated with IL-6 (20ng/ml) or LIF
(10ng/ml) for different time periods (30min, 1h, 2h and 4h) was determined by RT-PCR. *:
p < 0.05 vs. control group, #: p < 0.05 vs. all other groups, one-way ANOVA. B. The protein
synthesis in myotubes treated with IL-6 (20ng/ml) or LIF (10ng/ml) for different time
periods (1h, 2h and 4h) was determined by puromycin incorporation. *: p < 0.05 vs. control
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group, #: p < 0.05 vs. all other groups, one-way ANOVA. C-D. C2C12 myotubes were
transfected with control or SOCS3 siRNA for 24h, which was followed with 1h (C) or 4h
(D) IL-6 (20ng/ml) or LIF (10ng/ml) administration. The SOCS3 mRNA expression (C)
was measured by RT-PCR, [and puromycin incorporation (E) were measured by western
blot. *: main effect of IL-6/LIF, #: main effect of SOCS3 siRNA, two-way ANOVA.

Fig. 3.8: The IL-6 or LIF regulation on protein synthesis happens in differentiated
myotubes. A: The protein expression of Cyclin D1 in myoblasts and 4 days differentiated
myotubes treated with/without IL-6 (20ng/ml for 2h) or LIF (10ng/ml for 2h). B. Protein
expression of Myogenein in myoblasts, 4 days and 8 days differentiated myotubes. C. 8
days differentiated myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 2h.
The protein synthesis was measured by puromycin incorporation. *: p < 0.05, student’s ttest. D. C2C12 myotubes were incubated in differentiation medium supplemented with cell
cycle inhibitor Ara-C (50μM) for 24h after 2 days differentiation. After 24h recovery period,
myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 2h after Ara-C incubation.
The protein synthesis was measured by puromycin incorporation. *: p < 0.05, student’s ttest.
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Figure 3.1 ． Myotube protein synthesis and mTOR
signaling regulation by short term exposure of
different cytokines.
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Figure 3.1 ． Myotube protein synthesis and mTOR
signaling regulation by short term exposure of different
cytokines (continued).
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Figure 3.2: Role of gp130 in IL-6/LIF regulation of myotubes
protein synthesis and mTORC1 signaling.
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Figure 3.3: Time course regulation of IL-6 or LIF on myotube
gp130 dependent signaling pathways.
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Figure 3.4: Role of Akt-mTORC1 signaling in short term IL6/LIF regulation of myotube protein synthesis.
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Figure 3.4: Role of Akt-mTORC1 signaling in short
term IL-6/LIF regulation of myotube protein synthesis
(continued).
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Figure 3.5: Role of STAT3 signaling in IL-6/LIF regulation of myotube
protein synthesis.
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Figure 3.5: Role of STAT3 signaling in IL-6/LIF regulation of
myotube protein synthesis (continued).
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Figure 3.6: Role of ERK1/2 in LIF regulation of myotube protein
synthesis.
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Figure 3.7: Role of SOCS3 in time course regulation of IL-6/LIF on
myotube protein synthesis.
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Figure 3.7: Role of SOCS3 in time course regulation of IL-6/LIF
on myotube protein synthesis (continued).
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Figure 3.8: The IL-6 or LIF regulation on protein
synthesis happens in differentiated myotubes
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CHAPTER 4

LONG TERM REGULATION OF MYOTUBE PROTEIN
SYNTHESIS BY IL-6 RELATED CYTOKINES

Song Gao and James A. Carson. To be submitted to American Journal of Physiology –
Cell Physiology
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4.1 Abstract
The long term pathological elevation of IL-6 family of cytokines, including IL-6 and
LIF, play a key role in muscle wasting during cachexia. The cachexia induced muscle
wasting is caused by disrupted regulation of protein turnover, including both protein
degradation activation and protein synthesis suppression. Previously work has
demonstrated that IL-6 and LIF are able to induce muscle protein degradation by activating
gp130-STAT3 signaling pathways. However, a complete understanding about their role in
cachexia induced muscle protein synthesis suppression is limited. Therefore, we
investigated the long term regulation of IL-6 and LIF on protein synthesis in cultured
myotubes. C2C12 myotubes were treated with different doses of IL-6 or LIF for 24h. The
role of STAT3 and AMPK signaling were investigated by pharmaceutical inhibition or
siRNA knockdown. Both long term IL-6 and LIF exposure decreased myotube protein
synthesis in a dose dependent manner, which is associated with the suppression of AktmTOR signaling and activation of AMPK signaling. STAT3 signaling suppression had no
effects on IL-6/LIF suppression of myotube protein synthesis. Inhibition of AMPK
signaling by compound C during IL-6 or LIF treatment rescued the mTORC1 signaling and
protein synthesis suppression by IL-6 or LIF. However, longer AMPK signaling
suppression by siRNA knockdown decreased basal myotube protein synthesis. We also
demonstrated that in vivo IL-6 overexpression can inhibit skeletal muscle mTORC1
signaling and protein synthesis. These results demonstrate long term IL-6 and LIF exposure
is enough to suppress protein synthesis in skeletal muscle cells, which is not dependent on
STAT3 signaling. The different results from two AMPK signaling suppression experiments
demonstrate that hyper-activation of AMPK signaling by IL-6 and LIF mediates IL-6/LIF
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suppression mTOR signaling and protein synthesis, but basal AMPK signaling activity still
play a role in maintaining protein synthesis in myotubes. F

Key words: IL-6, LIF, muscle atrophy, mTOR, protein synthesis, STAT3, AMPK
4.2 Introduction
Cancer cachexia is metabolic syndrome that occurs in approximately 80% of cancer
patients and accounts for 22–30% of cancer related death (31, 261). Cancer cachexia is
characterized by unintentional loss of body weight caused by severe muscle wasting and
loss of adipose tissue (31). Chronic inflammation is associated with diseases that induce
muscle wasting, including cancer (6). Several cytokines are chronically up-regulated
during cachexia in both human cancer and animal models, including IL-6, LIF, TNF-α, IL1β, CNTF, IFN-γ and IL-10 (262, 263). It is clear that the pathological elevation of these
cytokines play a vital role in the development of muscle atrophy in cachexia (18, 125, 264,
265). However, further research is needed to understand whether inflammatory cytokines
exert direct or indirect effects on skeletal muscle, in altering protein turnover and inducing
wasting.

A large body of work has demonstrated the key role of long term elevated IL-6 and
LIF has a key role in muscle wasting with cancer cachexia (118, 125, 214, 266, 267), and
inhibition of IL-6 dependent signaling have now been considered as valuable therapeutic
strategies to combat muscle wasting associated with chronic inflammatory conditions (265).
The overexpression of IL-6 in transgenic mice and constant in vivo IL-6 infusion are
enough to induce muscular atrophy (212, 268). A recent study also highlighted the
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importance of LIF, another member of IL-6 family of cytokine, in cachexia induced muscle
wasting (204). However, further research is needed to understand whether IL-6 and LIF
exert direct or indirect effects on muscle wasting and muscle protein turnover in cachexia.

Skeletal muscle mass is regulated by a balance of protein synthesis and protein
degradation, termed as protein turnover. Altered protein turnover is an established
regulatory point of both skeletal muscle mass loss and muscle growth. The skeletal muscle
loss during cancer cachexia is associated with the activation of skeletal muscle protein
degradation and the suppression of muscle protein synthesis. Whereas several
inflammatory cytokine and their downstream signaling pathways, including TNF-α/ NFκB (143, 269), IL-6-glycoprotein 130-STAT3 (19, 202, 214, 266), and p38 MAPK (146),
have been identified as important regulators of cachexia induced muscle protein
degradation, gaps remain in our understanding of the mechanisms underlying the cachexia
suppression of muscle protein synthesis.

mTOR signaling pathway is the central regulator of muscle protein synthesis and
muscle mass (14). mTOR, which function as a protein complex mTORC1, is the central
regulator of protein synthesis can induce muscle protein synthesis through the
phosphorylation of the p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor
4E binding protein (4E-BP1), leading to increased ribosomal biogenesis and cap-dependent
translation initiation (13). mTORC1 integrates multiple upstream signaling pathways
involved in muscle mass regulation. In cancer cachexia, the dysregulation of protein
synthesis is tightly associated with suppression mTOR signaling as assessed by decreased
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phosphorylation of both 4E-BP1 and p70S6K1 (18, 19, 270). mTOR integrates several
different upstream signaling pathways regulation muscle protein synthesis and muscle
mass (241). mTOR signaling can be positively regulated by IGF-PI3K-Akt signaling (14,
15), and negatively regulated by AMPK signaling (17). Suppression of muscle mTOR
signaling has been demonstrated in cachexia patients and different animal models of cancer
cachexia (118). The muscular atrophy induced by IL-6 infusion is associated with the
reduction in p70S6K phosphorylation (212, 268). But the upstream signaling pathways
regulating mTOR signaling during cancer cachexia still need to be determined.

The IL-6 family of cytokines signals through gp130 by forming either a heterodimer
or homodimer with the cytokine, its receptor, and gp130. Gp130 dimerization leads to
activation of several intracellular signaling pathways (238). STAT3 signaling is a typical
molecular hallmark IL-6/gp130 signaling induction. The role STAT3 signaling in cachexia
induced muscle wasting has been well established (202, 214, 267). Present data
demonstrate that STAT3 activation is necessary and sufficient for muscle wasting by cancer
cachexia (202, 214). Induction of caspase-3, myostatin, and the ubiquitin-proteasome
system are key mechanisms of STAT3 signaling regulation of muscle wasting during
cachexia (202, 214, 215). However, no compelling evidence exist demonstrating the direct
regulation of IL-6/STAT3 on muscle protein synthesis, and the role of IL-6 or STAT3
signaling in muscle protein synthesis suppression during cancer cachexia is poorly
understood. In addition to the classical gp130 dependent signaling cascades, Long term IL6 exposure also results in AMPK signaling activation in skeletal muscle cells (20). AMPK
signaling can inhibit mTORC1 via the phosphorylation of different sites of TSC2 and
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mTORC1 protein Raptor (17). Induction of muscle AMPK signaling was also observed in
severe cachectic APCMIN/+ mice, a well-established IL-6 dependent cancer cachexia
animal model, which manifested decreased muscle protein synthesis and suppression of
mTOR signaling activity (18, 19). These results suggest that AMPK is a potential mediator
of IL-6 suppression of protein synthesis in skeletal muscle.

The purpose of this study is to determine if long term IL-6 or LIF administration can
regulate myotube protein synthesis in skeletal muscle cells. We hypothesized that long term
IL-6 or LIF would suppress protein synthesis in skeletal muscle cells by activating STAT3
or AMPK signaling pathways. We examined the effects of different doses of IL-6 and LIF
on mTOR signaling and protein synthesis in cultured myotubes. The role of STAT3
signaling and AMPK signaling were investigated by siRNA knockdown and
pharmaceutical inhibition.

4.3 Methods
Cell culture
C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin.
To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4
days after they reached ∼95% confluence.

Cytokine treatment
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Differentiated C2C12 myotubes were treated with different doses (20 or 100ng/ml) of
IL-6 (Sigma-Aldrich, St. Louis, MO) or LIF (Thermo Scientific, Waltham, MA) for 24h.
To exclude the potential effects of cytokines in serum, myotubes were maintained in serumfree condition during cytokine treatment.

RNA interference:
Three days after the onset of differentiation, C2C12 myotubes were transfected with
scramble siRNA (GE Dharmacon, Lafayette, CO, USA) or siRNA targeting to STAT3 or
AMPK (Santa Cruz Biotech, Santa Cruz, CA, USA) using Dharmafect 3 transfection
reagent (GE Dharmacon) according to the manufacturer’s instructions. Briefly, siRNA and
transfection reagent were separately diluted in serum-free and antibiotics-free DMEM and
incubated at RT for 5min. The diluted transfection reagent was then added to the siRNA
mixture and allowed to complex with siRNA for 20 min. siRNA-transfection reagent
complexes were then added to the antibiotics-free differentiation medium, and myotubes
were incubated for 24 h in the medium containing the transfection mixture. The final
concentration of siRNA was set at 100 nM.

STAT3 and AMPK signaling inhibition
To inhibit myotube STAT3 signaling, STAT3 specific inhibitor C-188-9 (10μM,
Sigma-Aldrich) was added to cell culture medium 2h before the IL-6/LIF administration.
After 2h incubation, the culture media containing C-188-9 was changed into fresh culture
medium containing IL-6 or LIF. To inhibit myotube AMPK signaling, AMPK specific
inhibitor compound C (10μM, Sigma-Aldrich) was added into cell culture medium during
96

the 24h of IL-6 and LIF treatment. For both C-188-9 and compound C experiments, equal
volume of DMSO was added to the culture medium of control groups.

Animals
The original C57BL/6 mice used in this study were purchased from Jackson
Laboratories (Bar Harbor, ME) and bred at the University of South Carolina's Animal
Resource Facility. All mice used in the present study were obtained from the investigator's
breeding colony within the Center for Colon Cancer Research Mouse Core. Mice were kept
on a 12:12-h light-dark cycle, and had access to standard rodent chow (no. 8604 Rodent
Diet; Harlan Teklad, Madison, WI) and water ad libitum.

The University of South

Carolina's Institutional Animal Care and Use Committee approved all animal
experimentation in this study.

In vivo IL-6 overexpression by electroporation
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase
circulating IL-6 levels in mice as previously described (271). Mice (Male C57BL/6, ~10
weeks old) were anesthetized with a 2% mixture of isoflurane (IsoSol, VEDCO, St. Joseph,
MO) and oxygen (1 L/min). The quadriceps muscle was used to synthesize and secrete
exogenous IL-6 into circulation from the injected expression plasmid, and was not used for
any analyses in the study. Briefly, mice were injected with 40 μg of IL-6 plasmid driven by
the CMV promoter, or control plasmid (pV1J), into the right quadriceps muscle. The leg
was shaved, and a small incision was made over the quadriceps muscle. Fat was dissected
away from the muscle, and the plasmid was injected in a 50 μl volume of sterile phosphate97

buffered saline (PBS). A series of eight 50 ms, 100 V pulses was used to promote uptake
of the plasmid into myonuclei, and the incision was closed with a wound clip.

Tissue Collection
All mice were sacrificed 5 days post intramuscular plasmid electroporation. After 5h
fasting, mice were anesthetized with a subcutaneous injection of ketamine-xylazineacepromazine cocktail (1.4 ml/kg body wt) at the time of death. Hindlimb muscles were
rapidly excised, cleared of excess connective tissue, rinsed in PBS, weighed, and snap
frozen in liquid nitrogen. The TA muscle was frozen in liquid nitrogen. Blood was collected
before muscle collection via retro-orbital eye bleed with heparinized capillary tubes, placed
on ice, and centrifuged (10,000 g for 10 min at 4°C). The supernatant was removed and
stored for plasma IL-6 analysis. Plasma and tissue samples were stored at −80°C until
further analysis.

Western Blot
Western blot analysis was performed as previously described (226). Briefly, cells were
washed by ice-cold PBS and then scraped into ice-cold RIPA buffer [50 mM Tris, 150 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM NaF,
1 mM NaVO4, 1 mM β-glycerophosphate, and 1% protease inhibitor cocktail (SigmaAldrich)]. Cell lysates were homogenized on ice and centrifuged at 4°C, and supernatants
were collected. Protein concentrations were determined by the Bradford reagent (Bio-Rad)
following the manufacturer’s instructions. Protein were fractionated in SDSpolyacrylamide gels and transferred to polyvinylidene fluoride membranes. After the
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membranes were blocked, antibodies for phosphorylated/total ERK1/2, STAT3, NF-κB p65,
Akt, p70S6K, 4EBP1, GAPDH (Cell Signaling Technology), gp130 (Santa Cruz
Biotechnology), and puromycin (Millipore, Billerica, MA) were incubated at dilutions
from 1:2,000 to 1:8,000 overnight at 4°C in 2% Tris-buffered saline-Tween 20 milk. Antirabbit or anti-mouse IgG-conjugated secondary antibodies (Cell Signaling Technology)
were incubated with the membranes at 1:2,000 to 1:5,000 dilutions for 2 h in 2% Trisbuffered saline-Tween 20 milk. Enhanced chemiluminescence (Advansta, Menlo Park, CA)
developed by autoradiography was used to visualize the antibody-antigen interactions.
Blots were analyzed by measuring the integrated optical density (IOD) of each band with
ImageJ software (National Institutes of Health, Bethesda, MD).

RNA isolation, cDNA synthesis, and real-time PCR
RNA isolation was performed using Trizol Reagent (Thermo scientific) according to
the manufacturer’s instructions. cDNA synthesis, and real-time PCR were performed as
previously described, using reagents from Applied Biosystems (Foster City, CA, USA).
Quantitative real-time PCR analysis was carried out in 20-ul reactions consisting of 2 ×
SYBR Green PCR buffer (AmpliTaq Gold DNA Polymerase, Buffer, dNTP mix, AmpErase
UNG, MgCl2), 0.1ul of cDNA, RNase-free water, and 60 nM of each primer. The
sequences of SOCS3 primers set are5’-TGCAGGAGAGCTGATTCTAC-3’ (forward) and
5’-TGACGCTCAACGTGAAGAAG (reverse). The sequence of GAPDH primers were
published elsewhere (19). Data were analyzed by ABI software using the cycle threshold
(CT), which is the cycle number at which the fluorescence emission is midway between
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detection and saturation of the reaction. The SOCS3 data of each sample was normalized
by its GAPDH results.

Protein synthesis measurement
The myotube protein synthesis was determined by puromycin incorporation as
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was
added into cell culture media (1 μM final concentration) 30 min before protein collection.
To determine protein synthesis in mouse skeletal muscle, 0.04 mmol/g BW puromycin
(solved in PBS) was given to mouse by i.p. injection 30 min before sacrifice. The amount
of puromycin incorporated into newly synthesized protein was determined by Western blots.
The protein samples from myotubes without puromycin labelling were used as negative
control.

Plasma IL-6 level
For each mouse, blood samples were taken at the time of electroporation (D-0), 4 days
post electroporation (D-5) and time of sacrifice (5 days post electroporation, D-5) by eye
bleeding. Mice were fasted for at least 5h before blood sample collection. Blood samples
were centrifuged by 10000 rpm for 10min at 4°C, and the supernatant were collected and
kept frozen at -80°C before assay. Plasma IL-6 was determined by mouse ELISA kid
purchased from BD Bioscience (Franklin Lakes, NJ) following manufacturer’s instructions.
In brief, 96-well plate was coated with capture antibody (1:250, solved in 0.1M sodium
carbonate, pH 9.5, 100 μl/well) overnight at 4°C. The plate was then blocked by assay
diluent (10% FBS in PBS, 100μl/well) for 1h at RT, incubated with IL-6 standards (range
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from 16pg/ml to 1000 pg/ml, solved in assay diluent, 100 μl/well) or plasma samples
(100μl/well) for 2h at RT, incubated with working detector (1: 250 detection antibody and
1:500 Sav-HRP reagent, solved in assay diluent), incubated in Tetramethybenzidine
(TMB)-H2O2 substrate (100μl/well) for 30min in dark. Plates were washed by PBS with
0.05% tween 3-7 time between steps. The reaction was stopped by adding 2N H2SO4 (100
μl/well). The absorbance at 450 nm was read in a Bio Rad iMark plate reader (Carlsbad,
CA)

Statistical Analysis
Student's t-test, one-way ANOVA, and two-way ANOVA (indicated in figure legends)
were used to examine the effects of cytokines and signaling inhibition. For all comparisons,
six replicates from two independent experiments were included. P values < 0.05 were
considered significant.

4.4 Results
Long term IL-6 and LIF exposure inhibited myotube mTORC1 signaling and protein
synthesis
To determine the regulation of myotube protein synthesis by long term exposure of IL-6
family of cytokines, myotubes were incubated with different doses of IL-6 or LIF for 24h.
24h exposure of 20 ng/ml IL-6 significantly decreased myotube protein synthesis, and 100
ng/ml IL-6 showed further suppression (Fig. 4.1A). Both 20 ng/ml and 100 ng/ml LIF
showed similar inhibitory effects on myotube protein synthesis (Fig. 4.1A). We also
measured the phosphorylation of p70S6K and 4EBP1, which are downstream targets of
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mTORC1. Both 20 ng/ml and 100 ng/ml IL-6 decreased p70S6K phosphorylation, while
only 100ng/ml LIF suppressed p70S6K phosphorylation (Fig. 4.1B). IL-6 and LIF also
suppressed 4EBP1 phosphorylation in a dose dependent manner (Fig. 4.1B). These results
demonstrate that long term IL-6 or LIF exposure can negatively regulate mTORC1
signaling and protein synthesis in cultured myotubes.

Long term IL-6 and LIF regulation on myotube signaling pathways.
To understand the potential mechanisms underlying the long term IL-6 and LIF suppression
of myotube protein synthesis, we investigated the effects of IL-6 and LIF on gp130
dependent signaling pathways, including STAT3, ERK1/2 and Akt. Long term IL-6
administrated increased STAT3 phosphorylation in a dose dependent manner (Fig. 4.2A).
However, none of LIF dosages demonstrate the induction STAT3 phosphorylation (Fig.
4.2A). Similar with STAT3 results, IL-6, but not LIF, increased ERK1/2 phosphorylation
(Fig. 4.2A). Interestingly, both IL-6 and LIF decreased Akt phosphorylation in a dose
dependent manner (Fig. 4.2A). The SOCS3 mRNA level was elevated in myotube treated
with LIF, but not IL-6 (Fig. 4.2B). Both IL-6 and LIF increased AMPK phosphorylation in
a dose dependent manner (Fig. 4.2C).

Role of STAT3 in IL-6/LIF regulation of myotube protein synthesis
STAT3 is a classical downstream effector of gp130 signaling and pathological activation
of STAT3 signaling plays a pivotal role in dysregulation of muscle protein turnover and
muscle wasting in cachexia. To determine the role of STAT3 signaling in protein synthesis
suppression by long term IL-6 or LIF, we inhibited STAT3 signaling by STAT3 specific
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inhibitor, C-188-9 and STAT3 siRNA knock-down. In C-188-9 experiment, myotubes were
pre-treated with C-188-9 for 2h prior to the addition of IL-6 or LIF (Fig. 4.3A). In STAT3
siRNA experiment, myotubes were transfected with control or STAT3 siRNA for 24h,
followed with 24h IL-6 or LIF treatment (Fig. 4.3A). C-188-9 decreased basal STAT3
phosphorylation (Fig. 4.3B, C), also blocked the IL-6 induction of STAT3 phosphorylation
(Fig. 4.3B). LIF did not change the STAT3 phosphorylation in either control or C-188-9
treated myotubes (Fig. 4.3C). Long term IL-6 or LIF exposure suppressed p70S6K
phosphorylation (Fig. 3C) and protein synthesis (Fig. 4.3D) in control myotubes.
Interestingly, C-188-9 alone decreased basal myotube p70S6K phosphorylation (Fig. 4.3C)
and protein synthesis (Fig. 4.3D). IL-6 or LIF did not result in further decrease in p70S6K
phosphorylation (Fig. 4.3C) or protein synthesis (Fig. 4.3C) in C-188-9 pretreated
myotubes. In STAT3 siRNA experiment, STAT3 siRNA transfection decreased myotube
STAT3 protein level, which was independent of IL-6 or LIF (Fig. 4.3E). STAT3 siRNA
transfection also decreased basal STAT3 phosphorylation, and blocked the induction of
STAT3 phosphorylation by IL-6 (Fig. 4.3E). Similar with the results of C-188-9
experiments, long term IL-6 or LIF exposure decreased protein synthesis in control siRNA
transfected myotubes (Fig. 4.3F). STAT3 siRNA transfection decreased protein synthesis
in both control and IL-6/LIF treated myotubes (Fig. 4.3F), but long term IL-6 or LIF
exposure did not change protein synthesis in STAT3 siRNA transfected myotubes (Fig.
4.3F). These results demonstrate STAT3 signaling is not necessary for myotube protein
synthesis suppression by long term IL-6 or LIF exposure.

Role of AMPK signaling in IL-6 and LIF regulation of myotube protein synthesis
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AMPK is an important upstream suppressor of mTORC1 signaling and the induction of
AMPK is involved in muscle protein synthesis suppression in different models of cancer
cachexia. We observed both IL-6 and LIF induced AMPK signaling (Fig. 4.2C). To
examine the role of AMPK signaling in myotube protein synthesis suppression by long
term IL-6 or LIF, myotube AMPK signaling was inhibited by AMPK inhibitor, compound
C or AMPK siRNA transfection. Myotubes were pretreated with compound C (10μM) 2h
before IL-6/LIF treatment, or transfected with control or AMPK siRNA for 24h before IL6/LIF treatment (Fig. 4.4A). As previously reported, compound C decreased basal AMPK
phosphorylation and blocked the induction of AMPK phosphorylation by IL-6 or LIF (Fig.
4.4B). Compound C increased basal p70S6K phosphorylation (Fig. 4.4C), and rescued the
IL-6 and LIF suppression of p70S6K phosphorylation (Fig. 4.4C). Most importantly,
compound C alone showed a dramatic protein synthesis induction (Fig. 4.4D). Compound
C also dramatically induced protein synthesis in the presence of IL-6 or LIF (Fig. 4.4D).
AMPK siRNA transfections decreased basal AMPK protein level, which was independent
of IL-6 or LIF (Fig. 4.4E). Similar with the inhibitory effects of compound C, AMPK
siRNA decreased basal AMPK phosphorylation, and prevented IL-6 or LIF induction of
AMPK phosphorylation (Fig. 4.4E). Surprisingly, AMPK siRNA transfection decreased,
but not increased, basal protein synthesis and p70S6K phosphorylation (Fig. 4.4F). Long
term IL-6 and LIF treatment showed no further protein synthesis suppression in AMPK
siRNA transfected myotubes (Fig. 4.4F). These results demonstrate a complex role of
AMPK signaling in IL-6/LIF regulation of myotube protein synthesis: AMPK signaling
activation by long term IL-6 and LIF exposure is a key mediator of myotube protein
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synthesis suppression, but basal AMPK signaling is still required for maintaining protein
synthesis in myotubes.

Regulation of in vivo IL-6 overexpression on skeletal muscle protein synthesis
To further determine if long term exposure of IL-6 family of cytokines can regulate skeletal
muscle protein synthesis in vivo, we overexpressed IL-6 in C57BL6 mice by transfecting
the IL-6 overexpression plasmid driven by the CMV promoter into quadriceps muscles.
The plasma IL-6 levels of both control and IL-6 overexpressing mice were below the
detection level at the time of plasmid transfection (Table. 4.1). We found the elevation of
plasma IL-6 4-days and 5-days post transfection in IL-6 overexpressing mice (135.4 ±
42.3pg/ml on day 4 and 423.7 ± 115.2pg/ml on day 5), but not in control mice (Table. 4.1).
5 days IL-6 overexpression did not the body weight or the hind limb muscle weights (Table.
4.1). Consistent with the elevation of plasma IL-6, the STAT3 phosphorylation in TA
muscle was also elevated in IL-6 overexpressing mice (Fig. 4.5A). Most importantly, IL-6
overexpression decreased the phosphorylation of p70S6K (Fig. 4.5B) and protein synthesis
(Fig. 4.5C) in TA muscles. These results demonstrate long term plasma IL-6 elevation can
inhibit mTORC1 signaling and decrease protein synthesis in skeletal muscles.

4.5 Discussion
Skeletal muscle wasting in cancer cachexia involves the disrupted homeostatic
regulation of muscle protein turnover, including the protein degradation activation and
protein synthesis suppression (118). However, our understanding of protein degradation
regulation during the wasting process exceeds our understanding of protein synthesis. Long
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term elevation of IL-6 family of cytokines, IL-6 and LIF, have acknowledged role in muscle
proteolysis and muscle wasting in cancer cachexia, but their role in cachexia induced
muscle protein synthesis suppression is poorly understood. Here, we report important and
novel finding that long term exposure of IL-6 or LIF can negatively regulate mTOR
signaling and protein synthesis in myotubes, and long term plasma IL-6 elevation also
decreased muscle protein synthesis in vivo. IL-6 and LIF suppression of myotube protein
synthesis is associated with the induction of gp130 and AMPK signaling. Inhibition of
STAT3 signaling pathway did not rescue the protein synthesis suppression by IL-6 or LIF.
AMPK signaling inhibition during IL-6/LIF exposure rescued their inhibition of protein
synthesis. However, long term AMPK signaling inhibition before IL-6 and LIF treatment
suppressed myotube protein synthesis. These results demonstrated that IL-6 or LIF alone
are enough to suppress protein synthesis in skeletal muscle cells by the hyper-activation of
AMPK signaling. However, basal AMPK signaling may play a role in maintaining protein
synthesis.

IL-6 family of cytokine induces STAT3 phosphorylation and transcriptional activation
though gp130 signaling. Activated STAT3 signaling induces expression of SOCS3, which
block the signaling transduction from gp130 to STAT3 and prevent the constant gp130
signaling inductions under physiological conditions. Here, we investigated the long term
IL-6/LIF regulation on myotube gp130 signaling. Long term IL-6 and LIF exposure
demonstrated differential regulation of gp130 signaling: 24h IL-6 exposure increased
phosphorylation of STAT3 and ERK1/2 in a dose dependent manner, but LIF did not change
their phosphorylation. Interestingly, the SOCS3 expression is only induced in myotube
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treated with LIF, but not IL-6, suggesting the IL-6 induced STAT3 and ERK1/2 signaling
is caused by disrupted SOCS3 dependent negative feedback mechanisms. Both IL-6 and
LIF decreased Akt phosphorylation, which is a potential contributor to IL-6/LIF
suppression of mTOR and protein synthesis. Taken together, these results demonstrate the
differential regulation of gp130 signaling between short term and long term IL-6/LIF
exposure.

STAT3 is a well-established downstream effector of IL-6 family of cytokines (238).
Once activated, STAT3 translocate into nucleus and regulate the transcription to target
genes, which involved in a large variety of cellular processes. STAT3 signaling activation
also induces the expression of SOCS3, which inhibits signal transduction from gp130 to its
downstream effector, and ensures a transient pattern of gp130 dependent signaling under
physiological conditions (193, 238). Constant elevation of IL-6 family of cytokines in
cachexia induces pathological activation of muscle gp130/STAT3 signaling, which plays a
key role in muscle proteolysis genes transcription and muscle wasting (18, 202, 214).
However, the potential regulation of STAT3 on muscle protein synthesis in cachectic
muscles has not been proposed yet. Here, we report that long term IL-6 administration
induced STAT3 signaling in myotubes, however, this induction was not observed in LIF
treated myotubes. We have shown short term administration of both IL-6 and LIF induced
a transient STAT3 phosphorylation, which was associated with the induction of SOCS3
expression. Interestingly, we observed increased SOCS3 expression in myotubes under the
long term exposure of LIF but not IL-6, suggesting the disrupted SOCS3 dependent
negative feedback loop may account for the IL-6 induction STAT3 signaling. Unlike the
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differential regulation of STAT3 signaling, both IL-6 and LIF demonstrate suppression of
myotube protein synthesis. Furthermore, we reported either STAT3 pharmaceutical
inhibitor C-188-9 or STAT3 siRNA knockdown was not able to rescue the IL-6/LIF
suppression of myotube protein synthesis. These result further support our previous
findings that STAT3 signaling inhibition did not rescue the LLC induced myotube protein
synthesis suppression (272), and demonstrate STAT3 signaling is not necessary for IL6/LIF suppression of muscle protein synthesis in cancer cachexia. Similar with the effects
of LLL12, long term STAT3 signaling inhibition by C-188-9 or STAT3 siRNA suppressed
myotube mTOR signaling and protein synthesis, which suggests that STAT3 signaling may
play a role in maintaining basal protein synthesis in skeletal muscle cells.

An energy deficiency or cachectic environment can induce the induction AMPK
signaling, which plays a role in catabolic shift of muscle protein turnover regulation,
through mTOR signaling inhibition (17), induction of FOXO-dependent E3 ubiquitin
ligase transcription (273), and increased autophagy processes (274). Muscle AMPK
signaling is chronically activated in severe cachectic ApcMIN/+ mice, an IL-6 dependent
cachexia animal model (18). Consistent with previous findings (20), long term IL-6 and
LIF induced AMPK phosphorylation in myotubes was observed. Most notable the
inhibition of myotube AMPK activity during IL-6/LIF treatment can rescue IL-6/LIF
suppression of protein synthesis. These results further strengthen the well-established
inhibitory role of AMPK signaling on protein synthesis regulation (68), and further
strengthen the role of pathological AMPK signaling induction as a key mediator of muscle
protein synthesis suppression in cancer cachexia (20). These results also demonstrate that
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AMPK is an important mediator of IL-6 and LIF suppression of myotube protein synthesis.
Surprisingly, long term AMPK signaling inhibition by siRNA transfection before IL-6/LIF
administration decreased basal protein synthesis, and showed no rescue effects on protein
synthesis suppression by IL-6 or LIF. One possible reason is that the induction of protein
synthesis by compound C is caused by its off-target effects (275). However, previously
reported was that compound C can block Akt/mTOR signaling independent of AMPK
suppression, which is opposite to our observations (272). Notably, unlike the AMPK
suppression by compound C during the IL-6/LIF administration, siRNA transfection was
conducted 24h prior to the addition of IL-6 or LIF. One potential possibility is that the
different duration of AMPK signaling inhibition opposite effects of two AMPK signaling
inhibitors. Previously studies also reported different duration of AMPK signaling showed
differential regulation of protein synthesis: AMPK signaling inhibition by compound C
during 24h palmitate treatment rescued palmitate suppression of p70S6K phosphorylation
in cultured myotubes (276). However, over 24h AMPK signaling inhibition by siRNA
knockdown resulted in induction (277) or suppression (278) of mTOR signaling in different
cell types. These results suggest a complicated, cell type specific, role of basal AMPK
signaling in protein synthesis regulation, and basal AMPK signaling may play a role in
maintaining myotube protein synthesis. In addition to the direct inhibitory effects on mTOR
signaling, AMPK is a documented signaling nexus controlling energy metabolism,
including glucose transportation, oxidative metabolism, mitochondrial biogenesis, fatty
acid oxidation and autophagy process (279). AMPK can sensitize the insulin action on
PI3K/Akt signaling by the inhibition of the insulin-induced negative feedback loop (272).
Another possibility is that long term inhibition of AMPK signaling by siRNA knock-down
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may inhibit protein synthesis indirectly by the dysregulation of metabolic homeostasis.
More work is still needed to determine the potential indirect regulation of AMPK signaling
on muscle protein synthesis regulation.

In summary, we examined the long term regulation of IL-6 related cytokines, IL-6 and
LIF on protein synthesis in cultured myotubes and skeletal muscles. Long term exposure
of IL-6 or LIF suppressed mTOR signaling and protein synthesis, which is not dependent
on STAT3 signaling. Interestingly, different duration of AMPK signaling inhibition
demonstrated a very complicated role in myotube protein synthesis regulation: activation
of AMPK signaling mediates the IL-6/LIF suppression of myotube protein synthesis, while
basal AMPK signaling is still necessary for maintaining protein synthesis. Furthermore, we
also demonstrated long term IL-6 elevation is enough to suppress skeletal muscle protein
synthesis in vivo. These results provide new insights of the role of IL-6 family of cytokines
on muscle mass regulation under pathological conditions and further extend the
understanding of the mechanism underlying skeletal muscle wasting in cancer cachexia.
However, due to the potential disruption of myotube protein synthesis by long term AMPK
signaling inhibition, targeting AMPK signaling may not be the optimal therapy to attenuate
muscle protein synthesis in cachexia. Further work is still needed to determine the
mechanisms underlying muscle protein synthesis suppression by IL-6-gp130 signaling in
cancer cachexia.

4.6 Figure Legend
Figure 4.1: Regulation of long term IL-6 and LIF on myotube protein synthesis and
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mTOR signaling. C2C12 myotubes were treated with difference doses (20ng/ml and
100ng/ml) of IL-6 or LIF for 24h. A. Protein synthesis was determined by puromycin
incorporation. B. The phosphorylation of p70S6K and 4EBP1 were measured by western
blot. For A and B, *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml group, one-way
ANOVA.

Figure 4.2: Regulation of long term IL-6 and LIF on myotube gp130 dependent
signaling and AMPK signaling. C2C12 myotubes were treated with difference doses
(20ng/ml and 100ng/ml) of IL-6 or LIF for 24h. A. The phosphorylation of STAT3, ERK1/2,
Akt were measured by western blot. *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml
group, one-way ANOVA. B. The SOCS3 mRNA expression was measured by RT-PCR. *:
p < 0.05 vs. control group, one-way ANOVA. C. The phosphorylation of AMPK were
measured by western blot. *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml group, oneway ANOVA.

Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of myotube
protein synthesis. A. Experiment design. B. Phosphorylation of STAT3 in myotubes
treated with/without IL-6, LIF or C-188-9, Dash lines represent different parts on the same
gel. *: p < 0.05 vs. all other groups, #: p < 0.05, main effect of C-188-9, two-way ANOVA.
C. Phosphorylation of p70S6K in myotubes treated with/without IL-6, LIF or C-188-9,
Dash lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p <
0.05, vs. IL-6 group, two-way ANOVA. D. Protein synthesis in myotubes treated
with/without IL-6, LIF or C-188-9 was determined by puromycin incorporation. Dash lines
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represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL6/LIF group, two-way ANOVA. E. Phosphorylation of STAT3 and total STAT3 in control
or STAT3 siRNA transfected myotubes treated with/without IL-6 or LIF. *: p < 0.05 vs. all
other groups, #: p < 0.05 vs. control groups, $: p < 0.05, main effect of STAT3 siRNA, twoway ANOVA. F. Protein synthesis in control or STAT3 siRNA transfected myotubes treated
with/without IL-6 or LIF was determined by puromycin incorporation. Dash lines represent
different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL-6/LIF group,
two-way ANOVA.

Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation of myotube
protein synthesis. A. Experiment design. B. Phosphorylation of AMPK in myotubes
treated with/without IL-6, LIF or compound C, Dash lines represent different parts on the
same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs. control groups, two-way ANOVA.
C. Phosphorylation of p70S6K in myotubes treated with/without IL-6, LIF or compound
C, Dash lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p
< 0.05 vs. IL-6/LIF group, two-way ANOVA. D. Protein synthesis in myotubes treated
with/without IL-6, LIF or compound C was determined by puromycin incorporation. Dash
lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs.
IL-6/LIF group, two-way ANOVA. E. Phosphorylation of AMPK and total AMPK in
control or AMPK siRNA transfected myotubes treated with/without IL-6 or LIF. *: p < 0.05
vs. all other groups, #: p < 0.05 vs. control groups, $: p < 0.05, main effect of AMPK siRNA,
two-way ANOVA. F. Protein synthesis in control or AMPK siRNA transfected myotubes
treated with/without IL-6 or LIF was determined by puromycin incorporation. Dash lines
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represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL6/LIF group, two-way ANOVA.

Figure 4.5: Regulation of in vivo IL-6 over-expression on muscle mTORC1 signaling
and protein synthesis. IL-6 was overexpressed in male C57BL/6 mice (~10 weeks old) by
transfecting 40 μg of IL-6 plasmid driven by the CMV promoter into quadriceps muscles.
All mice were sacrificed after 5 days overexpression. A-B. Phosphorylation of STAT3 (A)
and p70S6K (B) in TA muscles were measured by western blot. C. Protein synthesis in TA
muscles were determined by puromycin incorporation. *: p < 0.05 vs. control group,
Student’s t-test.

113

Table 4.1: Phenotype of IL-6 overexpression mice. Plasma IL-6 levels in
control or IL-6 overexpressing mice at the time of transfection (D-0), 4-days (D4) and 5 days (D-5) post transfection. Muscle wet weights were recorded during
sacrifice. *: p < 0.05 vs. control mice, Two-way Repeated Measures.

Plasma IL-6 (pg/ml)

Control (n=7)

IL-6 OE (n=8)

D-0

N.D.

N.D.

D-4

N.D.

135.4±42.3*

D-5 (Sac)

N.D.

423.7±115.2*

25.4 ±1.4

24.9±1.1

Solues

7.3±1.3

6.9±1.0

Plantaris

17.3±1.4

17.0±1.7

Gastroc

124.2±6.5

120.6±6.4

EDL

8.1±1.2

8.1±1.2

T.A.

43.5±3.2

44.8±3.3

17.1±0.1

17.0±0.1

Body Weight
Muscle Weight

Tibia Length
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Figure 4.1: Regulation of long term IL-6 and LIF on myotube protein
synthesis and mTOR signaling.
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Figure 4.2: Regulation of long term IL-6 and LIF on myotube gp130
dependent signaling and AMPK signaling.
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Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of
myotube protein synthesis.

117

Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of
myotube protein synthesis (continued).
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Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation
of myotube protein synthesis.
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Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation of
myotube protein synthesis (continued).
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Figure 4.5: Regulation of in vivo IL-6 over-expression on muscle mTORC1
signaling and protein synthesis.
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CHAPTER 5
IL-6 AND LIF REGULATION OF MECHANICAL STIMULI
INDUCED MYOTUBE AND SKELETAL MUSCLE PROTEIN
SYNTHESIS

Song Gao, Justin P. Hardee and James A. Carson. To be submitted to American Journal of
Physiology – Cell Physiology
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5.1 Abstract
Mechanical stimulus from stretch or contractions can activate muscle and myotube
protein synthesis through the induction of mTOR signaling. Short term, physiological
elevation IL-6 and LIF plays a key role in mechanical stimulus induced muscle hypertrophy.
While long term, pathological elevation of IL-6 and LIF are key players in cachexia
induced atrophic environment, which also has a potential to disrupt muscle mechanical
signaling. IL-6 and LIF role in muscle hypertrophy and atrophy has been established, but
the effect of this cytokines on mechanical signaling in skeletal muscle has not been
determined. We investigated whether IL-6 or LIF can regulate the stretch or eccentric
contraction induction of protein synthesis in myotubes or skeletal muscles, respectively. To
determine short term IL-6 or LIF regulation on myotube mechanical signaling, C2C12
myotubes were stretched for 4h in the presence of IL-6 or LIF. To determine the long term
IL-6 or LIF regulation on myotube mechanical signaling, C2C12 myotube were
preincubated in IL-6 or LIF for 24h and stretched in last 4h. To determine the IL-6
regulation of muscle protein synthesis induction by eccentric contractions, High Frequency
Electrical Stimulation (HFES) induced eccentric contractions of the left tibialis anterior
muscle the control and IL-6 overexpressing mice was conducted. Protein synthesis and
mTOR signaling regulation were examined in each experiment. Short term IL-6 and LIF
administration increased basal mTOR signaling activity and protein synthesis, but stretch
in the presence of IL-6 or LIF decreased mTOR signaling activity and protein synthesis in
IL-6/LIF treated myotubes. Long term IL-6 or LIF treatment decreased mTOR signaling
activity and protein synthesis and attenuated the stretch induction of protein synthesis.
However, HFES increased mTOR signaling activity and protein synthesis in both control
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and IL-6 overexpressing mice. These results demonstrate that IL-6 and LIF can dissociate
stretch-induced signaling from protein from protein synthesis in cultured myotubes. But
IL-6 had no influence on muscle protein synthesis regulation by eccentric contraction
induced mechanical signaling.

Key words: IL-6, LIF, mTOR, protein synthesis, mechanical signaling, cachexia

5.2 Introduction
Skeletal muscle mass has a well-documented role in health and quality of life. The
skeletal muscle mass is sensitive to large variety of systemic changes including the physical
activity level and inflammatory cytokines, which can regulate multiple cellular processes
involved in protein synthesis and protein degradation in skeletal muscle fibers (1). IL-6
family of cytokines have a pleiotropic functions in different tissues and organs, and plays
a role in both skeletal muscle hypertrophy and atrophy (5). In response to contractions or
overload, skeletal muscle produces and releases significant levels of IL‐6, which has been
associated with stimulation of hypertrophic muscle growth and myogenesis through
regulation of the proliferative capacity of muscle stem cells. Paradoxically, chronic
elevation of IL-6 and LIF can promote muscle wasting in cancer cachexia. Until now, no
clear explanation about contradictory role of IL-6 family of cytokines in muscle mass
regulation exists.

Mechanical stimuli such as loading or stretch induce an anabolic response in skeletal
muscle that is important for the maintenance of mass and function (23). Cultured myotubes
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respond to chronic or intermittent stretch through increased protein synthesis,
morphological maturation, and development of the contractile apparatus (280, 281).
Eccentric contractions induced by high frequency electrical stimulation (HFES) in vivo is
also a strong inducer of muscle signaling associated with hypertrophy (90, 95, 282), and
demonstrated a therapeutic effects to attenuating muscle mass loss in tumor bearing mice
(283, 284). The signaling pathways induced by mechanical stimulation, known as
mechanical signaling, can regulate skeletal muscle hypertrophy via the induction of mTOR
signaling and subsequent muscle protein synthesis (22, 101). The subsequent
phosphorylation of p70S6K, S6RP and 4EBP1 by mTOR signaling activation are key
inducer of molecular processes involved in muscle protein synthesis, including ribosomal
RNA and protein transcription, ribosomal biogenesis, translation initiation, and the
induction of protein synthesis (46). Until now, multiple signaling pathways including
phospholipase D/ phosphatidic acid (285, 286) and ERK1/2 (16) are involved in the process.
Exercise or muscle overload also induce a short term elevation of plasma IL-6 and muscle
expression of IL-6 and LIF (8, 237), and both IL-6 and LIF are necessary for overloadinduced muscle hypertrophy (7, 8). IL-6 and LIF dependent signaling has been associated
with stimulation of hypertrophic muscle growth through regulation of the proliferative
capacity of muscle stem cells, but their role in mechanical stimuli induction of muscle
protein synthesis still need to be determined.

Unlike their positive role of mechanical stimuli induced skeletal muscle hypertrophy,
chronic elevation of systematic IL-6 and LIF plays a key role in muscle wasting under some
pathological conditions, include cancer cachexia. Disruption of protein turnover
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homeostasis is a major reason of cachexia induced muscle wasting. IL-6 and LIF can
upregulate genes involved protein degradation by activating gp130/STAT3 signaling axis
is well established, but the direct IL-6/LIF regulation on muscle mTOR signaling or protein
synthesis during cachexia has not been proposed yet. Chronic systemic inflammation has
the potential to inhibit muscle protein synthesis dissociating muscle mTOR signaling from
anabolic stimuli, including IGF-1 (287), leucine (288) and resistant exercise (175), which
is known as anabolic resistance. Our previous work has demonstrated that the catabolic
factors from cancer cells can disrupt protein synthesis induction by mechanical stimuli.
Severely cachectic ApcMin/+ mice demonstrated impaired mTOR signaling induction by
muscle contractions, which was restored by NF-κB and STAT3 inhibitor, PDTC (25). LLC
derived cachectic factors can dissociate stretch-induced signaling from protein synthesis
through ERK1/2 and p38 signaling induction (226). However, not known is whether long
term pathological elevated IL-6 or LIF are involved in disruption of muscle protein
synthesis by mechanical signaling.

Clearly both mechanical stimuli and cachexia can induce IL-6 and LIF elevation in
skeletal muscle microenvironment (219, 231), but little evidence supporting the direct
regulation of IL-6 or LIF on muscle protein synthesis exists. Regulating the muscle
sensitivity to the mechanical stimuli has the potential to contribute to the muscle protein
synthesis and muscle mass regulation (25, 226), but the ability of the physiological or
pathological elevated IL-6 and LIF to interact with muscle mechanical signaling still need
of further investigation. The purpose of this study was to examine if IL-6/LIF would
regulate protein synthesis induction by stretch in cultured myotubes or eccentric
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contractions in skeletal muscles. We hypothesized that short term administration of IL-6 or
LIF would strengthen the stretch induction of myotube protein synthesis, while long term
exposure of IL-6 or LIF would attenuate stretch induction of protein synthesis and eccentric
contraction induced protein synthesis in skeletal muscle. The effects of different duration
of IL-6 and LIF exposure on stretch induction of myotube protein synthesis were examined.
We also investigated the high-frequency stimulation induced muscle protein synthesis in
IL-6 over-expressing mice.

5.3 Methods
Cell culture
C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin.
To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4
days after they reached ∼95% confluence.

Cell Stretch
Cell stretch experiment was conducted as previously described with small
modifications (226). The representative image of cell stretching device was shown in
Figure 1A. Static stretching device consists of a small frame with two axles (part 1)
separated by lateral supports (part 2). The axles were threaded to accept screw nuts (part
3). Silastic membranes (GLOSS/GLOSS, 0.02 in., Speciality Manufacturing, Saginaw, MI,
part 5) were mounted onto the devices by two friction-fit C-clamps (part 4). The assembled
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stretching device was then immersed into distilled H2O, autoclaved, and transferred into a
sterile 100-mm petri dish. The screw nuts were set to 30 cycles from baseline when the
stretching device was assembled (left). Approximately 175 μl type I collagen solution
(Advanced Biomatrix, San Diego, CA; diluted into 1 mg/ml by PBS, pH 7-8, adjusted by
sterile 10N NaOH) was applied onto one edge of Silastic membrane on each stretching
device. The collagen solution was then drawn across the substrate with a sterile cell scraper.
Excess collagen was aspirated, and the culture dish containing the stretching device was
transferred to a 37°C incubator for 1 h. After the incubation period, stretching device was
washed by sterile distilled H2O twice and air dried under UV overnight. C2C12 myoblasts
were suspended (∼1 × 106 cells/ml) and plated onto Silastic membrane mounted in a
stretching device (∼1.5–2 × 105 cells/stretching device). The cells were grown to ∼95%
confluence and differentiated into myotubes. To induced 5% stretch, screw nuts on both
axles were rotated by 1.5 cycles using sterile forceps (right side). Myotubes were constantly
stretched by for 4h.

Cytokine treatment
To determine the regulation of short term IL-6 or LIF exposure on stretch induction of
protein synthesis, C2C12 myotubes were stretched by 5% for 4h in the presence of IL-6
(20ng/ml, Sigma-Aldrich, St. Louis, MO) or LIF (10 ng/ml, Thermo Scientific, Waltham,
MA). To determine the regulation of long term IL-6 or LIF exposure on stretch induction
of protein synthesis, C2C12 myotubes were incubated in IL-6 (100ng/ml) or LIF (100ng/ml)
for 24h. The stretch (5%) was conduction in last 4h of IL-6/LIF incubation. The myotube
were kept in serum-free DMEM during the short term and long term IL-6/LIF incubation.
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Animals
The original C57BL/6 mice used in this study were purchased from Jackson
Laboratories (Bar Harbor, ME) and bred at the University of South Carolina's Animal
Resource Facility. All mice used in the present study were obtained from the investigator's
breeding colony within the Center for Colon Cancer Research Mouse Core. Mice were kept
on a 12:12-h light-dark cycle, and had access to standard rodent chow (no. 8604 Rodent
Diet; Harlan Teklad, Madison, WI) and water ad libitum.

The University of South

Carolina's Institutional Animal Care and Use Committee approved all animal
experimentation in this study.

In vivo IL-6 overexpression by electroporation
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase
circulating IL-6 levels in mice as previously described (271). Mice were anesthetized with
a 2% mixture of isoflurane (IsoSol, VEDCO, St. Joseph, MO) and oxygen (1 L/min). The
quadriceps muscle was used to synthesize and secrete exogenous IL-6 into circulation from
the injected expression plasmid, and was not used for any analyses in the study. Briefly,
mice were injected with 40 μg of IL-6 plasmid driven by the CMV promoter, or control
plasmid (pV1J), into the right quadriceps muscle. The leg was shaved, and a small incision
was made over the quadriceps muscle. Fat was dissected away from the muscle, and the
plasmid was injected in a 50 μl volume of sterile phosphate-buffered saline (PBS). A series
of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid into myonuclei,
and the incision was closed with a wound clip.
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HFES
After 5 days IL-6 overexpression, mice were subjected to HFES. HFES of the left
hindlimb was performed as previously described (90), with slight modifications. Mice were
anesthetized via isoflurane (2% in O2 with 1.5% maintenance), the left leg/hip region was
shaved, and two needle electrodes were placed on the left leg subcutaneously posterior to
the femur to stimulate the sciatic nerve. Tetanic muscle contractions were generated using
a Grass Stimulator (Grass Instruments, Quincy, MA) for 10 sets of 6 repetitions (100 Hz,
6–12 V, 1-ms duration, 3-s repetition duration). Ten seconds of rest were given between
repetitions, and 50 s of rest were given between sets. The stimulation protocol recruits all
motor units of the hindlimb. The maximal force production of the plantar flexors
(gastrocnemius, soleus, and plantaris) are greater than the dorsiflexors (TA and EDL) (61,
62), which results in net plantar flexion of the ankle (90). Therefore, the dorsiflexors
undergo lengthening eccentric muscle contractions against the shortening concentric
plantar flexors. Each session lasted ∼25 min in duration. Following each stimulation
procedure, mice were given an intraperitoneal injection of warm saline and returned to
cages upon complete recovery.

Tissue Collection
All mice were sacrificed 3h post HFES. Mice were anesthetized with a subcutaneous
injection of ketamine-xylazine-acepromazine cocktail (1.4 ml/kg body wt) at the time of
death. Hindlimb muscles were rapidly excised, cleared of excess connective tissue, rinsed
in PBS, weighed, and snap frozen in liquid nitrogen. The TA muscle was frozen in liquid
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nitrogen. Blood was collected before muscle collection via retro-orbital eye bleed with
heparinized capillary tubes, placed on ice, and centrifuged (10,000 g for 10 min at 4°C).
The supernatant was removed and stored for plasma IL-6 analysis. Plasma and tissue
samples were stored at −80°C until further analysis.

Plasma IL-6 level
For each mouse, blood samples were taken at the time of electroporation (D-0), 4 days
post electroporation (D-5) and time of sacrifice (5 days post electroporation, D-5) by eye
bleeding. Mice were fasted for at least 5h before blood sample collection. Blood samples
were centrifuged by 10000 rpm for 10min at 4°C, and the supernatant were collected and
kept frozen at -80°C before assay. Plasma IL-6 was determined by mouse ELISA kid
purchased from BD Bioscience (Franklin Lakes, NJ) following manufacturer’s instructions.
In brief, 96-well plate was coated with capture antibody (1:250, solved in 0.1M sodium
carbonate, pH 9.5, 100 μl/well) overnight at 4°C. The plate was then blocked by assay
diluent (10% FBS in PBS, 100μl/well) for 1h at RT, incubated with IL-6 standards (range
from 16pg/ml to 1000 pg/ml, solved in assay diluent, 100 μl/well) or plasma samples
(100μl/well) for 2h at RT, incubated with working detector (1: 250 detection antibody and
1:500 Sav-HRP reagent, solved in assay diluent), incubated in Tetramethybenzidine
(TMB)-H2O2 substrate (100μl/well) for 30min in dark. Plates were washed by PBS with
0.05% tween 3-7 time between steps. The reaction was stopped by adding 2N H2SO4 (100
μl/well). The absorbance at 450 nm was read in a Bio Rad iMark plate reader (Carlsbad,
CA)
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Protein synthesis measurement
The myotube protein synthesis was determined by puromycin incorporation as
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was
added into cell culture media (1 μM final concentration) 30 min before protein collection.
To determine protein synthesis in mouse skeletal muscle, 0.04 mmol/g BW puromycin
(solved in PBS) was given to mouse by i.p. injection 30 min before sacrifice. The amount
of puromycin incorporated into newly synthesized protein was determined by Western blots.
The protein samples from myotubes without puromycin labelling were used as negative
control.

Western Blot
Western blot analysis of protein samples from cultured myotubes and TA muscles was
performed as previously described (19). Frozen TA muscle was homogenized in ice-cold
Mueller buffer, and cells were washed by ice-cold PBS and then scraped into ice-cold RIPA
buffer. The protein concentration was determined by the Bradford method. Protein were
fractionated in SDS-polyacrylamide gels and transferred to polyvinylidene fluoride
membranes. After the membranes were blocked, antibodies for phosphorylated/total
p70S6K (Cell Signaling Technology, Danvers, MA) and puromycin (Millipore, Billerica,
MA) were incubated at dilutions from 1:2,000 to 1:8,000 overnight at 4°C in 2% Trisbuffered saline-Tween 20 milk. Anti-rabbit or anti-mouse IgG-conjugated secondary
antibodies (Cell Signaling Technology) were incubated with the membranes at 1:2,000 to
1:5,000 dilutions for 2 h in 2% Tris-buffered saline-Tween 20 milk. Enhanced
chemiluminescence (Advansta, Menlo Park, CA) developed by autoradiography was used
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to visualize the antibody-antigen interactions. Blots were analyzed by measuring the
integrated optical density (IOD) of each band with ImageJ software (National Institutes of
Health, Bethesda, MD).

Statistical Analysis
Two-way ANOVA were used to examine the effects of stretch and cytokine treatment.
Two-way repeated measures were used to examine the effects of IL-6 overexpression and
HFES in animal experiments. P values < 0.05 were considered significant.
5.4 Results:
Short term IL-6 or LIF administration disrupted stretch induction of myotube protein
synthesis
To determine if short term IL-6 and LIF will regulate stretch induction of myotube
protein synthesis, we stretched myotubes for 4h in the presence of either IL-6 or LIF.
Consistent with our previous finding, 4h stretch in control condition increased myotube
proteins synthesis (Fig. 5.1B). 4h administration of IL-6 and LIF significantly increased
basal myotube protein synthesis. However, 4h stretch in the presence of either IL-6 or LIF
resulted in a decrease, but not further increased in myotube protein synthesis (Fig. 5.1B).
Consistent with the changes in protein synthesis, 4h stretch increased the phosphorylation
of p70S6K (Fig. 5.1C). Either IL-6 or LIF alone also increased p70S6K phosphorylation,
but stretch decreased p70S6K phosphorylation of p70S6K in IL-6 or LIF treated myotubes
(Fig. 5.1C). These results demonstrate that although short term IL-6 or LIF alone is an
positive regulator of myotube protein synthesis, both IL-6 and LIF reversed the stretch
regulation of mTOR signaling and protein synthesis in myotubes.
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Long term IL-6 or LIF administration attenuated stretch induction of myotube protein
synthesis
To determine if long term IL-6 and LIF will regulate stretch induction of myotube
protein synthesis, we pre-incubated myotubes for 24h and stretched for in last 4h of IL6/LIF incubation. Stretch in absence of IL-6 or LIF increased myotube protein synthesis
(Fig. 5.2A). Long term exposure of both IL-6 and LIF resulted in protein synthesis
suppression (Fig. 5.2A). Most importantly, 4h stretch was not able to increase myotube
protein synthesis in the presence of either IL-6 or LIF (Fig. 5.2A). Consistent with the
changes in protein synthesis, long term exposure of IL-6 or LIF decreased p70S6K
phosphorylation (Fig. 5.2B). Stretch increased p70S6K phosphorylation in control
myotubes, but not in IL-6 or LIF treated myotubes (Fig. 5.2B). These results demonstrate
long term IL-6 or LIF exposure was able to attenuate stretch induction of protein synthesis
and mTOR signaling in cultured myotubes.

IL-6 overexpression had no effect on eccentric contraction induced muscle protein
synthesis
To determine the regulation of IL-6 on muscle protein synthesis inductions by eccentric
contractions, we conducted high frequency electrical stimulation (HFES) in control and IL6 overexpressing mice. In control mice, plasma IL-6 level was below the detection level at
the time of at the time of electroporation (D-0) and 4 days post electroporation (D-4). The
plasma IL-6 level of control mice increased to 139.8 ± 84.1 pg/ml at the time of sacrifice
(D-5, 3h post electrical stimulation). In mice transfected with IL-6 plasmids, the plasma
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IL-6 was not detected at the time of electroporation (D-0), but rises as early as 4 days post
electroporation (148.6 ± 34.2 pg/ml). The plasma IL-6 level in IL-6 overexpressing mice
reached to 769.9 ± 217.2 pg/ml at the time of sacrifice, which was significantly higher than
control mice (Fig. 5.3A). We also examined the effects of HEFS on muscle STAT3 and
p70S6K phosphorylation in control and IL-6 overexpressed mice. The HFES induced
eccentric contraction significantly increased muscle p70S6K phosphorylation in both
control and IL-6 overexpressing mice and IL-6 overexpression showed no effects on
p70S6K phosphorylation in either control or contracted muscles (Fig 5.3B). IL-6
overexpressing increased STAT3 phosphorylation (Fig. 5.3C). Interestingly, the HFES
increased STAT3 phosphorylation in control mice, but did not further increase muscle
STAT3 phosphorylation in IL-6 overexpressing mice (Fig. 5.3C). Similar with the changes
in p70S6K phosphorylation, HFES induced eccentric contraction increased muscle protein
synthesis both control and IL-6 overexpressing mice (Fig. 5.3D). These results
demonstrated that 5 days IL-6 overexpression had no effect on muscle protein synthesis
induction by eccentric contractions.

5.5 Discussion
The IL-6 family of cytokines IL-6 and LIF play a critical and enigmatic roles in local
regulation of the inflammatory process and skeletal muscle mass during physiological and
pathological conditions (5). Low levels of IL-6 can promote activation of satellite cells,
muscle regeneration and muscle growth while chronically elevated production of IL-6
promote skeletal muscle wasting (5, 237, 289). The sensitivity of muscle protein synthesis
regulation to mechanical stimulus is a potential regulator of muscle mass. But there is very
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limited understanding about the potential interaction of IL-6/LIF with skeletal muscle
mechanical signaling. Here, we reported that both short term and long term IL-6 and LIF
exposure disrupted the stretch induction of myotube protein synthesis. These results
suggest IL-6 and LIF may indirectly contribute to muscle protein synthesis suppression by
dissociating protein synthesis regulation from mechanical stimulation. However, IL-6 had
no influence of muscle mechanical signaling induced by eccentric contractions, which
demonstrate the 5-day did not change the muscle plasticity to eccentric contraction induced
protein synthesis.

The role of IL-6 and LIF in skeletal muscle hypertrophy is tightly associated with
muscle mechanical signaling (290). IL-6 and LIF are secreted by muscle fibers during
exercise or overload. The muscle production of IL-6 and LIF are necessary for overload
induced muscle hypertrophy (7, 8). However, potential regulation of IL-6 and LIF on
overload induced muscle protein synthesis has not been proposed yet. Here we report that
although short term exposure of IL-6 or LIF itself stimulated myotube mTORC1 signaling
and protein synthesis, stretch resulted in the presence of IL-6 or LIF resulted in suppression
and not further activation of myotube protein synthesis which is completely opposite to our
hypothesis. These results, as well as previous findings that overload induced muscle protein
synthesis was not attenuated in IL-6 deficient mice (8), suggest that muscle produced IL-6
may not be a positive regulator of mechanical stimuli induction of muscle protein synthesis.
However, these results go against our previous work which demonstrated that LIF-gp130
signaling play an important role in myotube mechanical signaling regulation of protein
synthesis, even in the LLC derived atrophic conditions (226). Notably, the LIF level in
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LLC conditional medium was ~1000 fold lower than that in our current experiment (226).
One potential explanation is that the effects of LIF on myotube mechanical signaling is
dose sensitive, or the LIF dose used in our current experiment is at supra-physiological
level. Nonetheless, further work in this area is required to explain the seeming
contradictory role of IL-6/LIF in stretch induction of myotube protein synthesis.

Increased mechanical signaling has been theorized to have potential for attenuating
cancer-induced muscle mass loss by activating muscle protein synthesis. However, under
pathological conditions, such as sarcopenia, diabetes and cancer cachexia, skeletal muscle
protein synthesis regulation show a resistance to multiple anabolic stimulus (175, 256, 288),
including mechanical signaling (25, 226), which would have the potential to accelerate the
wasting process and negatively impact the therapeutic potential of exercise and physical
activity interventions. However, present understanding concerning the potential mediators
of cachexia induced muscle mechanical signaling disruption is lacking. Here we reported
in addition to their direct inhibitory effects on basal myotube protein synthesis, long term
IL-6/LIF exposure also attenuated myotube protein synthesis induction by stretch. These
results clearly demonstrated that the pathological long term exposure of IL-6 and LIF are
enough to dissociate stretch induced mechanical signaling from myotube protein synthesis.
In addition, these results also provide some clues to further mechanistic studies of cachexia
induced muscle anabolic resistance (25, 226), by highlighting the importance of IL-6
family of cytokines in muscle mechanical signaling disruption. However, there is little
understanding about the potential signaling pathways in involved in mechanical signaling
disruption during cachexia. Our previous work suggest that STAT3, NFκB, ERK1/2 and
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p38 MAPK signaling may play a role in attenuated mechanical induction of muscle or
myotube mTOR signaling and protein synthesis in atrophic environment derived from
cancer cells (25, 226). However, the mechanisms underlying the cachexia induced muscle
mechanical signaling disruption and muscle anabolic resistance is far from fully understood.

HFES of the sciatic nerve produces eccentric contractions of the rodent TA and EDL
muscles is a widely used mechanical stimuli model inducing muscle protein synthesis and
hypertrophy. HFES induced eccentric contractions are also able to attenuate muscle protein
and muscle mass loss in tumor-bearing mice (283, 284). Here we report that the IL-6
overexpression did not change the protein synthesis induction by HFES induced eccentric
contractions. However, our current results cannot clearly explain the different regulation of
IL-6/LIF on protein synthesis induction between in vitro and in vivo mechanical stimuli
models. The difference in IL-6 level between two different models is a potential reason.
Previously reported that plasma IL-6 concentrations did reach ~22 pg/ml after strenuous
exercise (291), which is ~1000 fold less than the IL-6 doses used in our in vitro experiment
(20ng/ml). The plasma IL-6 level of our IL-6 over-expressing mice is also ~200 fold lower.
Although mechanical stimuli also induced muscle production of IL-6, which results in
higher IL-6 level in muscle microenvironment than its plasma level (289), it is possible that
the doses of IL-6 used in cell stretch experiment (20ng/ml) is supra-physiological level,
although it showed beneficial effects on basal myotube mTOR signaling and protein
synthesis regulation. The different IL-6 effects on proteins synthesis induction in different
models of mechanical stimuli may also due to the different mechanical signaling induced
by passive stretch and eccentric contractions. Although both stretch and eccentric
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contraction are able to induce mTOR signaling and protein synthesis in vitro and in vivo,
there is limited understanding about the upstream regulators mTOR signaling in these
mechanical stimuli models. The work here do demonstrate that the induction of mTOR
signaling, protein synthesis, as well as some stress and inflammatory signaling pathways
including PI3K/Akt, p38 MAPK, ERK1/2, NFκB and AMPK signaling in our myotube
stretch model (226, 292, 293). But the potential role of these signaling pathways in stretch
induction in stretch induction of myotube protein synthesis is far from fully understood.
Mechanical stretch can induce muscle mTOR signaling through growth factor/Akt
independent mechanisms (52). Further studies demonstrated that the induction of muscle
DGKζ kinase activity and subsequent accumulation of phosphatidic acid, a direct activator
of mTORC1 independent of TSC1/2 complex, is the key mechanism of stretch induced
mTOR signaling and protein synthesis in skeletal muscles (294). However, the role of this
signaling pathway has not been proposed in eccentric contraction model. Instead, the
phosphorylation of RxRxxS/T consensus motif on TSC2 (24) and S696, T706, and S863
site Raptor (295) play a key role in muscle mTOR signaling induction by eccentric
contractions. But the upstream regulators of these phosphorylation sites are still need to be
determined. One possibility is that IL-6 and LIF disrupt the mechanical signaling pathways
specific to stretch but not eccentric contractions. In addition of direct activation of mTOR
signaling in Akt independent mechanisms (16), eccentric contraction or stretch can also
induce muscle expression of growth factors IGF-1, and subsequent induction of Akt/mTOR
signaling pathway (296, 297). Interestingly, even pathological long term IL-6 exposure did
not block the insulin induction of Akt/mTOR signaling in cultured myotubes (20), which
suggest that eccentric contraction induced muscle secretion of IGF-1 is a redundant
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mechanism to induce muscle mTOR signaling and protein synthesis in the presence of IL6. Unlike the in vivo muscle eccentric contraction model, the potential myotube secreted
IGF-1 was diluted in culture medium and unable to induce myotube protein synthesis in
cell stretch model. However, much more work is still required to investigate the potential
difference in mechanical signaling pathways induced by stretch and eccentric contractions.

Taken together, our results are a starting point for future studies concerning the
potential importance for crosstalk between IL-6/LIF and myotube and skeletal muscle
mechanical signaling regulation of protein synthesis. Our results demonstrate that long
term pathological exposure of IL-6 can dissociate the stretch induced mechanical signaling
from mTORC1 signaling and protein synthesis in cultured myotubes. These results provide
new insights for IL-6/LIF regulation of muscle protein synthesis suppression under
pathological conditions, and suggest that long term pathological elevated IL-6/LIF may
contribute muscle protein synthesis suppression indirectly by attenuating protein synthesis
induction by mechanical stimulation. However, in vivo IL-6 overexpression mice did not
change the muscle protein synthesis induction by high-frequency eccentric contractions,
which demonstrate IL-6 alone cannot disrupt the mechanical signaling induced by muscle
eccentric contractions, and suggest that HFES induced muscle eccentric contractions is a
promising therapy to induce muscle protein synthesis and attenuate muscle wasting under
pathological conditions.

5.6 Figure Legends
Figure 5.1: Short term IL-6 or LIF regulation on stretch induced myotube protein
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synthesis and mTOR signaling. C2C12 myotubes were stretched for 4h in the presence
of IL-6 or LIF. A. Representative figure of cell stretch. The screw nuts were set to 30 cycles
from the baseline when stretch device was assembled (left) and were rotated by another 1.5
cycles when cells were stretched (right). B. Protein synthesis in myotubes stretched in the
presence of IL-6 or LIF was determined by puromycin incorporation. Dash lines represent
different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05 vs. IL-6/LIF treated
non-stretched group, two-way ANOVA. C. Phosphorylation of p70S6K in myotubes
stretched in the presence of IL-6 or LIF was determined by western blot. Dash lines
represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05 vs. IL6/LIF treated non-stretched group, two-way ANOVA.

Figure 5.2: Long term IL-6 or LIF regulation on stretch induced myotube protein
synthesis and mTOR signaling. C2C12 myotubes were incubated in IL-6 or LIF for 24h
and stretched in last 4h of IL-6/LIF incubation. A. Protein synthesis in myotubes stretched
in the presence of IL-6 or LIF was determined by puromycin incorporation. Dash lines
represent different parts on the same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs.
control group, two-way ANOVA. B. Phosphorylation of p70S6K in myotubes stretched in
the presence of IL-6 or LIF was determined by western blot. Dash lines represent different
parts on the same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs. control group, twoway ANOVA.

Figure 5.3: Regulation of IL-6 overexpression on eccentric contraction induced
muscle mTOR signaling and protein synthesis. A. Plasma IL-6 level of control and IL141

6 overexpressing mice at the time of electroporation (D-0), 4 days post electroporation (D4) and sacrifice (Sac), *: p < 0.05 vs. D-4 of IL-6 group, #: p < 0.05 vs. D-5 of control
group, two-way repeated measures. B. The phosphorylation of STAT3 in TA muscles of
non-stimulated control leg (Right, R) and HFES induced contracted leg (Left, L) was
measure by western blot. *: significant different from control group, #: significant different
from control-ECC group, two-way repeated measures. C. The phosphorylation of p70S6K
in TA muscles of non-stimulated control leg (Right, R) and HFES induced contracted leg
(Left, L) was measure by western blot. *: p < 0.05, main effect of HFES, two-way repeated
measures. D. The protein synthesis in TA muscles of non-stimulated control leg (Right, R)
and HFES induced contracted leg (Left, L) was determined by puromycin incorporation. *:
p < 0.05, main effect of HFES, two-way repeated measures.
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Figure 5.1: Short term IL-6 or LIF regulation on stretch induced myotube
protein synthesis and mTOR signaling.
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Figure 5.2: Long term IL-6 or LIF regulation on stretch induced
myotube protein synthesis and mTOR signaling.
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Figure 5.3: Regulation of IL-6 overexpression on eccentric contraction
induced muscle mTOR signaling and protein synthesis.
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Figure 5.3: Regulation of IL-6 overexpression on eccentric contraction
induced muscle mTOR signaling and protein synthesis.
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CHAPTER 6
OVERALL DISCUSSION
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Major findings
IL-6 family of cytokines have the pleiotropic functions in different tissues and organs,
including skeletal muscles. Skeletal muscle serves as both a biological target and source of
the IL-6 family of cytokines. Short term systematic elevation and muscle production of IL6 and LIF is required for mechanical stimuli induced muscle hypertrophy. However, the
long term systematic elevation of IL-6 and LIF are key regulator of muscle wasting in
cachexia. Regulation of muscle protein synthesis plays a key role in both mechanical
stimuli induced muscle hypertrophy and cachexia induced muscle atrophy, but the IL-6 and
LIF regulation of muscle protein synthesis under physiological or pathological conditions
has not been proposed yet. Finally, mechanical stimuli from passive stretch and eccentric
contractions is a strong hypertrophic stimulator on skeletal muscle by inducing muscle
protein synthesis pathways, but the mechanical stimuli induced muscle protein synthesis
pathways can be attenuated in cachexia induced catabolic environment. The overall
purpose of this dissertation is to determine if physiological short term or pathological long
term exposure of IL-6 and LIF will regulate protein synthesis and interact with mechanical
signaling in myotubes and skeletal muscles. We hypothesized that physiological, short term
inflammatory cytokine exposure would induce basal muscle protein synthesis through
gp130 activation of Akt-mTOR signaling, while pathological, long term cytokine exposure
would suppress basal muscle protein synthesis through gp130 activation of AMPK
signaling. Furthermore, physiological or pathological cytokine exposure would either
amplify or suppress mechanical regulation of muscle protein synthesis, respectively.

The data presented in this dissertation support our hypothesis that short term IL-6/LIF
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exposure increased protein synthesis, while long term IL-6/LIF suppression decreased
basal myotube protein synthesis. gp130 siRNA knockdown and Akt signaling inhibition
blocked myotube protein synthesis induction by IL-6 and LIF, which support our
hypothesis that gp130/Akt signaling plays a key role in myotube protein synthesis
induction by short term IL-6 and LIF. However, mTOR signaling inhibition did not
completely block the IL-6/LIF induction of myotube protein synthesis, which highlighted
the mTOR independent mechanisms. As we expected, AMPK signaling inhibition during
long term IL-6/LIF exposure rescued IL-6/LIF suppression on protein synthesis, which
goes with our hypothesis that AMPK is a key mediator of protein synthesis suppression by
long term IL-6/LIF exposure. Unexpectedly, the IL-6/LIF regulation of mechanical
signaling differs in different models mechanical stimuli models: Regardless of their
differential effects on basal myotube protein synthesis regulation, both short term and long
term IL-6/LIF exposure attenuated stretch induction of myotubes protein synthesis, but in
vivo IL-6 overexpression had no effect on muscle protein synthesis induction by eccentric
contractions.

Myotube protein synthesis regulation by IL-6 and LIF.
The current understanding of the mechanical stimuli induced IL-6/LIF’s role in
skeletal muscle hypertrophy focuses on their regulation on proliferation and differentiation
of satellite cells, while the induction of protein degradation related genes though
gp130/STAT3 signaling is considered as the major mechanisms of IL-6 regulation of
muscle wasting in cachexia. The muscle protein mTOR signaling is plays a key role in
muscle mass regulation. The results in this dissertation demonstrate both IL-6 and LIF have
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the capability to stimulate and suppress mTOR signaling and protein synthesis in culture
myotubes, and the duration of IL-6/LIF exposure is a key determinant of their differential
effects. These results further strengthen the dual role of IL-6 family of cytokines in muscle
mass regulation, and suggest that differential regulation of protein synthesis, at least,
contribute to the IL-6/LIF regulation on muscle hypertrophy and atrophy in physiological
and pathological conditions, respectively.

gp130 dependent signaling regulation by IL-6/LIF.
All IL-6 family of cytokines induce intracellular signaling pathways though their
functional receptor complex which is composed by their specific receptor and gp130.
Regardless of different compositions of protein subunits, the functional receptor complexes
of all IL-6 family of cytokines require at least one copy of gp130 protein. The formation of
ligand-receptor protein complex leads to the phosphorylation tyrosine residues in the distal
cytoplasmic domains of gp130 by activating constitutively bound Janus family kinases, or
Tyk2. Phosphorylated gp130 can recruit and phosphorylate its downstream effectors,
including STAT3. Not surprisingly, we reported the siRNA knock-down of gp130
attenuated IL-6/LIF induction of myotube protein synthesis. These results demonstrated
gp130 is necessary for short term IL-6/LIF induction of myotube protein synthesis and
further support the central role of gp130 in biological processes regulated by IL-6 family
of cytokines. We also measured the IL-6/LIF time course regulation of gp130 dependent
signaling pathways. Both IL-6 and LIF induced a transient induction of STAT3
phosphorylation, which went back to basal level after 4h IL-6/LIF exposure. The transient
pattern of STAT3 phosphorylation is associated with the increased expression of SOCS3,
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which can inhibit gp130 signaling pathways by competitively binding with JAK1 and
JAK2. These results showed the induction of classical SOCS3 dependent negative feedback
loop of gp130 signaling. Interestingly, the IL-6/LIF induced myotube protein synthesis
showed a similar time course pattern as STAT3: the IL-6/LIF induction of myotube protein
synthesis peaks at 2h, then showed a trend to go back to basal level. Due to the importance
of gp130 in IL-6/LIF induction of protein synthesis, these results suggest IL-6/LIF induced
SOCS3 dependent negative feedback loop may also suppress the IL-6/LIF induction of
protein synthesis. Indeed, previous report which showed SOCS3 is a potential regulator of
muscle protein synthesis suppression in IL-6 overexpressing mice (268). However, more
work is required to determine the role of IL-6/LIF induced STAT3-SOCS3 dependent
negative feedback loop in time course regulation of myotube protein synthesis.

We also investigated the long term IL-6/LIF regulation on myotube gp130 signaling.
Long term IL-6 and LIF exposure demonstrated differential regulation of gp130 signaling:
24h IL-6 exposure increased phosphorylation of STAT3 and ERK1/2 in a dose dependent
manner, but LIF did not change their phosphorylation. Interestingly, the SOCS3 expression
is only induced in myotube treated with LIF, but not IL-6. Suggesting the IL-6 induced
STAT3 and ERK1/2 signaling is caused by disrupted SOCS3 dependent negative feedback
mechanisms. Both IL-6 and LIF decreased Akt phosphorylation, which is a potential
contributor to IL-6/LIF suppression of mTOR and protein synthesis. However, more work
is required to determine the upstream regulators of Akt signaling induced by long term IL6/LIF exposure. Taken together, these results demonstrated the differential regulation of
gp130 signaling between short term and long term IL-6/LIF exposure.
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Role of Akt signaling in short term IL-6/LIF regulation of myotube protein synthesis
The Akt signaling has emerged as a key intermediary in the response of muscle to
activity, nutrients growth factors, and cytokines. The activation of PI3K/Akt signaling
results in anabolic shift of muscle protein turnover. It can stimulate muscle protein
synthesis though the classical mTOR signaling, and suppress muscle protein degradation
by the phosphorylation of FOXO3, thus inhibit its transcriptional induction of genes
involved in ubiquitin proteasome system: MuRF-1 and Atrogin-1. The gp130 activation by
IL-6 family of cytokines also has the potential to induce PI3K/Akt signaling, but the precise
mechanisms still remain to be determined and this regulation seems to be cell specific. In
cardiac myocyte, both IL-6 and LIF can induce the gp130-PI3K-Akt signaling axis and
subsequent protein synthesis, which plays a key role in IL-6/LIF induced cardiac muscle
hypertrophy. We have found that short term IL-6 and LIF exposure increased Akt
phosphorylation in cultured myotubes, which established the IL-6/LIF regulation on
PI3K/Akt signaling in skeletal muscle cells. Most, importantly, inhibition of PI3K/Akt
signaling by PI3K inhibitor wortmannin completely blocked the IL-6/LIF induction of
protein synthesis. These results demonstrated the central role of PI3K/Akt signaling
induction in IL-6/LIF regulation of myotube protein synthesis. Interestingly, long term IL6 or LIF exposure decreased Akt phosphorylation, suggesting the disrupted signaling
transduction from gp130 to Akt, or the presence of other PI3K/Akt suppressor. Mice
overexpressing IL-6 showed decreased plasma IGF-1 level (268). and IL-6 is able to induce
muscle expression of SOCS3 (260) and myostatin (298), which can negatively regulate of
PI3K/Akt signaling by the degradation of IRS-1 (299), These results suggest the IL-6 and
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LIF may suppress myotubes Akt signaling by transcriptional regulation of upstream
regulators of Akt. Suppressed Akt signaling is an obvious negative regulator of mTOR
signaling and protein synthesis, which showed significant decreased in long term IL-6/LIF
treated myotubes. However, IL-6 and LIF suppression of myotube mTOR signaling and
protein synthesis was completely restored by the inhibition of AMPK, which is an
independent upstream regulator mTOR signaling. Our previous work also reported that
insulin induction of myotube mTOR signaling was not attenuated by long term IL-6
exposure. However, future work is still needed to determine the role of Akt signaling in
muscle protein synthesis regulation by long term exposure of IL-6 family of cytokines.

Role of mTOR signaling in short term IL-6/LIF regulation of myotube protein synthesis
The mTOR signaling plays a pivotal role in the regulation of skeletal muscle protein
synthesis, and mTOR signaling activation is necessary for muscle hypertrophic process in
response to multiple anabolic stimulus, such as growth factors, energy status, amino acids
and mechanical stimuli. Akt is considered an important upstream regulator of mTOR
signaling, therefore, we further investigated the role of mTOR signaling in short term IL6/LIF induction of myotube protein synthesis. As we expected, mTOR signaling inhibition
by rapamycin decreased basal protein synthesis. Surprisingly, we found mTOR inhibition
did not completely block the protein synthesis induction by either IL-6 or LIF. These results
clearly demonstrate short term IL-6 and LIF can induce myotube protein synthesis through
mTOR independent mechanisms, and unravel a novel aspect of protein synthesis regulation
in muscle cells. Although it has been repeatedly demonstrated that mTOR signaling plays
a central role in muscle protein synthesis induction by large varieties of anabolic stimulus,
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several studies reported the mTOR independent muscle protein synthesis induction by
glucose or leucine supplementation. The direct phosphorylation eIF4G, which leads to
increased protein translation initiation, is a key mechanism of mTOR independent protein
synthesis induction by leucine, but the potential upstream regulator still need to be
determined. In cancer cells, the ERK1/2-MNK signaling cascade can also bypass mTORC1
and activate protein synthesis in by phosphorylating eIF4E. Future work is still needed to
identify the mTOR independent signaling pathways mediating IL-6/LIF induction of
myotube protein synthesis. Our results showed Akt signaling inhibition blocked myotubes
protein synthesis induction, suggesting this IL-6/LIF induced mTOR independent activator
is still dependent on Akt signaling. But more work is still needed to determine the mTOR
independent myotube protein synthesis activators induced by IL-6/LIF.

Role of STAT3 signaling in IL-6/LIF regulation of myotube protein synthesis
STAT3 signaling is an important downstream effects of gp130. Once phosphorylated
and activated , STAT3 proteins dimerize and translocate into nucleus to induce
transcriptions of its target genes. STAT3 induction has a documented role in IL-6 regulation
of muscle hypertrophy and atrophy.

STAT3 pathway was shown to be necessary for

myoblast proliferation based on its capacity to regulate the expression of cell cycle
associated genes (197). STAT3 signaling is also involved in myogenessis by regulation
MyoD gene expression (196). The pathological induction of STAT3 also play a key role in
regulation expression of genes involved in protein degradation during cancer cachexia.
However, no study demonstrated the role of STAT3 signaling in muscle protein synthesis
regulation during IL-6 family of cytokines induced muscle hypertrophy or atrophy. Here,
154

we report inhibition of STAT3 signaling by siRNA knock or different pharmaceutical
inhibitors did not influence the myotube protein synthesis regulation by short term or long
term exposure of IL-6 and LIF. This findings also go with our previous reports that STAT3
signaling inhibition did not the rescue the cachexia suppression of muscle protein synthesis
in vitro and in vivo. These results demonstrate STAT3 signaling is not necessary for
myotube protein synthesis regulation by either short term or long term IL-6 and LIF
exposure, and suggests that STAT3 is not directly involved in muscle protein synthesis
regulation.

Role of AMPK signaling in IL-6/LIF regulation of AMPK signaling
An energy deficiency or cachectic environment can induce the induction AMPK
signaling, which plays a role in catabolic shift of muscle protein turnover regulation,
through mTOR signaling inhibition (17), induction of FOXO-dependent E3 ubiquitin
ligase transcription (273), and increased autophagy processes (274). The severe cachectic
ApcMin/+ mice showed increased muscle AMPK signaling activity, which may contribute
to muscle protein synthesis regulation.
We reported the long term exposure of IL-6 or LIF induced AMPK signaling in
myotubes. Most importantly, AMPK inhibition by compound C during the IL-6/LIF
administration rescued the myotube protein synthesis suppression by IL-6/LIF. These
results, consistent with our previously findings (20), clearly demonstrate induction of
pathological AMPK signaling activation is a key mediator of IL-6/LIF suppression of
protein synthesis under pathological conditions. However, long term inhibition of AMPK
signaling by siRNA knockdown decreased basal myotube protein synthesis and showed no
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rescue effects on protein synthesis suppression by IL-6/LIF, which demonstrate the basal
AMPK signaling is required still required for maintaining basal protein synthesis in
myotubes. It is possible that basal AMPK signaling contributes protein synthesis
maintenance by maintaining metabolic homeostasis (279). Further work is the required to
determine the mechanisms underlying the AMPK signaling induction by long term
elevation of IL-6 family of cytokines.

Interaction of IL-6/LIF with mechanical signaling induced by stretch and eccentric
contractions.
Mechanical stimuli is an important anabolic regulator of muscle protein synthesis and
muscle hypertrophy (21). Therefore, it is theorized that regulating the sensitivity of muscle
proteins synthesis can contribute to muscle mass regulation. However, there is quite limited
understanding about the potential regulation of IL-6 and LIF in muscle mechanical
signaling which regulate protein synthesis. In this dissertation we reported the regulation
of IL-6 and LIF on mechanical signaling in myotube stretch models. Unlike what we
hypothesized they disrupted stretch regulation of myotubes protein synthesis. These results
suggest the potential role of IL-6 family of cytokines in muscle anabolic resistance, which
is observed in many pathological conditions including cancer cachexia (25, 300). It is
possible that suppression of protein synthesis induction by mechanical stimuli from daily
activities contribute the protein synthesis suppression under IL-6/LIF involved
pathological conditions. However, we did not observe similar attenuation effects in HEFS
induced muscle eccentric contraction model. It is possible muscle eccentric contraction can
induce different anabolic signaling pathways which is independent from IL-6 regulations.
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However, lots of work is still needed to determine the potential interactions of downstream
signaling pathways regulated by IL-6/LIF and mechanical stimulus.

Conclusions and Future Directions
In summary, we demonstrated that short term exposure of IL-6 family of cytokines IL6 and LIF can induce myotube proteins synthesis by inducing gp130-Akt signaling axis,
while the long term exposure of IL-6 or LIF decreased myotube protein synthesis by
activation of AMPK signaling. Finally, the IL-6 and LIF showed differential regulation on
mechanical signaling in different experimental models mechanical stimuli: IL-6 or LIF
administration blocked the myotube protein synthesis induction by mechanical stretch, but
in vivo IL-6 overexpression had no effect on eccentric contraction induced muscle protein
synthesis. These findings suggest that IL-6 family of cytokines have the potential to
activate and suppress protein synthesis as well as interact with mechanical signaling in
skeletal muscle cells. Our work provides a new insight of the mechanism of the IL-6 family
of cytokines’ role in muscle mass regulation under physiological and pathological
conditions.

Although the data presented in this dissertation push forward our understanding about
the role of IL-6 and LIF in muscle mass regulation, there are still a lot of gaps of our
understanding. We have demonstrated the IL-6 and LIF have the ability to positively and
negatively regulation protein synthesis in cultured myotubes, but the relative importance
of protein synthesis activation or suppression in IL-6/LIF regulation of muscle mass still
need to be determined. Our current results also exclude the potential crosstalk of IL-6/LIF
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with other cytokines under physiological and pathological conditions. The molecular
mechanism underlying the IL-6/LIF activation or suppression of myotube protein synthesis
is also far from fully understood. Finally, we still need to determine the potential
interactions of IL-6/LIF induced intracellular signaling pathways on mechanical signaling
in different mechanical stimuli models.
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C2C12 Cell Culture
Materials and Reagents
C2C12 Myoblast (ATCC, Catalog #: CRL-1772)
Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Catalog #: 30-2002)
Fetal Bovine Serum (FBS) (ATCC, Catalog #: 30-2020)
Horse Serum (ATCC, Catalog #: 30-2020)
100 × Penicillin/Streptmycin Solution (10,000 U/mL) (Thermo Scientific, Catalog #:
15140122)
Trypsin-EDTA (Thermo Scientific, Catalog #: 25200056)
Cell culture flasks
6-well plates
Cell culture hood
CO2 incubator (37°C, 5% CO2)
Culture Mdium:
Growth Media: DMEM with 10% FBS, 100U/ml Penicillin/Streptmycin
Differentiation Media: DMEM with 2% FBS, 100U/ml Penicillin/Streptmycin
Revive Cells
1. Pre-warm growth media in 37°C water bath for ~20min
2. Transfer ~10ml warm growth medium into a 15ml falcon tube.
3. Thaw frozen cells in 37°C water bath, keep the lower part of cryogenic vial into the
water, swirl and shake gently.
4. When the ice chunk disappears, transfer cells suspend in cryogenic vial into warm
growth media in 15ml falcon tube immediately.
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5. Centrifuge cell suspend 1500rpm for 5min at 37°C.
6. Remove supernatant, re-suspend cells with ~10ml growth medium.
7. Transfer cell suspend into a cell culture flasks, keep cells in 37°C, 5% CO2 incubator.
Divide Cells (Keep the coverage of C2C12 myoblasts less than 80% to maintain their
differentiation ability)
1. Pre-warm growth medium in 37°C water bath for ~20min
2. Remove old cell culture medium.
3. Wash cells with sterile PBS once (~6ml per 75cm2 cell culture flask)
4. Add Trypsin-EDTA onto cells (1ml per 75cm2 cell culture flask), put cell culture flask
into 37°C, 5% CO2 incubator. Incubate for 3-5min.
5. When most cells are detached from the flask, add warm growth medium (at least 3ml
per 75cm2 cell culture flask).
6. Add more growth medium to the desired volume (8-10ml per 75cm2 cell culture flask,
2 ml for one well of 6-well plate).
7. Transfer cell suspend to new cell culture flask/6-well plats, keep cells in 37°C, 5% CO2
incubator
Freeze Cells
1. Trypsin digestion of cells grown in cell culture flask (step 1-5 in ‘Divide Cells’ section).
2. Transfer cell suspend to 15ml or 50ml falcon tubes, centrifuge cell suspend 1500rpm
for 5min at 37°C.
3. Remove supernatant, re-suspend cells with growth medium containing 5% DMSO.
4. Aliquot cells suspend into cryogenic vials.
5. Put cryogenic vials into isopropanol bath, and transfer vials into -80°C.
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6. For longer storage, transfer cells into liquid nitrogen when cells are frozen in -80°C
fridge.
Differentiation
1. Trypsin digestion of cells grown in cell culture flask (step 1-5 in ‘Divide Cells’ section).
2. Transfer cell suspend to 6-well plates, keep cells in 37°C, 5% CO2 incubator.
3. When cells reach 95%-100% coverage, switch old growth media into differentiation
medium, keep cells in 37°C, 5% CO2 incubator.
4. Change differentiation medium every 2 days during differentiation.
5. Myotubes forms after 4-5 days of differentiation.

siRNA Transfection
Materials and Reagents
5 × siRNA Buffer (GE Healthcare-Dharmacon, Catalog #: 002000)
RNase-free H2O (GE Healthcare-Dharmacon, Catalog #: 002000)
siRNA
DMEM (no serum or antibiotics)
Complete cell culture medium (without antibody)
Dharmafect III Transfection Reagent (GE Healthcare-Dharmacon, Catalog #: T-2003)
1. Make 1 × siRNA buffer using 5 × siRNA Buffer and RNase-free H2O. Dilute siRNA
to 20μM stock solution by 1 × siRNA buffer, store siRNA aliquot into -20°C.
2. Calculate the volume of siRNA stock concentration and Dharmafect III Transfection
Reagent required for experiment. One well of 6-well plate requires 2ml culture medium,
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in which the final concentration of siRNA is 20-100nM, and the volume of transfection
reagent is 1-10μl.
3. Prepare two sets of 15ml falcon tubes, termed as Tube 1 and Tube 2.
4. In Tube 1, dilute siRNA stock solution using serum free DMEM up to 200μl/each well
(for cell culture of 6-well plates), mix by pipetting gently.
5. In Tube 2, dilute Dharmafect III Transfection Reagent stock solution using serum free
DMEM up to 200μl/each well (for cell culture of 6-well plates), mix by pipetting gently.
6. Let Tube 1 and Tube 2 sit at room temperature for 5min.
7. Transfer contents of Tube 1 to Tubes 2, mix by pipetting gently. Let the mixture sit at
room temperature for 20min.
8. Add complete cell culture medium without antibiotics to the mixture of step 7, volume
up to 2ml/well (for 6-well plate culture). This is transfection medium.
9. Wash cells by sterile PBS twice, add transfection medium to cell culture.
10. Incubate cells in transfection medium for 24-48h.
Protein Sample Collection from Cultured Cells
Materials and Reagents
RIPA Buffer: 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.5%
sodium deoxycholate, 0.1% SDS, 5 mM NaF, 1 mM NaVO4, 1 mM βglycerophosphate, and 1% protease inhibitor cocktail (added bofore use)
1. Remove cell culture medium.
2. Wash cells with ice-cold PBS.
3. Add ice-cold RIPA buffer onto the cells (~100-150μl/well of 6-well plate).
4. Scrape cells off using rubber scraper.
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5. Transfer RIPA buffer containing cell lysate into an ependorf tube, keep samples on ice.
6. Ultra-sound sonicate cell lysate on ice (3-5 time, 5s each time with 5-10s interval
between 2 sonications).
7. Centrifuge samples 13000rpm for 10min at 4°C.
8. Transfer supernatant to a new ependorf tube, discard pellets.
9. Run protein assay (Bradford).
10. Store samples in -80°C.
Protein Sample Collection from Tissues
Materials and Reagents
Mueller Buffer:
Mueller Buffer
HEPES
Triton-X100
EGTA (pH 8.0)
EDTA (pH 8.0)
Na4P2O7
β
glycerophosphat
e
NaF
NaVO4
dH2O
Protease
Inhibitor

Stock
Solution
500mM
100%
500mM
500mM
100mM

Desired
Concentration
50mM
0.10%
4mM
10mM
15mM

Volume
of
needed(ul)
600
6
48
120
900

2M

100mM

300

500mM
1M
-

25mM
5mM
-

300
50
3585

-

-

60
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stock

Mueller Diluent:
Mueller Diluent

Stock
Solution
100%
100mM
500mM

Desired
Concentration
50%
50mM
2.5mM

Volume
of
needed(ul)
1500
1500
15

stock

Glycerol
Na4P2O7
EGTA (pH 8.0)
β
mercaptoethano 500mM
1mM
6
l
Protease
30
Inhibitor
1. Weigh out the samples to be used and place weighted portion into an ependorf tube
labeled with the sample and M.
2. Add 10ul/mg tissue of Mueller buffer to the homogenization tube and add sample.
3. Homogenize in glass on glass tissue homogenizer keeping the sample in ice while
homogenizing. (homogenize ~30s check sample repeat if needed)
4. Wash glass tissue homogenizer 3 times by dH2O between two samples.
5. Transfer tissue homogenate back to ependorf tube.
6. Spin samples at 13,000rpm for 10min at 4°C.
7. Transfer supernatant to clean ependorf tube labeled with sample and D, discard the
pellet.
8. Add 5ul/mg tissue of Diluent buffer to the D tube and vortex.
9. Run protein assay (Bradford).
10. Dilute samples down to a working concentration in a new tube labeled with the sample
and the working concentration. Keep both D tube and diluted samples in -80°C.
Protein Assay (Bradford Assay)
Materials and Reagents
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Bradford Reagent (Bio-Rad, Catalog #: 5000006)
1. Make a stock of 1mg/ml BSA in PBS, store aliquot in -20°C.
2. In a clear flat bottom 96 well plate create a standard curve with the 1ug/ul BSA solution
from 0-14ug in duplicate or triplicate
3. Dilute samples 1:5 in a new tube with water (5ul sample: 20ul dH20)
4. Add 5ul of the diluted samples to the wells of the plate being sure to run them in duplicate
or triplicate
5. Make a 1:5 dilution of Bradford reagent. You will need enough for 300ul/well. Be sure
to clean the glassware well before you use it with soap and water.
6. Add 300ul of diluted Bradford reagent to each well.
7. Let sit in dark drawer for 15 minutes
8. Read in plate reader at 595nm
9. Calculate protein concentration based on standard curve
a. Create curve being sure to subtract out the zero value from both curve and samples.
b.

Calculate

protein

concentration

using

y=mx+b

(sample=con*slope+intercept -> con=(sample-intercept)/slope)

SDS Page/Western Blot
Materials and Reagents
For SDS-PAGE gel
Acrylamide Solution (38.5% Acrylamide + 1% Bis-Acrylamide)
1.5M Tris-HCL, pH 8.8
1.0M Tris-HCL, pH 6.8
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equation

10% SDS
10% APS.
TEMED
4×SDS Loading Buffer: 200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8% SDS, 0.4%
bromophenol blue, 40% glycerol
SDS Running Buffer: 25mM Tris, 200mM Glycine, 0.1% SDS
Protein Ladder (Bio-Rad, Catalog #: 1610373)
Transfer Buffer: 25mM Tris, 200mM Glycine, 20% Methanol
1×TBST: 50 mM Tris-Cl, 150 mM NaCl, 0.1% Tween-20
5% milk (solved in 1×TBST)
ECL plus (Thermo Scientific, Catalog #: 1610373)
SDS Page
1. Make gel. Base the % off of what molecular weight the protein of interest is.
2. Prepare samples
a. Pipette desired amount of protein into ependorf tube
b. Add correct volume of 4 × SDS loading dye
c. Vortex and do a quick spin
d. Heat in heat block at 100°C or in boiling water for 5 minutes
e. Quick spin
3. Load 4ul of protein ladder to the 1st lane in the gel
4. Load all of sample on gel
5. Run gel at 200V for ~1h or until samples have run through the gel
Transfer
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6. Prepare 750ml of transfer buffer
7. Prepare membrane by placing in a small amount of methanol for 1 minute
8. Pour methanol into the transfer buffer and wash membranes with the transfer buffer
9. Set up the transfer with the black side of the holder facing down, sponge, blotting paper,
gel, membrane (be sure there are absolutely no bubbles between the gel and the membrane),
blotting paper, sponge, white/clear side.
10. Carefully close the sandwich and place in the transfer box black side to black side and
clear side facing the red side of the transfer box.
11. Place ice pack in the box and pour remaining transfer buffer into the box.
12. Transfer either overnight at 70mA or for 200min at 200mA making sure to pack well
with ice.
Probing
13. Prepare 5% milk in 1×TBST solution
14. Remove membrane from transfer and place in ponceau solution for 3-5 minutes
15. Rinse off excess ponceau with dH2O and place membrane in plastic sheet and scan into
computer
16. Wash off ponceau with 1×TBST
17. Block the membrane for 1h in 5% TBST milk solution (made in step 13)
18. Incubate in primary antibody in milk solution
19. Wash membranes 3× with 1×TBST for 5 minutes each
20. Incubate in secondary antibody in milk solution for 1 hour
21. Wash membranes 3× with 1×TBST for 5 minutes each
22. Develop with ECL or ECL quantum.
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RNA Isolation (from cell culture)
Materials and Reagents
RNase AWAY (Thermo Scientific, Catalog #: 10328011)
Trizol Reagents (Thermo Scientific, Catalog #: 15596026)
Chloroform
Isopropanol Alcohol
DEPC H2O
75% ethanol in DEPC H2O
1. Clean work area thoroughly with alcohol
2. Label 3 sets of sterile RNAase free 1.5mL eppendorf tubes
3. Remove cell culture medium, and wash cells once by ice-cold PBS
4. Remove PBS, add Trizol reagent onto the cell (1ml Trizol for each well of 6-well plate).
5. Scrape cell off from cell culture plate gently with rubber scraper, pipette cell suspended
in Trizol up and down several times with 1ml pipette to brake cell thoroughly.
6. Transfer cell homogenate to a sterile 1.5mL tube.
7. Let samples sit at RT for ~5 minutes.
8. Add 200ul of chloroform to each tube
9. Shake tubes (DO NOT VORTEX) for 15-30s (should be the color of pepto bismal).
10. Let samples sit at RT for 2-3min.
11. Spin samples at 12000rpm for 15 minutes at 4°C.
12. Clean gloves and pipette with RNAase AWAY.
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13. Transfer clear supernatant to new tube carefully, Do NOT disturb the protein interface
(white layer) or organic phase (red/pink colored).
14. Add 500ul of isopropanol and invert to mix.
15. Incubate for 20-30 minutes at RT.
16. Spin samples at 12000rpm for 10 minutes at 4°C, gel like pellet can be visualized at the
bottom of tube.
17. Dump the supernatant being careful not to lose the pellet.
18. Add 1mL 75% EtOH in DEPC to RNA pellet invert to break loose.
19. Spin at 9500rpm for 5 min at 4°C.
20. Repeat steps 18-20 once.
21. Air dry tubes upside down in hood for 10-20 minutes (on towel of Kimwipes).
22. Add ~20-40ul of DEPC water to dissolve pellet, pipette to solve RNA (Keep track of
the amount of DEPC added).
23. Read on spec (1-2ul RNA+800ul dH2O) in quartz cuvette/NANO DROP and record
260/280/and 230 measurements. (Good quality of RNA samples should have 260/280
ratio > 1.8 and 260/230 > 1.8. Do not use samples with 260/280 below 1.6)
24. Calculate and Record RNA concentration: RNA= (OD260*40*0.8)/ volume RNA
added to cuvette.
25. Store RNA samples in -80°C.

cDNA synthesis
Materials and Reagents:
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Catalog #: 4368813)
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DEPC H2O
1. Prepare reverse transcriptase cocktail as follows and keep on ice.
Reagent
ul/sample
DEPC
4.2
10X RT buffer
2.0
dNTP mix
0.8
10X
Random 2.0
Primers
Reverse
1.0
Transcriptase
10.0
Total
2. In a cold block add 3ug of RNA in a 200ul PCR tube and volume to 10ul with DEPC
water.
3. Add 10ul of reverse transcriptase cocktail to each tube.
4. Put in thermocycler on program as follows:
a. 25°C for 10 min
b. 42°C for 50 min
c. 70°C for 15 min
d. 4°C Hold
5. Store all samples in -20°C.
RT PCR
Materials and Reagents:
iTaq™ Universal SYBR® Green Supermix (Bio-Rad, Catalog #: 1725121)
ddH2O
1. Dilute cDNA samples 1:10 and 1:100 (serial dilution) with ddH2O, keep samples on
cold block.
2. Fill out plate template, all samples are in duplicate.
3. Prepare master mix solutions as follows, keep master mix on ice.
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Reagent
Syber Green Mix
Forward Primer (20uM)
Reverse Primer (20uM)

ul/sample
10.0
1.0
1.0

12.0
Total
4. Load 8ul of cDNA to each well as per template.
5. Load 12ul of master mix solution into each well, DO NOT introduce bubbles.
6. Cover plate with plate cover sheet
7. Spin plate in centrifuge in environmental genomics core
8. Put plate onto Applied Biosystems 7300 Real-Time PCR System
9. Add dissociation step and set volume to 20ul.
10. Start analysis.
11. Turn OFF machine when finished.

IL-6 Electroporation
1. Prepare plasmids. They are typically at a concentration of 2-3 ug/ul. Dilute to 1 ug/ul in
sterile saline. Need 40 ug of plasmid per injection.
2. Start anesthesia with Isoflurane at 1-2%/1L O2. (Change percentage of isoflurane based
on the level of consciousness of the mice.)
3. Add mice to the anesthesia box.
4. Place mouse under nose cone. Shave top of quad. Alcohol off skin and betadyne.
5. Sterilize Scissors with bead sterilizer and alcohol. Make a small vertical snip with
scissors over quad.
6. Inject plasmid (50 ug at 1 ug/ul=50 ul) VERY SLOWLY in the middle of the quad using
insulin syringe.
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7. Electroporate with default setting. 100 mV; 50 ms; 8 pulses. Make sure electrodes are
under the skin, next to the quad. Touch foot pedal once to start the electrical current.
8. Close the incision with a wound clip.
9. Return mouse to cage.
10. Remove wound clip in 7-10 days.

IL-6 ELISA
Materials and Reagents:
Coating Buffer: 100mM Sodium Carbonate, pH 9.5.
Assay Diluent: PBS with 10% FBS
Wash Buffer: PBS with 0.05% Tween-20
TMB-ELISA Substrate Solution (Thermo Scientific, Catalog #: 34028)
Stop Solution: 2N H2SO4
Mouse IL-6 ELISA Kit (BD Bioscience, Catalog #: 555240)
IL-6 Standard (Reconstitute by dH2O to 1ng/ml)
Capture Antibody (Anti-Mouse IL-6 monoclonal antibody, 1:250)
Detection Antibody (Biotinylated Anti-Mouse IL-6 monoclonal antibody,1:500)
Enzyme

Reagent

(Streptavidin-horseradish

peroxidase

conjugate

(SAv-

HRP)1:250)
1. Coat microwells with 100 μL per well of Capture Antibody diluted 1:250 in Coating
Buffer. Seal plate and incubate overnight at 4°C.
2. Aspirate wells and wash 3 times with ≥ 300 μL/well Wash Buffer. After last wash,
invert plate and blot on absorbent paper to remove any residual buffer.
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3. Block plates with ≥ 200 μL/well Assay Diluent. Incubate at RT for 1 hour.
4. Prepare the IL-6 standards.
a) Prepare a 1000 pg/mL standard from the stock standard. Vortex to mix.
b) Add 300 μL Assay Diluent to 6 tubes. Label as 500 pg/mL, 250 pg/mL, 125pg/mL,
62.5 pg/mL, 31.3 pg/mL, and 15.6 pg/mL.
c) Perform serial dilutions by adding 300 μL of each standard to the next tube and
vortexing between each transfer. Assay Diluent serves as the zero standard (0
pg/mL).
5. Aspirate/wash as in step 2.
6. Pipette 100 μL of each standard, sample, and control into appropriate wells. Seal plate
and incubate for 2 hours at RT.
7. Aspirate/ wash as in step 2, but with 5 total washes.
8. Add 100 μL of Working Detector (1:500 Detection Antibody + 1:250 SAv-HRP
reagent, solved in Assay Diluent) to each well. Seal plate and incubate for 1 hour at RT.
9. Aspirate/ wash as in step 2, but with 7 total washes.
10. Add 100 μL of TMB-ELISA Substrate Solution to each well. Incubate plate (without
plate sealer) for 30 minutes at room temperature in the dark.
11. Add 50 μL of Stop Solution to each well.
12. Read absorbance at 450 nm within 30 minutes of stopping reaction.
13. Calculate protein concentration based on standard curve
a) Create curve being sure to subtract out the zero value from both curve and samples.
b) Calculate

protein

concentration

using

y=mx+b

(sample=con*slope+intercept -> con=(sample-intercept)/slope)
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equation

Cell Stretch
Materials and Reagents:
Uniaxle Stretch Device (See schematic picture below).

Silastic Sheet (GLOSS/GLOSS, 0.02’’, Speciality Manufacturing Inc.)
Type I Collagen from rat tail (Advanced Biomatrix, Catalog #: 34028)
10N NaOH (Sterile filtered)
pH paper.
1. Assemble cell stretch device.
a) Cut silastic sheet into 1.5’×2’ squares.
b) Adjust screw nuts (part 3) on two side arms (part 1) 30 cycles from baseline (part
2)
c) Fix the silastic sheet (part 5) with two C-shaped rings (part 4).
2. Immerse cell stretch devices into a beaker of dH2O, seal the beaker with foil and
autoclave (liquid program).
3. Autoclave a pair of twizzles.
4. Pick out cell stretch devices out of dH2O inside cell culture hood, transfer cell stretch
devices into sterile petri dishes (see picture below).
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5. Dilute Type I collagen solution by ice-cold sterile PBS to 200μg/ml, use 10N NaOH to
adjust pH to ~7.0-8.0 (estimate pH by pH paper).
6. Carefully pipette ~1ml diluted Type I collagen solution onto the silastic sheet of
stretching device. Use pipette to spread out the solution throughout the sheet carefully.
7. Leave stretching device in RT overnight, the collagen can polymerize into fibers to
make gel-like solution.
8. Air dry the collagen solution on the stretching device in the cell culture hood.
9. Wash off the crystalized salt on the silastic sheet of stretching device by dH2O.
10. Prepare C2C12 myoblasts suspend by trypsin digestion (see step 1-5 in ‘Divide Cell’
section of C2C12 cell culture).
11. Pipette ~1ml C2C12 myoblasts suspend on to the silastic sheet of stretching device.
Use pipette to spread out the cell suspend throughout the sheet carefully.
12. Shake the petri dish containing stretching device very gently to help cells attach onto
the silastic sheet evenly.
13. Transfer petri dish containing stretching device into 37°C, 5% CO2 incubator.
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14. After ~2h, add more growth medium to cover the cells on silastic sheet of stretching
devices.
15. Induce differentiation when C2C12 myoblast reach over 95% coverage on stretching
devices.
16. After 4-5 days differentiation, rotate screw nuts (part 3) on two side arms (part 1) by
sterile twizzles to induce stretch (1.5 cycles to induce 5% stretch).
High Frequency Electrical Stimulation (HFES)
1. Start anesthesia with Isoflurane at 1-2%/1L O2. (Change percentage of isoflurane based
on the level of consciousness of the mice).
2. Add mice to the anesthesia box.
3. Place mouse under nose cone. Shave top of left quad. Alcohol off skin and betadyne.
4. Place two needle electrodes on the left leg subcutaneously posterior to the femur to
stimulate the sciatic nerve. Use tape to fix the electrodes and make sure the electrodes
can attach the skin.
5. Start electrical stimulation
6. Electrical stimulation parameters:
a) 10 sets of 6 repetitions
b) Each repetition: 100 Hz, 6–12 V, 1-ms duration, 3-s repetition duration.
c) 10s interval between 2 repetitions.
d) 50s interval between 2 sets.
7. Use twizzles to help the hindlimb back to basal position after each repetition.
8. Give mouse an intraperitoneal injection of warm saline (~1ml) and put mouse back to
cage upon complete recovery
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The Role of Glycoprotein130 in Inflammatory cytokines and Mechanical
Stimuli Regulation of Skeletal Muscle Protein Synthesis

by
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Introduction and Aims
Skeletal muscle provides a fundamental basis for human function, including
locomotion, respiration and homeostasis of metabolism. Maintaining skeletal muscle mass
is critical for physical activity level, quality of life and decreased mortality. The skeletal
muscle mass is sensitive to multiple systematic changes related to nutritional status,
physical activity level, inflammatory cytokines and muscle wasting diseases. The
regulation of skeletal muscle mass involves the balance between protein synthesis and
degradation, which is termed as protein turnover (1). However, significant gaps remain in
our understanding of skeletal muscle protein turnover regulation by hypertrophic or
atrophic stimuli in health and disease.
Glycoprotein 130 (gp130) is signal-transducing receptor that forms part of the receptor
complex for IL-6 family of cytokines (3). Formation of functional ligand-receptor complex
results in gp130 activation of multiple downstream signaling pathways, including STAT3,
ERK1/2 and PI3K-Akt, which regulate many physiological and pathophysiological
processes including immune system regulation, inflammation, wound healing and cell
survival (4). Two members of IL-6 family of cytokines, IL-6 and Leukemia Inhibitory
Factor (LIF), have recognized roles in skeletal muscle mass regulation (5) (7, 8). Skeletal
muscle undergoing repeated contractions or overload can produce IL-6 and LIF, which is
thought to initiate important autocrine and paracrine signaling that contributes to metabolic
adaptations and muscle hypertrophy through, at least in part, the activation of satellite cell
proliferation and fusion to myofibers (7, 8). Physiological elevation of IL-6 family of
cytokines by exercise or muscle contractions under physiological conditions is transient,
and goes back to basal level 3-4h post exercise (6). However, long-lasting elevated
224

systemic levels of IL-6 family of cytokines is associated with the pathological
inflammatory conditions in some types of cancer and other chronic disease states. It has
been well demonstrated that constant elevation of IL-6 has been demonstrated as a key
mediator of different muscle wasting diseases such as rheumatoid arthritis, chronic kidney
disease and cancer cachexia (9-11). Currently, there is not a clear understanding of this
complex dichotomy involving the effects LIF and IL-6 on muscle mass regulation.
The muscle protein synthesis regulation is a key determinant of muscle mass (12).
The integration of muscle protein synthesis through mTOR signaling is an acknowledged
control point of skeletal muscle mass (12). Activation of mTOR signaling plays a central
role in muscle hypertrophic response to multiple hypertrophic stimulus, including growth
factors, hormones, nutrition and mechanical stimuli (16), while the muscle mTOR
signaling and protein synthesis suppression is associated with muscle wasting (17-19).
Once activated, mTOR can induce muscle protein synthesis through the phosphorylation
of the p70S6K and 4E-BP1 (13). Multiple upstream signaling pathways, including PI3KAkt, ERK1/2 and AMPK, regulate mTORC1 by phosphorylating different sites of tuberous
sclerosis 1/2 (TSC1/2). TSC2 phosphorylation by PI3K-Akt or ERK1/2 can relieve TSC1/2
suppression on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTOR
signaling (14-16), while AMPK suppress mTOR signaling by phosphorylation of TSC2
and subsequent enhancement of the inhibition of TSC1/2 on mTOR (17).
Although gp130 signaling is involved in both muscle hypertrophy and atrophy, the
potential gp130 signaling regulation of muscle protein synthesis in physiological or
pathological conditions still needs to be determined. gp130 induction can activate
PI3K/Akt and ERK1/2 signaling, two upstream stimulator of mTOR, through JAK and Ras
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dependent mechanisms, respectively (3). Short term IL-6 or LIF exposure can stimulate
Akt-mTOR signaling in cardiomyocytes, which is a key mechanism of IL-6 and LIF
induced cardiac hypertrophy (18, 25). However, the specific interaction between these
cytokines and the PI3K/Akt-mTORC1 or gp130-ERK1/2-mTORC1 signaling axis within
skeletal muscle fibers needs further investigation. Unlike the potential anabolic effects of
short term IL-6/gp130 signaling action, pathological long term activation of IL-6-gp130
dependent signaling is associated with suppression of muscle protein synthesis (18, 19).
Chronic in vivo systemic IL-6 overexpression or in vitro IL-6 administration can decrease
mTOR and p70S6K phosphorylation in skeletal muscles or cultured myotubes (20). The
induction of AMPK signaling is a potential mediator of IL-6 suppression of muscle mTOR
(20), but the mechanisms of IL-6 induction of muscle AMPK signaling is not well
understood.
Mechanical stimuli such as loading, stretch or muscle contractions can induce skeletal
muscle hypertrophy by stimulating muscle protein synthesis (21, 22), that is important for
the maintenance of mass and function (23). The induction of mTOR signaling through
TSC2 dependent mechanisms plays a key role (24), but the biochemical events connecting
the mechanical stimuli and mTOR activation still need to be determined. Physiological
elevation of IL-6 family of cytokines during exercise or overload have a documented role
in muscle metabolic adaptations and muscle hypertrophy (4-6). Pathological induction of
muscle inflammatory or stress signaling pathways has the potential to inhibit muscle
anabolic signaling induced by mechanical stimuli. Muscle contraction-induced mTOR
signaling is attenuated in severely cachectic ApcMin/+ mice, which is associated with
muscle STAT3 and NF-κB signaling activation (25). AMPK activation is also sufficient to
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prevent mTOR induction by electrically-stimulated muscle contractions (26). However, the
role of physiological or pathological IL-6/gp130 signaling in mechanical stimuli induced
muscle protein synthesis have not been investigated.

The overall goal of this dissertation is to examine gp130 regulation of anabolic
signaling in skeletal muscle during physiological and pathological conditions.
Specifically, we will investigate the role of gp130 signaling in basal muscle protein
synthesis regulation during either physiological short term or pathological long term
exposure to inflammatory cytokines. Additionally, we will investigate if physiological or
pathological gp130 signaling regulates the induction of protein synthesis by mechanical
stimuli. We hypothesize that physiological, short term inflammatory cytokine exposure will
induce basal muscle protein synthesis through gp130 activation of Akt-mTOR signaling,
while pathological, long term cytokine exposure will suppress basal muscle protein
synthesis through gp130 activation of AMPK signaling. Furthermore, physiological or
pathological cytokine exposure will either amplify or suppress mechanical regulation of
muscle protein synthesis, respectively.
In this study, we propose to address the following specific aims.
Aim. 1: Determine if physiological, short term exposure of inflammatory cytokines
IL-6 or LIF can stimulate muscle protein synthesis through gp130 regulation of AktmTOR signaling.
Aim 1.1: Determine if short term IL-6 or LIF exposure will stimulate myotube protein
synthesis.
Aim 1.2: Determine if gp130 or Akt-mTOR signaling is necessary for myotube protein
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synthesis regulation by short term IL-6 or LIF exposure.
Aim 1.3: Determine if in vivo short term IL-6 infusion will stimulate muscle protein
synthesis.
Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress
muscle protein synthesis through AMPK signaling.
Aim 2.1: Determine if long term IL-6 or LIF exposure will suppress myotube protein
synthesis.
Aim 2.2: Determine if gp130 regulation of AMPK signaling is necessary for long term
IL-6 or LIF regulation of myotube protein synthesis.
Aim 2.3: Determine if in vivo long term IL-6 overexpression will suppress skeletal
muscle protein synthesis.
Aim 3: Determine if physiological or pathological administration of IL-6 or LIF
cytokines can regulate the induction of muscle protein synthesis by mechanical stimuli.
Aim 3.1 Determine if short term IL-6 or LIF exposure will potentiate stretch induction
of myotube protein synthesis through gp130 regulation of Akt signaling.
Aim 3.2 Determine if long term IL-6 or LIF exposure will disrupt stretch induction of
myotube protein synthesis though gp130 or AMPK dependent mechanisms.
Aim 3.3 Determine if in vivo short term IL-6 infusion or long term IL-6 overexpression
will regulate muscle protein synthesis induction by eccentric contractions.
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Overall working model

IL-6 and LIF can activate or suppress skeletal muscle mTOR signaling and protein
synthesis, which is determined by the duration of cytokine exposure. Short term IL-6 or
LIF can induce mTOR signaling and subsequent protein synthesis through gp130PI3K/Akt signaling axis under physiological conditions, while pathological long term IL6 or LIF exposure can suppress muscle mTOR signaling and protein synthesis, which is
dependent on gp130 and AMPK signaling. Furthermore, short term or long term IL-6/LIF
exposure can potentiate or suppress muscle protein synthesis induction by mechanical
stimuli, including stretch and eccentric contractions. The phosphorylation of TSC1/2 on
different sites is a converging regulatory point of protein synthesis regulation by IL-6/LIF
and mechanical stimuli.

Preliminary Data
1. gp130 siRNA knock-down decreased basal myotube protein synthesis. C2C12
myotubes were transfected with gp130 siRNA for 24h. gp130 siRNA knockdown
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significantly decreased myotube gp130 protein, as well as gp130 downstream STAT3
phosphorylation (Fig. B1A). gp130 siRNA knockdown also significantly decreased
p70S6K phosphorylation (Fig. B1A) and protein synthesis (Fig. B1B).

A.

B.

Figure B1: Effect of gp130 siRNA knock-down on myotube mTOR signaling
and protein synthesis. C2C12 myotubes were tranfected with control or gp130 siRNA
for 24h. A. gp130, p-STAT3, total STAT3, p-p70S6K (T389), total p70S6K were measured
by western blot. B. protein synthesis was measured by puromycin incorporation. *:p < 0.05,
student’s t-test

2. Long term IL-6 administration increased AMPK phosphorylation and
suppressed mTOR signaling in C2C12 myotubes. C2C12 myotubes were treated with
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different doses (5ng/ml and 20ng/ml) of IL-6 for 24h. 20ng/ml IL-6 significantly increased
AMPK phosphorylation (Fig. B2A) and decreased mTOR and its downstream target
4EBP1 phosphorylation (Fig. B2B)

A.

B.

Figure B2: Effect of long term (24h) IL-6 administration on AMPK and
mTOR signaling in C2C12 myotubes. A. representative Western blot and
quantification of total and phosphorylated AMPK. B. representative Western blot
and quantification of total and phosphorylated Akt, mTOR and 4EBP1. *:
significant from control, p<0.05, one-way ANOVA.

3. Cell stretch induction of myotube hypertrophy, mTOR signaling and protein
synthesis. Differentiated C2C12 myotubes were subjected to 5% stretch for either 4h or
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24h. Stretch for 24h significantly increased C2C12 myotube mean diameter (Fig. B3A).
Related to growth signaling, both 4h and 24h stretch induced p70S6K and S6RP
phosphorylation (Fig. B3B). However, neither stretch time point demonstrated an increase
4EBP1 phosphorylation (Fig. B3B). Myotube protein synthesis rate was also significantly
increased by both 4h and 24h stretch (Fig. B3C). These results demonstrate stretch can
induce a strong anabolic stimulus to cultured myotubes.

A.

B.

C.

Figure B3: Effect of mechanical stretch on myotube mTOR signaling pathway and
protein synthesis. C2C12 myotubes were stretched for 4h and 24h. A. Mean diameter of
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myotubes after 4h and 24h stretch. B. Phosphorylation (ratio between phospho and total)
of p70S6K, S6RP and 4EBP1 was measured by western blot. C: Protein synthesis rate was
measured by western blot against puromycin. NC: Negative Control, the protein sample
from C2C12 myotubes without puromycin treatment. For A and B, bar graphs represent
fold changes relative to control group. All values are means ± SE. * p < 0.05 vs. Control,
one-way ANOVA.
4. Skeletal muscle mTOR signaling and protein synthesis induction by eccentric
contractions. ~13 weeks of C57BL/6 mice were subjected to high frequency electrical
stimulation (HFES) to induced eccentric contractions in TA and EDL muscles of their left
legs, while the right legs were used as intra-animal control. Mice were sacrificed 3h post
electrical stimulation. The eccentric contractions activated mTOR signaling in TA muscle,
which was reflected by the induction of p70S6K and its downstream target, S6RP
phsophorylation (Fig. B4A). Consistent with the changes in p70S6K and S6RP, eccentric
contractions also increased protein synthesis (measured by puromycin incorporation) in TA
muscle (Fig. B4B)
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A.

B.

Figure B4: Eccentric contractions induction of skeletal muscle mTOR
signaling and protein synthesis. ~13 week of control B6 were subjected to
high frequency electric stimulation to induce eccentric contractions on their
left TA muscles. A. Phosphorylation of p70S6K and S6RP were measured
by western blot. B. Protein synthesis was measured by western blot against
puromycin.
Research Design and Methods
Overall Research Design
The overall purpose of this study is to monitor the regulation of physiological short
term and pathological long term gp130 cytokines, IL-6 and LIF, on basal mechanical
stimuli induced muscle protein synthesis. We will use in vitro and in vivo approaches in all
three aims. In vitro myotubes model will be treated with different level of IL-6 or LIF for
different time periods to model the short term or long term exposure of inflammatory
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cytokines under physiological or pathological conditions, respectively. The role of gp130
receptor or gp130 downstream signaling pathways will be investigated by RNA
interference or specific pharmaceutical inhibitors. In aim 3, cultured myotubes will be
stretched to apply mechanical stimuli in vitro. The regulation of short term and long term
IL-6 on muscle protein synthesis will also investigated in vivo by IL-6 infusion and long
term IL-6 over-expression, respectively. To investigate the regulation of short term or long
term IL-6 exposure on muscle mechanical signaling, muscle eccentric contractions will be
induced by electrical stimulation. The primary outcomes includes Akt-mTOR signaling
(phosphorylation of Akt, TSC2 and p70S6K) and protein synthesis (measured by
puromycin incorporation) in myotubes or skeletal muscles.

Aim. 1: Determine if physiological, short term exposure of inflammatory cytokines
IL-6 or LIF can stimulate muscle protein synthesis through gp130 regulation of AktmTOR signaling.
Aim 1.1: Determine if short term IL-6 or LIF exposure will stimulate myotube protein
synthesis.
Aim 1.2: Determine if gp130 or Akt-mTOR signaling is necessary for myotube protein
synthesis regulation by short term IL-6 or LIF exposure.
Aim 1.3: Determine if in vivo short term IL-6 infusion will stimulate muscle protein
synthesis through gp130 dependent mechanisms.

Overview: We will use both in vitro and in vivo approaches in this aim. Myotubes will
be treated with IL-6 or LIF for 1-4 hours, which mimics physiological elevation of
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inflammatory cytokines. The role of gp130 regulation of Akt-mTOR signaling will be
investigated. The primary outcomes include protein synthesis regulation and gp130
downstream signaling pathways. We will further examine this regulation in vivo using short
term IL-6 administration. Muscle specific gp130 knock-out mice will be used to examine
the role of gp130 in short term IL-6 regulation of muscle protein synthesis.
In this aim, we will conduct four experiments. In experiment 1.1, we will determine if short
term (1-4h) IL-6 or LIF exposure will stimulate Akt-mTOR signaling and protein synthesis
in cultured myotubes. In experiment 1.2, we will knock-down myotube gp130 by siRNA
transfection before short term IL-6 or LIF exposure to determine if gp130 is necessary for
short term IL-6 or LIF regulation of myotube protein synthesis. In experiment 1.3, we will
inhibit myotube Akt-mTOR signaling by wortmannin (PI3K inhibitor) or rapamycin
(mTORC1 inhibitor) during IL-6 or LIF treatment to determine if Akt-mTOR signaling is
necessary for short term IL-6 or LIF regulation of myotube protein synthesis. In experiment
1.4, we will inject IL-6 into control or skm-gp130-/- mice to determine if short term (1-2h)
in vivo IL-6 infusion will stimulate muscle mTOR signaling or protein synthesis through
gp130 dependent mechanisms.

Experiment 1.1 will determine if short term (1-4h) IL-6 or LIF exposure will
stimulate Akt-mTOR signaling and increase protein synthesis in cultured myotubes.
Hypothesis 1.1: Short term IL-6 or LIF exposure will activate Akt-mTOR signaling
and increase protein synthesis in cultured myotubes.
Design:
This experiment will determine the effect of different doses and duration of IL-6/LIF
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administration on myotube protein synthesis regulation. In dose response study, C2C12
myotube will be treated with different level (5, 10, 20 or 100ng/ml) of IL-6 family of
cytokines (IL-6 and LIF) or control cytokines (TNF-α and IL-1β) for 2h. In time response
study, C2C12 myotube will be treated with IL-6 (20ng/ml) or LIF (10ng/ml) for different
time periods (30min, 1h, 2h and 4h). All inflammatory cytokines will be solved in serumfree DMEM to exclude the potential influence of cytokines or growth factors in serum. To
measure protein synthesis, puromycin (1μM) will be added to cell culture medium 30min
before protein sample collection. The treatment groups are listed in table 1. All groups
contains at least 6 replicates from 2 independent experiments.
Study

Cytokine
-

IL-6

LIF
Cytokine Dose Response study

TNF-α

IL-1β

-

IL-6
IL-6/LIF Time course study

LIF
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Dose (ng/ml)

Duration (h)

-

2

5

2

10

2

20

2

100

2

5

2

10

2

20

2

100

2

5

2

10

2

20

2

100

2

5

2

10

2

20

2

100

2

-

0

20

0.5

20

1

20

2

20

4

20

0.5

20

1

20

2

20

4

Primary Outcomes:
Protein synthesis: Protein synthesis will be determined by puromycin incorporation as
previously described.
Akt-mTOR signaling: The activity of mTORC1 will be determined by the phosphorylation
of p70S6K (T389) and 4EBP1 (T37/46), which are two downstream targets of mTORC1
and central mediators of mTOR activation of protein synthesis. The Akt signaling will be
examined by measuring the phosphorylation of Akt (T308). The phosphorylation of Akt
downstream target, TSC2 (T1462), which mediates the mTOR signaling activation by Akt,
will also be examined. The total level of p70S6K, 4EBP1, Akt and TSC2 will also be
measured. The phosphorylated or total proteins will be measured by western blot
Secondary Outcomes:
gp130 downstream signaling pathways: The gp130 protein and the phosphorylation of
STAT3 (Y705), ERK1/2 (T402/Y404), two other gp130 downstream targets, will be
measured by western blot to determine the regulation of IL-6 or LIF on gp130 dependent
signaling. To further examine STAT3 signaling activity and potential negative feedback of
gp130 signaling induction (see literature review), the mRNA expression of SOCS3 will be
measured by RT-PCR.
Other upstream regulator of mTOR signaling: The phosphorylation of AMPK, which is a
suppressor of mTOR signaling and associated with long term IL-6 elevation, will be
measured by western blot. The mRNA expression of REDD1, which can suppress mTOR
signaling, will be measured by RT-PCR.

Experiment 1.2 will determine if gp130 siRNA knock-down will block myotube
238

protein synthesis regulation by short term IL-6 or LIF exposure.
Hypothesis 1.2: gp130 knock-down will block myotube protein synthesis induction by
short term IL-6 or LIF exposure.
Design:
This experiment will determine if inhibition of gp130 dependent signaling pathways
by gp130 siRNA knock-down will affect myotube protein synthesis regulation by short
term IL-6 or LIF exposure. C2C12 myotubes will be transfected with control (scramble)
siRNA or gp130 siRNA for 24h before short term IL-6 or LIF exposure. The control or
gp130 siRNA transfected myotubes will be treated with IL-6 (20ng/ml) or LIF (10ng/ml)
for 1h or 2h as described in experiment 1.1. To measure protein synthesis, puromycin (1μM)
will be added to cell culture medium 30min before protein sample collection. The treatment
groups are listed in table 2. All groups contains at least 6 replicates from 2 independent
experiments.
Group

Cytokine

siRNA

1

-

Control

2

IL-6

Control

3

LIF

Control

4

-

gp130

5

IL-6

gp130

6

LIF

gp130

Primary Outcomes:
Protein synthesis: see experiment 1.1
Akt-mTOR signaling: see experiment 1.1
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Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
Other upstream regulator of mTOR signaling: see experiment 1.1.

Experiment 1.3 will determine if inhibition of Akt-mTOR signaling will block
myotube protein synthesis regulation by short term IL-6 or LIF exposure.
Hypothesis 1.3: Pharmaceutical inhibition of Akt -mTOR signaling will block myotube
protein synthesis induction by short term IL-6 or LIF exposure.
Design:
This experiment will determine if inhibition of PI3K-Akt signaling by wortmannin
(PI3K inhibitor) or inhibition of mTOR signaling by rapamycin (mTORC1 inhibitor) will
block the myotube protein synthesis regulation by short term IL-6 or LIF exposure. The
C2C12 myotubes will be pretreated with DMSO (vehicle control), wortmannin (1μM,
solved in DMSO) or rapamycin (10nM, solved in DMSO) for 1h before the short term IL6 or LIF administration (20ng/ml IL-6 for 2h or 10ng/ml LIF for 2h as described in
experiment 1.1). The DMSO, wortmannin or rapamycin will be kept in culture medium
during IL-6 of LIF administration. To measure protein synthesis, puromycin (1μM) will be
added to cell culture medium 30min before protein sample collection. The treatment groups
are listed in table 3. All groups contains at least 6 replicates from 2 independent
experiments.
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Group

Cytokine

Inhibitor

1

-

DMSO

2

IL-6

DMSO

3

LIF

DMSO

4

-

Wortmannin

5

IL-6

Wortmannin

6

LIF

Wortmannin

7

-

Rapamycin

8

IL-6

Rapamycin

9

LIF

Rapamycin

Primary Outcomes:
Protein synthesis: see experiment 1.1
Akt-mTOR signaling: see experiment 1.1
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
Other upstream regulator of mTOR signaling: see experiment 1.1.

Experiment 1.4 will determine if in vivo short term IL-6 infusion will stimulate
muscle Akt-mTOR signaling and protein synthesis.
Hypothesis 1.4: In vivo short term IL-6 infusion will stimulate muscle Akt-mTOR
signaling and increase muscle protein synthesis.
Design:
This experiment will examine the effect of short term IL-6 infusion on muscle AktmTOR signaling and protein synthesis in vivo. Male C57BL/6 mice (~8 week old) will be
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fasted for 5h, followed with intraperitoneal (i.p.) injection of PBS or IL-6 (3ng/kg BW,
solved in PBS) as previously described (301). Mice will be sacrificed 30min or 1h post IL6 injection. A pilot study will be conducted to determine the optimal duration of IL-6
exposure, which demonstrate the significant difference in protein synthesis between PBS
and IL-6 treated group.

To measure protein synthesis, 0.04mmol/g body weight

puromycin will be injected into mice (I.P. injection) 30min before sacrifice. The experiment
groups and mouse calculation are listed in table 4. At least 8 mice will be included in each
experiment group, see table 4 for experiment groups and mice number calculations.

Genotype
Cytokine

C57BL/6
PBS

IL-6

30mi

30mi

Cytokine exposure time
Number of Mice

n

n

3*

3*

PBS

IL-6

PBS

IL-6

1h

1h

30min or 1h#

30min or 1h#

3*

3*

5

5

Total

22 (22 C57BL/6)

Primary Outcomes:
Protein synthesis: Protein synthesis in TA muscle will be determined by western blot
analysis of incorporated puromycin as previously described.
Akt-mTOR signaling: To measure muscle PI3K-Akt signaling activity, the phosphorylation
of Akt (T308) and TSC2 (T1462) in TA muscle will be examined. The phosphorylation of
p70S6K (T389), S6 Ribosomal Protein and 4EBP1 (T37/46) will be examined to determine
the mTOR signaling activity.
Secondary Outcomes:
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gp130 signaling pathways: The phosphorylation of STAT3 (Y705), ERK1/2 (T402/Y404)
in TA muscle will be measured by western blot. The mRNA expression of SOCS3 in gastroc
muscle will be measured by RT-PCR.
AMPK signaling: The phosphorylation of AMPKα (T172) and Acetyl-CoA Carboxylase
(S79) and total AMPKα in TA muscle will be measured by western blot.
Plasma IL-6 level:

Plasma IL-6 levels of blood samples taken from the retroorbital eye

sinus at sacrifice to ensure validity of in vivo IL-6 infusion. The plasma IL-6 will be
measured by ELISA using specific mouse IL-6 kit.
Muscle weight: the wet weight of hindlimb muscles (soleus, plantaris, gastroc, EDL, TA
and quadceps) will be recorded during sacrifice.

Experiment 1.5 (alternative) will determine if short term IL-6 infusion will
stimulate muscle mTOR signaling or protein synthesis in muscle specific gp130 knock
out mice.
Hypothesis 1.5: Short term IL-6 administration will not induce muscle mTOR
signaling or protein synthesis in skm-gp130-/- mice.
Design:
This experiment will be conducted if short term IL-6 exposure can regulate muscle
mTOR signaling or protein synthesis (significant difference between control (PBS) and IL6 treated mice). Skeletal muscle gp130 knock-out mice (skm-gp130-/- mice, C57BL/6
background) will be administrated by short term IL-6 in these experiment to examine if
gp130 is necessary for short term IL-6 regulation of muscle protein synthesis.

Skm-

gp130-/- mice will be generated by crossing gp130 fl/fl mice with cre-expressing mice
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driven by myosin light chain, and will be genotyped to validate homozygous for the gp130flox and mlc-Cre genes as previously described (19). skm-gp130-/- mice will be injected
with PBS (control) or IL-6 (3ng/g BW) as described in experiment 1.4. All mice will be
sacrifice 30min or 1h post injection (the same cytokine treatment time as experiment 1.4).
To measure protein synthesis, 0.04mmol/g body weight puromycin will be injected into
mice (I.P. injection) 30min before sacrifice. See table 5 for experiment groups and mice
number calculations.
Genotype
Cytokines

skm-gp130-/PBS

IL-6

30min or

30min or

1h*

1h*

Number of Mice

8

8

Total

16 (16 skm-gp130-/-)

Cytokine exposure time

Primary Outcomes:
Protein synthesis: see experiment 1.4.
Akt-mTOR signaling: see experiment 1.4
Secondary Outcomes:
Genotyping: The muscle specific gp130 knock-out of each skm-gp130-/- mouse will be
further validated by genotyping PCR using DNA samples collected by its quadceps muscle,
liver heart and spleen.
Muscle gp130 level: The loss of skeletal muscle gp130 protein in skm-gp130-/- mice will
be validated by examining gp130 protein in membrane fraction of quadceps muscle.
gp130 signaling pathways: see experiment 1.4
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AMPK signaling: see experiment 1.4.
Plasma IL-6 level:

see experiment 1.4.

Muscle weight: see experiment 1.4.

Overall Aim 1 Interpretation:
In experiment 1.1:
Increased myotube Akt or TSC2 phsophorylation by short term IL-6 or LIF
administration will indicate that physiological, short term IL-6 or LIF exposure can
activate myotube Akt signaling.
Increased myotube p70S6K or 4EBP1 phsophorylation by short term IL-6 or LIF
administration will indicate that physiological, short term IL-6 or LIF exposure can
activate myotube mTOR signaling.
Increased myotube puromycin incorporation by short term IL-6 or LIF
administration will indicate that physiological, short term IL-6 or LIF exposure can
increased myotube protein synthesis.
In experiment 1.2:
Attenuated increase of Akt or p70S6K phosphorylation by short term IL-6 or LIF
administration in gp130 siRNA transfected myotubes will indicate that gp130 is
necessary for myotube Akt-mTOR signaling activation by short term IL-6 or LIF
exposure.
Attenuated increase of puromycin incorporation by short term IL-6 or LIF
administration in gp130 siRNA transfected myotubes will indicate that gp130 is
necessary for myotube protein synthesis induction by short term IL-6 or LIF
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exposure.
In experiment 1.3:
Attenuated increase of protein synthesis by short term IL-6 or LIF administration
in the presence of wortmannin will indicate that Akt signaling is necessary for
myotube protein synthesis induction by short term IL-6 or LIF exposure.
Attenuated increase of protein synthesis by short term IL-6 or LIF administration
in the presence of rapamycin will indicate that mTOR signaling is necessary for
myotube protein synthesis induction by short term IL-6 or LIF exposure.
In experiment 1.4:
Increased muscle Akt, p70S6K, S6RP or 4EBP1 phsophorylation by IL-6 infusion
in WT mice will indicate that in vivo short term IL-6 elevation can activate muscle
Akt-mTOR signaling pathway.
Increased muscle protein synthesis by IL-6 infusion in WT mice will indicate that
in vivo short term IL-6 elevation can induce muscle protein synthesis.
In experiment 1.5:
Attenuated Akt, p70S6K, S6RP or 4EBP1 phsophorylation induction by IL-6
infusion in skm-gp130-/- mice will indicate that gp130 is necessary for muscle AktmTOR signaling activation by short term IL-6 exposure.
Attenuated protein synthesis induction by IL-6 infusion in skm-gp130-/- mice will
indicate that gp130 is necessary for muscle protein synthesis induction by short
term IL-6 exposure.

Methods of Aim 1:
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C2C12 cell culture:
All cells are kept in 37°C, 5% CO2, humidified incubator. C2C12 myoblasts (from
American Type Culture Collection, Manassas, VA, USA) are cultured in DMEM,
supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin. To maintain
the myoblasts phenotype of C2C12 cells, the cells will be digested by trypsin and divided
into more cell culture flasks before they reach 80% confluence.

To induce C2C12

myoblasts differentiation, C2C12 myoblasts will be allowed to reach ~95% confluence,
then incubate in differentiation medium (DMEM supplemented with 2% horse serum, 50
U/ml penicillin, and 50 µg/ml) for 4-5 days. The differentiation medium will be switched
every 2 days.
RNA interference:
Scramble siRNA (GE Healthcare, Pittsburgh, PA, USA, 100nM final concentration) or
siRNAs specifically targeting gp130, p38α, STAT3 and AMPK (Santa Cruz Biotechnology,
100nM final concentration) will be transfected into cultured myotubes (3 days
differentiation) by Dharmafect 3 transfection reagent (GE Healthcare, 5μl in each well of
6-well plate) following manufacturer’s instructions.
Akt-mTOR downstream signaling inhibition:
To inhibit gp130 downstream STAT3 signaling, myotubes will be STAT3 specific
inhibitor, LLL12 (100nM, BioVision, Milpitas, CA, USA) will be added to cell culture
media during stretch. Similarly, ERK1/2 signaling will be inhibited by adding PD98059
(20µM, Cell Signaling Technology) during stretch.
skm-gp130 knock-out mice:
Male mice on a C57BL/6 background were bred with the gp130 fl/fl mice provided by
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Dr. Colin Stewart’s lab in collaboration with Dr. Hennighausen (NCI) (302). Gp130 fl/fl
mice will be bred with cre-expressing mice driven by myosin light chain from Dr. Steven
Burden (NYU) (303). The resulting fl/fl cre/cre (skm-gp130) will have a skeletal muscle
deletion of the gp130 protein. Offspring were genotyped

(described in detail below) for

cre recombinase (forward 5’ AAG CCC TGA CCC TTT AGA TTC CAT TT 3’, reverse 5’
AAA ACG CCT GGC GAT CCC TGA AC 3’, wild type 5’ GCG GGC TTC TTC ACG
TCT TTC TTT 3’), floxed gp130 (forward 5’ ACG TCA CAG AGC TGA GTG ATG CAC
3’, reverse 5’ GGC TTT TCC TCT GGT TCT TG 3’), by taking tail snips at the time of
weaning. All mice are group housed and provided standard rodent chow (Harlan Teklad
Rodent Diet, #8604) and water ad libitum. The room are maintained on a 12:12 light:dark
cycle with the light period starting at 07:00. Mice will be killed by injecting ketamine
cocktail (90 mg/kg BW Ketamine, 7 mg/kg BW Xylazine and 1 mg/kg BW Acepromazine,
solved in PBS, IP injection 15min before sacrifice), and hindlimb muscles (Soleus,
Plantaris, Gastroc, EDL, TA and Quadceps) on both sides and important organs will be
quickly isolated and frozen in liquid nitrogen during sacrifice. All animal experimentation
protocols are approved by the University of South Carolina’s Institutional Animal Care and
Use Committee.
Genotyping:
All animals will be genotyped using a tail snip. At 4-5 weeks of age animals a weaned,
numbered, and a small tail snip (~1-2mm) collected. The tail snip is digested in 200ul of
tail digest buffer and 5ul of proteinase K. Tails are incubated overnight in a water bath set
at 37°C. After incubation samples are heat shocked at 95°C in a dri-bath for 10 minutes.
DNA Extraction and Genotyping:
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To screen the genotypes of mouse colony, a small snip of tail from each mouse will be
in ~50-100μl tailing buffer (25mM NaOH, 0.2mM EDTA, PH 8.0) at 50°C overnight to
degrade mouse tissues and expose genomic DNA. The digestion process will then be
stopped by incubating on 90°C hotplate for 10min, and samples will be stored at 4°C. The
DNA in organs/tissues (~20mg) frozen in -80°C will be collected using DNAzol Reagent
(Invitrogen) following manufacturer’s instructions. Genotyping PCR will be conducted
using GO-Taq Green Mater Mix (Promega). Each PCR reaction mix will contain 12.5μl
GO-Taq Green Mater Mix, 9.5μl dH2O, 0.5μl forward primer, 0.5μl reverse primer and 2μl
DNA sample. The amplified DNA fragment will be stained by Midori Green Florescence
dye and separated in agarose gel (1% agarose,), and visualized under UV light.
RNA Extraction and RT-PCR:
The RNA extraction, cDNA synthesis and RealTime PCR (RT-PCR) will be conducted
as previously described (18, 19). RNA in cultured myotubes and mouse muscles will be
collected using Trizol Reagent (Invitrogen). Myotubes cultured will be scraped into Trizol
(1ml for each cell stretching device or 1 well of 6-well plate) by cell scraper. Frozen tissues
will be homogenized in 1 ml of Trizol on ice (Use new 14 ml Polyproplylen tube, rinse
polytrone with EtOH, then dH2O each homogenization). After homogenization, samples
will be spinned at 14000rpm for 10min at 4°C and supernatant will be kept. The RNA
samples in Trizol will then be phase-seperated by chloroform, precipitated by isopropanol,
washed by 75% EtOH (solved in DEPC H2O) and air dried following the manufacturer’s
instructions. RNA sample will the solved in DEPC H2O and the OD260 and 260/280 ratio
of each RNA sample will be measured by Nanodrop 2000 spectrometer (Thermo Fisher
Scientific, Waltham, MA, USA) to determine their concentration and quality. The RNA
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samples whose 260/280 ratio larger than 1.8 will be used to make cDNA. The cDNA
samples will be synthesized using High Capacity cDNA Reverse Transcript Kit (Applied
Biosystems, Foster City, CA, USA) following the manufacturer’s instructions. 2μg RNA
sample will be included in 20μl reaction mix. cDNA sample will be further diluted either
1:10 or 1:100 with sdH2O and analyzed by RT-PCR using SYBR Green Master mix
(Applied Biosystems). The 20ul reaction mix contains 9.0μl of diluted cDNA, 10μl 2x
SYBR Master mix, 0.08μl forward primer (20μM), 0.08μl reverse primer (20μM) and
0.84μl sdH2O. The sequence of each primer is listed below.

Protein Extraction and Western Blot:
The protein extraction from cultured cells and mouse tissues and western blot analysis
will be performed as previously described (19). To collect proteins from cultured cells, cell
will be washed twice by ice-cold PBS, and scraped into ice-cold RIPA buffer [50mM Tris,
150mM NaCl, 1% Triton X100, 1mM EDTA, 0.5% Sodium Deoxycholate, 0.1% SDS,
5mM NaF, 1mM NaVO4 , 1mM β- glycerophosphate and 1% Protease Inhibitor Cocktail
(Sigma-Aldrich)]. Cell lysates will be homogenized on ice by ultrasound sonication,
centrifuged (12000rpm, 10min) at 4°C and supernatants will be collected. To collect
proteins from mouse tissue, the frozen tissues will be homogenized in ice-cold Mueller
Buffer (50mM HEPES, 4mM EGTA, 10mM EDTA, 15mM NaP2O7, 10mM βglycerophosphate, 25mM NaF, 5mM NaVO4, 0.1% Triton X-100, 1% Protease Inhibitor
Cocktail, pH 7.4), centrifuged (12000rpm for 10min) at 4°C and supernatants will be
collected and mixed with Diluent Buffer (50mM NaP2O7, 2.5mM EGTA, 1mM βmercaptoethanol, 50% glycerol, 1% Protease Inhibitor Cocktail, pH 7.4). The volume of
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Mueller Buffer will be determined by tissue weight (Mueller Buffer: 20µl/mg tissue;
Diluent Buffer: 10µl/mg tissue). Protein concentrations will be determined by the Bradford
reagent (BioRad). Homogenates were fractionated in SDS-polyacrylamide gels and
transferred to PVDF membranes. After the membranes were blocked, antibodies for
Phosphorylated/ total ERK1/2, Akt, STAT3, NF-κB p65, AMPK, MAPKAPK-2, p70S6K,
S6RP, 4EBP1, GAPDH (Cell Signaling Technology), p38 MAPK (Santa Cruz
Biotechnology), and puromycin (Millipore, Billerica, MA, USA) were incubated at
dilutions from 1:2000 to 1:8000 overnight at 4°C in 2% TBST milk. Anti-rabbit or antimouse IgG-conjugated secondary antibodies (Cell Signaling Technology) were incubated
with the membranes at 1:2000 to 1:5000 dilutions for 2h in 2% TBST milk. Enhanced
chemiluminescence (Advansta, Menlo Park, CA, USA) developed by autoradiography was
used to visualize the antibody–antigen interactions. Blots were analyzed by measuring the
integrated optical density (IOD) of each band with ImageJ software (NIH, Bethesda, MD,
USA).
Protein Synthesis Measurement:
Protein synthesis measurement will be conducted as previously described (19). Briefly,
to measure protein synthesis in mouse tissues, 0.04mmol/g body weight puromycin (EMD
Chemicals, San Diego, CA, USA, solved in 300µl PBS) will be injected into mice (IP
injection) 30min before sacrifice. To measure protein synthesis in cultured cells, puromycin
stock solution (1mM, solved in sterile PBS) will be added to cell culture media (1µM final
concentration) 30min before protein collection. The puromycin integrated into peptides
will be monitored by western blot using mouse puromycin primary antibody (Millipore,
Billerica, MA, USA) and HRP-Rabbit anti-Mouse IgG2a secondary antibody (Invitrogen).
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The gel or PVDF membranes will be stained by commassie blue or ponceau to validate the
protein integrity and equal loading of each protein sample.
Statistical Analysis:
All statistical analysis will be conducted by Prism Software. In experiment 1.1, 1.2 and
1.3, the main effect of short term IL-6/LIF administration, main effect of gp130
antibody/siRNA/inhibitor and their interactions will be determined by two-way ANOVA.
In experiment 1.4, the effect of in vivo short term IL-6 administration will be determined
by student’s t-test.

If experiment 1.5 is conducted, the results from experiment 1.4 and

1.5 will be analyzed by two-way ANOVA to determine the main effect of IL-6, gp130
knock-out and their interaction. If necessary, post-hoc analysis will be conducted using
Student-Newman-Kelus (SNK) method. p < 0.05 will be considered as significant.

Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress
muscle protein synthesis through AMPK signaling.
Aim 2.1: Determine if long term IL-6 or LIF exposure will suppress myotube protein
synthesis.
Aim 2.2: Determine if gp130 regulation of AMPK signaling is necessary for long term
IL-6 or LIF regulation of myotube protein synthesis.
Aim 2.3: Determine if in vivo long term IL-6 overexpression will suppress muscle
protein synthesis through gp130 dependent mechanisms.

Overview:
We will use both in vitro and in vivo approaches in this this aim. Myotubes will be
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treated with IL-6 or LIF for 24h, which mimics pathological elevation of inflammatory
cytokines. The role of gp130 regulation of

AMPK signaling will investigated. The

primary outcomes include protein synthesis regulation and gp130 downstream signaling
pathways. We will also examine this regulation in vivo by long term IL-6 over-expression
in control or muscle gp130 knock-out mice.
In this aim, we will conduct four experiments. In experiment 2.1, we will determine if
long term (24h) IL-6 or LIF exposure will induce AMPK signaling and suppress protein
synthesis in cultured myotubes. In experiment 2.2, we will knock-down myotube gp130 by
siRNA transfection before long term IL-6 or LIF exposure to determine if gp130 is
necessary for pathological, long term IL-6 or LIF regulation of myotube protein synthesis.
In experiment 1.3, we will inhibit myotube AMPK signaling by AMPK siRNA transfection
before IL-6 or LIF treatment to determine if AMPK signaling is necessary for long term
IL-6 or LIF regulation of myotube protein synthesis. In experiment 1.4, we will overexpress
IL-6 into control or skm-gp130-/- mice to determine if long term in vivo IL-6
overexpression will inhibit muscle mTOR signaling or protein synthesis through gp130
dependent mechanisms.

Experiment 2.1 will determine if long term 24h IL-6 or LIF exposure will activate
AMPK signaling and suppress protein synthesis in cultured myotubes.
Hypothesis 2.1: Long term IL-6 or LIF exposure will activate AMPK signaling and
suppress in cultured myotubes.
Design:
This experiment will determine the effect of long term exposure of IL-6/LIF on
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myotube AMPK, Akt-mTOR signaling and protein synthesis. C2C12 myotube will be
treated with different level (20 or 100ng/ml) of IL-6 or LIF for 24h. To measure protein
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein
sample collection. The treatment groups are listed in table 6. All groups contains at least 6
replicates from 2 independent experiments.
Group

Cytokine

Dose (ng/ml)

1

-

-

2

IL-6

20

3

IL-6

100

4

-

-

5

IL-6

20

6

LIF

100

Primary Outcomes:
Protein synthesis: see experiment 1.1.
AMPK signaling: The phosphorylation of AMPKα (T172) and total AMPKα protein will
be measured by western blot. The phosphorylation of Acetyl-CoA Carboxylase (S79), a
direct downstream target of AMPK will also be examined to determine the kinase activity
of AMPK.
Akt-mTOR signaling: see experiment 1.1
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1
REDD1 mRNA expression: see experiment 1.1.
Myotube Diameter: The mean diameter of myotubes of each treatment group will be
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determined by measuring diameters of myotubes from at least 10 randomly selected fields
as previously described.
Mitochondrial dynamics and oxidative metabolism: The protein level of FIS1 (Marker of
mitochondrial fission), Overall 4HNE level (Marker of oxidative stress) will be measured
by western blot. The PGC-1α mRNA will be examined by RT-PCR.
Ubiquitin proteasome system: The mRNA level of Atrogin-1 and MURF-1 will be
measured by RT-PCR. The Atrogin-1, MURF-1 protein and overall ubiquitination will be
measured by western blot.

Experiment 2.2 will determine if gp130 siRNA knock-down will block myotube
protein synthesis regulation by long term IL-6 or LIF exposure.
Hypothesis 2.2: gp130 siRNA knock-down will rescue myotube protein synthesis
suppression by long term IL-6 or LIF exposure.
Design:
This experiment will determine if inhibition of gp130 dependent signaling pathways
by gp130 siRNA knock-down will affect myotube protein synthesis regulation by long term
IL-6 or LIF exposure. C2C12 myotubes will be transfected with control (scramble) siRNA
or gp130 siRNA for 24h prior to long term IL-6 or LIF treatment as described in experiment
2.1. The control or gp130 siRNA transfection mix will also be added into culture medium
during IL-6 or LIF administration. To measure protein synthesis, puromycin (1μM) will be
added to cell culture medium 30min before protein sample collection. The treatment groups
are listed in table 7. All groups contains at least 6 replicates from 2 independent
experiments.
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Group

Cytokine

siRNA

1

-

Control

2

IL-6

Control

3

LIF

Control

4

-

gp130

5

IL-6

gp130

6

LIF

gp130

Primary Outcomes:
Protein synthesis: see experiment 1.1
AMPK signaling: see experiment 2.1
Akt-mTOR signaling: see experiment 1.1
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
REDD1 mRNA expression: see experiment 1.1.
Myotube Diameter: see experiment 2.1
Mitochondrial dynamics and oxidative metabolism: see experiment 2.1
Ubiquitin proteasome system: see experiment 2.1

Experiment 2.3 will determine if AMPK inhibition by AMPK siRNA knock-down
will block myotube protein synthesis regulation by long term IL-6 or LIF exposure.
Hypothesis 2.3: AMPK signaling inhibition by AMPK siRNA knock-down will rescue
myotube protein synthesis suppression by long term IL-6 or LIF exposure.
Design:
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This experiment will determine if inhibition of AMPK signaling pathways by AMPK
siRNA knock-down will affect myotube protein synthesis regulation by long term IL-6 or
LIF exposure. C2C12 myotubes will be transfected with control (scramble) siRNA or
AMPK siRNA for 24h prior to long term IL-6 or LIF treatment as described in experiment
2.1. The control or gp130 siRNA transfection mix will also be added into culture medium
during IL-6 or LIF administration. To measure protein synthesis, puromycin (1μM) will be
added to cell culture medium 30min before protein sample collection. The treatment groups
are listed in table 8. All groups contains at least 6 replicates from 2 independent
experiments.
Group

Cytokine

siRNA

1

-

Control

2

IL-6

Control

3

LIF

Control

4

-

AMPK

5

IL-6

AMPK

6

LIF

AMPK

Primary Outcomes:
Protein synthesis: see experiment 1.1
AMPK signaling: see experiment 2.1
Akt-mTOR signaling: see experiment 1.1
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
REDD1 mRNA expression: see experiment 1.1.
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Myotube Diameter: see experiment 2.1
Ubiquitin proteasome system: see experiment 2.1

Experiment 2.4 will determine if in vivo long term IL-6 over-expression will
suppress skeletal muscle mTOR signaling or protein synthesis.
Hypothesis 1.4: In vivo long term IL-6 infusion will suppress induce AMPK signaling
and suppress protein synthesis in skeletal muscles.
Design:
This experiment will examine the effect of long term IL-6 over-expression on muscle
mTOR signaling and protein synthesis. Male C57BL/6 mice will be bred as described in
experiment 1.4. The quadriceps muscle of ~8 week old WT or skm-gp130-/- mice will be
will be electroporated with control or IL-6 expressing plasmid to induce IL-6
overexpression as previously described. Mice will be fasted for 5h and sacrificed 2 weeks
post plasmid transfection. To measure the changes of plasma IL-6 level, blood samples
will be collected from the retroorbital eye sinus under brief isoflurane anesthesia 7 days
following each electroporation and at sacrifice. To measure protein synthesis, 0.04mmol/g
body weight puromycin will be injected into mice (I.P. injection) 30min before sacrifice.
To investigate the effect of long term IL-6 exposure on protein synthesis induction, all mice
will be subjected to high-frequency electrical stimulation 3h before sacrifice (see Aim 3
experiment design and experiment 3.6 for detail). The skeletal muscle of right TA muscle
(none contracted control side) will be used for the analysis in this experiment.
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Genotype

C57BL/6

Plasmids

control

IL-6

Number of Mice

8

8

Total

16 (16 C57BL/6)

Primary Outcomes:
Protein synthesis: see experiment 1.4.
AMPK signaling: The phosphorylation of AMPKα (T172) and Acetyl-CoA Carboxylase
(S79) and total AMPKα in TA muscle will be measured by western blot.
Akt-mTOR signaling: see experiment 1.4.
Secondary Outcomes:
gp130 signaling pathways: see experiment 1.4
Serum IL-6 level:

To examine the changes in circulating IL-6 level post transfection, the

IL-6 level in blood samples collected 1 week post electrophoration and at sacrifice will be
measured by ELISA using specific mouse IL-6 kit.
gp130 signaling pathways: The phosphorylation of STAT3 (Y705), ERK1/2 (T402/Y404)
in TA muscle will be measured by western blot. The mRNA expression of SOCS3 in gastroc
muscle will be measured by RT-PCR.
Muscle weight: see experiment 1.4.
Body composition: The proportion of bone, muscle and adipose tissue of each mouse at the
time of electroporation and sacrifice will be measured by DEXA scan.

Overall Aim 2 Interpretation:
In experiment 2.1:
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Increased myotube AMPK and Acetyl-CoA Carboxylase phosphorylation by long
term IL-6 or LIF administration will indicate that long term IL-6 or LIF exposure
can stimulate AMPK signaling in myotubes
Decreased p70S6K, 4EBP1 phosphorylation and puromycin incorporation by long
term IL-6 or LIF administration will indicate that long term IL-6 or LIF exposure
can suppress mTOR signaling and protein synthesis in myotubes.
In experiment 2.2:
Attenuated AMPK increase and Acetyl-CoA Carboxylase phosphorylation by long
term IL-6 or LIF administration in gp130 siRNA transfected myotubes will indicate
gp130 is necessary for myotube AMPK signaling induction by long term IL-6 or
LIF exposure.
Attenuated p70S6K, 4EBP1 phosphorylation decrease by long term IL-6 or LIF
administration in gp130 siRNA transfected myotubes will indicate gp130 is
necessary for myotube protein synthesis suppression by long term IL-6 or LIF
exposure.
Attenuated puromycin incorporation decrease by long term IL-6 or LIF
administration in gp130 siRNA transfected myotubes will indicate gp130 is
necessary for myotube protein synthesis suppression by long term IL-6 or LIF
exposure.
In experiment 2.3:
Attenuated p70S6K, 4EBP1 phosphorylation decrease by long term IL-6 or LIF
administration in AMPK siRNA transfected myotubes will indicate gp130 is
necessary for myotube protein synthesis suppression by long term IL-6 or LIF
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exposure.
Attenuated puromycin incorporation decrease by long term IL-6 or LIF
administration in AMPK siRNA transfected myotubes will indicate gp130 is
necessary for myotube protein synthesis suppression by long term IL-6 or LIF
exposure.
In experiment 2.4:
Decreased muscle p70S6K, 4EBP1 phosphorylation by IL-6 overexpression will
indicate that in vivo long term IL-6 exposure can suppress mTOR signaling.
Decreased muscle puromycin incorporation by IL-6 overexpression will indicate
that in vivo long term IL-6 exposure can suppress protein synthesis in skeletal
muscle.

Methods of Aim 2:
C2C12 cell culture: see Aim 1.
RNA interference: see Aim 1.
IL-6 Overexpression:
An IL-6 plasmid was used to increase circulating IL-6 levels in C57BL/6 as previously
described (125). Electroporation of plasmid DNA in the quadriceps muscle was used for
endogenous IL-6 production and subsequent secretion in circulation. IL-6 plasmid (50 μg)
driven by the CMV promoter or empty control vector was injected intramuscularly. Mice
were anesthetized with a 2% mixture of isoflurane and oxygen (1L/min). The leg was
shaved, and a small incision was made over the quadriceps muscle. Fat was dissected away
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from the muscle, and the plasmids were injected in a 50-μl volume of PBS. A series of eight
50-ms, 100-volt pulses was used to promote uptake of the plasmid into myofibers, and then
the incision was closed with a wound clip. C57BL/6 and skm-gp130-/- mice were killed
after 2 weeks of IL-6 overexpression.
Protein Synthesis Measurement: see Aim 1.
Protein Collection and Western Blot: See Aim 1.
DNA Collection and genotyping: See Aim 1.
RNA Collection and RT-PCR: See Aim 1.
Myotube Diameter Measurement:
Diameter of myotube will be measured as previously described (304). Briefly, myotube
cultures were photographed under a phase-contrast microscope at ×40 after indicated
treatment. The diameters were measured in a more than ≥150 myotubes from ≥10 random
fields using ImageJ Software. Myotubes were measured at least 3 points evenly distributed
along their length. The measurements were conducted in a blinded fashion, and results were
expressed as micrometers.
Statistical Analysis:
All statistical analysis will be conducted by Prism Software. In experiment 2.1-2.3, the
IL-6/LF, signaling inhibitions and their interactions will be determined by two-way
ANOVA. In experiment 2.4, the effect of IL-6 overexpression will be determined by
student’s t-test. If necessary, post-hoc analysis will be conducted using Student-NewmanKelus (SNK) method. p < 0.05 will be considered as significant.

Aim 3: Determine if physiological or pathological administration of IL-6 or LIF
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cytokines can regulate the induction of protein synthesis by mechanical stimuli.
Aim 3.1 Determine if short term IL-6 or LIF exposure will potentiate stretch induction
of myotube protein synthesis through gp130 regulation of Akt signaling.
Aim 3.2 Determine if long term IL-6 or LIF exposure will disrupt stretch induction of
myotube protein synthesis though gp130 or AMPK dependent mechanisms.
Aim 3.3 Determine if in vivo short term IL-6 infusion or long term IL-6 overexpression
will regulate muscle protein synthesis induction by eccentric contractions.

Overview:
We will use both in vitro and in vivo approaches in this this aim. Control or gp130
deficient myotubes will be stretched in the presence of short term or long term
inflammatory cytokine administration as in aim 1 and aim 2. The gp130 regulation of Akt
or AMPK signaling will be examined. The primary outcomes include protein synthesis
regulation and gp130 downstream signaling pathways. We will also examine if in vivo short
term or long term IL-6 exposure which is similar to aim 1 and aim 2 will alter the acute
protein synthesis induction by eccentric contractions.
In this aim, we will conduct five experiments. In experiment 3.1, control or gp130 siRNA
transfected myotubes will be stretched in the presence of short term IL-6/LIF exposure to
determine if stretch induction of myotube protein synthesis will be potentiated by
physiological elevation of inflammatory cytokines through gp130 dependent mechaisms.
In experiment 3.2, control or gp130 siRNA transfected myotubes will be stretched after
long term IL-6 or LIF exposure to determine if pathological elevation of inflammatory
cytokines will suppress stretch induction of myotube protein synthesis. In experiment 3.3,
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we will use PI3K inhibitor wortmannin to investigate the role of Akt signaling in the
physiological IL-6 or LIF regulation of stretch induced myotube protein synthesis.

In

experiment 3.4, we will use AMPK siRNA to investigate the role of AMPK signaling in
the phathological IL-6 or LIF regulation of stretch induced myotube protein synthesis.

In

experiment 3.5, we will examine the effect of in vivo short term IL-6 infusion or long term
IL-6 overexpression on muscle protein synthesis induction by eccentric contractions.

Experiment 3.1 will determine if short term IL-6 or LIF exposure will potentiate
stretch induction of myotube protein synthesis through gp130 dependent mechanisms.
Hypothesis 3.1: Firstly, short term IL-6 or LIF exposure will potentiate stretch
induction of myotube protein synthesis. Secondly, knock-down myotube gp130 will block
the regulation of short term IL-6 or LIF exposure on basal and stretch induced myotube
protein synthesis.
Design:
C2C12 myoblasts will be grown and differentiate into myotubes on silastic membrane
of stretching devices. Differentiated myotubes will be transfected with control or gp130
siRNA for 24h as described in experiment 1.2. After 24h of siRNA transfection, myotubes
will be stretched by 5% for 4h in the presence or absence of IL-6 (20ng/ml) or LIF
(10ng/ml). To measure protein synthesis, puromycin (1μM) will be added to cell culture
medium 30min before protein sample collection. The treatment groups are listed in table
10. All groups contains at least 6 replicates from 2 independent experiments.
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siRNA

Cytokine

Control

-

Stretch
0%
5%
0%

Control

IL-6
5%
0%

Control

LIF
5%
0%

gp130

5%
0%

gp130

IL-6
5%
0%

gp130

LIF
5%

Primary outcomes:
Protein synthesis: see experiment 1.1.
Akt-mTOR signaling pathway: see experiment 1.1.
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
AMPK signaling pathway: see experiment 1.2

Experiment 3.2 will determine if long term IL-6 or LIF exposure will attenuate
stretch induction of myotube protein synthesis through gp130 dependent mechanisms.
Hypothesis 3.2: Long term IL-6 or LIF exposure will attenuate stretch induction of
myotube protein synthesis, which will be rescued by gp130 siRNA knock-down.
265

Design:
C2C12 myotubes grown on silastic membrane of stretching device will be transfected
with control or gp130 siRNA as described in experiment 3.1. After 24h of siRNA
transfection, myotubes will be administrated with IL-6 or LIF for 24h as described in
experiment 2.1, and will be stretched by 5% in last 4h of IL-6/LIF administration. To
measure protein synthesis, puromycin (1μM) will be added to cell culture medium 30min
before protein sample collection. The treatment groups are listed in table 11. All groups
contains at least 6 replicates from 2 independent experiments.
siRNA

Cytokine

Control

-

Stretch
0%
5%
0%

Control

IL-6
5%
0%

Control

LIF
5%
0%

gp130

5%
0%

gp130

IL-6
5%
0%

gp130

LIF
5%

Primary outcomes:
Protein synthesis: see experiment 1.1
Akt-mTOR signaling pathway: see experiment 1.1
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AMPK signaling pathway: see experiment 1.2
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
Myotube Diameter: see experiment 2.1

Experiment 3.3 will determine if inhibition of Akt signaling by wortmannnin will
block the regulation of short term IL-6 or LIF exposure on stretch induced myotube
protein synthesis.
Hypothesis 3.3: Inhibition of Akt signaling by wortmannnin will block the potentiation
effect of short term IL-6 or LIF exposure on stretch induced myotube protein synthesis.
Design:
C2C12 myotubes will be cultured on silastic membrane of stretch devices and will be
stretched for 4h in the presence or absence of IL-6 or LIF as described as described in
experiment 3.1. To inhibit myotube PI3K-Akt signaling, myotubes will be pretreated with
DMSO or wortmannin 1h before stretch as described in experiment 1.3. To measure protein
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein
sample collection. The treatment groups are listed in table 12. All groups contains at least
6 replicates from 2 independent experiments.
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Inhibitor

Cytokine

Stretch

DMSO

0%
-

(Control)

5%

DMSO

0%
IL-6

(Control)

5%

DMSO

0%
LIF

(Control)

5%
0%

wortmannnin

5%
0%

wortmannnin

IL-6
5%
0%

wortmannnin

LIF
5%

Primary outcomes:
Myotube protein synthesis: see experiment 1.1.
Akt-mTOR signaling pathway: see experiment 1.1.
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
Myotube Diameter: see experiment 2.1

Experiment 3.4 will determine if inhibition of AMPK signaling by AMPK siRNA
knock-down will block the regulation of long term IL-6 or LIF exposure on stretch
induced myotube protein synthesis.
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Hypothesis 3.4: AMPK siRNA knock-down will restore the stretch induction myotube
protein synthesis in long term IL-6 or LIF treated myotubes.
Design:
C2C12 myotubes grown on silastic membrane of stretching device will be transfected
with control or AMPK siRNA as described in experiment 3.1. After 24h of siRNA
transfection, myotubes will be treated with IL-6 or LIF for 24h and will be stretched by 5%
in last 4h of IL-6/LIF incubation as described in experiment 3.2. To measure protein
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein
sample collection. All groups contains at least 6 replicates from 2 independent experiments.
siRNA

Cytokine

Control

-

Stretch
0% (same cohort of experiment3.2)
5% (same cohort of experiment3.2)
0% (same cohort of experiment3.2)

Control

IL-6
5% (same cohort of experiment3.2)
0% (same cohort of experiment3.2)

Control

LIF
5% (same cohort of experiment3.2)
0%

AMPK

5%
0%

AMPK

IL-6
5%
0%

AMPK

LIF
5%

Primary outcomes:
Protein synthesis: see experiment 1.1.
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Akt-mTOR signaling pathway: see experiment 1.1.
AMPK signaling pathway: see experiment 1.2
Secondary Outcomes:
gp130 downstream signaling pathways: see experiment 1.1.
Myotube Diameter: see experiment 2.1

Experiment 3.5 will determine if in vivo short term IL-6 exposure will affect
muscle protein synthesis induction by eccentric contractions.
Hypothesis 3.5: Short in vivo term IL-6 exposure by infusion will potentiate muscle
protein synthesis induction by eccentric contractions, while long term IL-6 exposure by IL6 overexpression will attenuate muscle protein synthesis induction by eccentric
contractions.
Design:
This experiment will determine if short term IL-6 infusion or long term IL-6
overexpression will potentiate or attenuate muscle protein synthesis induction by eccentric
contractions, respectively. To induce short term IL-6 elevation in vivo, male C57BL/6 mice
(~8 weeks old) will be injected with PBS or IL-6 as described in experiment 1.4 after 1.5h
fasting. The eccentric contractions of TA and EDL muscles on left leg will be induced by
High-frequency Electrical Stimulations 30min post IL-6 injection. The sedentary right leg
will be used as intra-animal control. All mice will be sacrificed 3h post electrical
stimulation and 0.04mmol/g body weight puromycin will be injected into mice (I.P.
injection) 30min before sacrifice.
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Genotype

C57BL/6
PBS

Cytokine

IL-6
(control)

Number of Mice

8

Total

8
16 (16 C57BL/6)

Primary outcomes:
Muscle protein synthesis: see experiment 1.1.
Muscle Akt-mTOR signaling pathway: see experiment 1.1.
Secondary Outcomes:
Plasma IL-6 level:

Blood samples will be collected from retroorbital eye sinus before,

after high frequency electrical stimulation and at sacrifice time. see experiment 1.4.
gp130 downstream signaling pathways:

Experiment 3.6 will determine if in vivo long term IL-6 overexpression will affect
muscle protein synthesis induction by eccentric contractions.
Hypothesis 3.6: Long term IL-6 overexpression will attenuate muscle protein synthesis
induction by eccentric contractions.
Design:
This experiment use the same cohort of mice as experiment 2.4. The control or IL-6
plasmid transfected C57BL/6 mice will be subjected to high frequency electrical
stimulation as described in experiment 3.5. The mice will be sacrificed 3h post contraction.
The protein sample of right TA muscle will be analyzed in experiment 2.4 and both right
and left TA muscles will be analyzed in this experiment.
Primary outcomes:
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Muscle protein synthesis: see experiment 1.1.
Muscle Akt-mTOR signaling pathway: see experiment 1.1.
Secondary Outcomes:
AMPK signaling: see experiment 1.4.
Plasma IL-6 level:

see experiment 1.4.

Muscle weight: see experiment 1.4.
Body composition: see experiment 2.4.

Overall Aim 3 Interpretation:
In experiment 3.1
Increased protein synthesis induction by stretch in the presence of short term IL-6 or
LIF exposure (significant interaction term between cytokines and stretch) in control siRNA
transfected myotubes will indicate that short term IL-6 or LIF can potentiate stretch
induction of myotube protein synthesis.
Attenuated protein synthesis induction by stretch in short term IL-6 or LIF treated gp130
deficient myotubes will indicate that gp130 is necessary for short term IL-6 or LIF
stimulation of stretch induced myotube protein synthesis.
In experiment 3.2
Attenuated protein synthesis induction by stretch in the presence of long term IL-6 or
LIF exposure (significant interaction term between cytokines and stretch) in control siRNA
transfected myotubes will indicate that long term IL-6 or LIF can suppress stretch induction
of myotube protein synthesis.
Restored stretch induction of protein synthesis long term IL-6 or LIF treated, gp130
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deficient myotube will indicate that gp130 is necessary for long term IL-6 or LIF
suppression of stretch induced myotube protein synthesis.
In experiment 3.3
Attenuated protein synthesis induction by stretch in IL-6 (or LIF) and wortamannin
treated myotubes will indicate that PI3K-Akt signaling is necessary for short term IL-6 or
LIF stimulation of stretch induced myotube protein synthesis.
In experiment 3.4:
Restored stretch induction of protein synthesis long term IL-6 or LIF treated, AMPK
deficient myotube will indicate that AMPK signaling induction is necessary for long term
IL-6 or LIF suppression of stretch induced myotube protein synthesis.
In experiment 3.5:
Increased muscle protein synthesis induction by eccentric contraction in IL-6 treated
mice will indicate that in vivo short term IL-6 exposure can potentiate eccentric contraction
induced muscle protein synthesis.
In experiment 3.6:
Attenuated muscle protein synthesis induction by eccentric contraction in IL-6
overexpressing mice will indicate that in vivo long term IL-6 exposure can suppress
eccentric contraction induced muscle protein synthesis.

Methods of Aim 3:
C2C12 cell culture: see Aim 1.
Cell stretch:
Cell stretch experiments will be conducted using methods previously described (86,
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305). Static stretching device consists a small frame with two axles (part 1 in Fig. B5A, B)
separated by lateral supports (part 2 in Fig. B5A, B). The axles were threaded to accept
screw nuts (part 3 in Fig. B5A, B). Silastic membranes (GLOSS/GLOSS, 0.02’’, Speciality
Manufacturing, Saginaw, MI, USA, part 5 in Fig. B5A, B) were mounted onto the devices
by two friction-fit C-clamps (part 4 in Fig. B5A, B). The assembled stretching device was
then immersed into distilled H2O, autoclaved and transferred into sterile 100mm petri-dish
(Fig. B5A). The screw nuts were set to 30 cycles from baseline when stretching device was
assembled (Fig. B5B, left). Approximately 300-400 µL type-I collagen solution (Advanced
Biomatrix, San Diego, CA, USA, diluted to ~500μg/ml by PBS, adjust final pH to 7-8 by
sterile 10N NaOH) was evenly scraped onto the silastic sheet attached onto stretching
device and incubate in 4“C overnight. After incubation, stretching device was washed by
sterile distilled H2O twice and air dried under UV overnight. C2C12 myoblasts were
suspended (~1 × 106 cells/mL) and plated onto silastic membrane mounted in a stretching
device (~1.5-2 × 105 cells/ stretching device). The cells were grown to ~95% confluence
and differentiated into myotubes. To induced 5% stretch, screw nuts on both axles were
rotated by 1.5 cycles using sterile forceps (Fig. C5B, right). Myotubes were constantly
stretched by for 4h or 24h.
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A.

B.

Figure B5. Schematic figure of cell stretch method. A: Cell stretch device.
Static stretching device is a small frame with two threaded axles (part 1) and
two lateral supports (part 2). The distance between two lateral supports was
adjusted by rotating screw nuts (part 3) on both axles. The silastic membrane
where cells were grown (part 5) was fixed on lateral supported by two frictionfit C-clamps (part 4). B. Representative image of cell stretch. The screw nuts
were set to 30 cycles from the base line when stretch device was assembled
(left) and were rotated by another 1.5 cycles when cells were stretched (right).
RNA interference: see Aim 1.
High Frequency Electrical Stimulation (HFES):
HFES of the left hindlimb was performed as previously described, with modiﬁcations
(90). During each stimulation procedure, mice will be anesthetized by isoﬂurane (2% in
O2 with 1.5% maintenance), the left leg/hip region will be shaved, and two needle
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electrodes will be placed on the left leg subcutaneously posterior to the femur to stimulate
the sciatic nerve. Tetanic muscle contractions will be generated using a Grass Stimulator
(Grass Instruments, Quincy, MA) for 10 sets of 6 repetitions (100 Hz, 6–12 V, 1ms duration,
3s repetition duration). Ten seconds of rest will be given between repetitions, and 50 s of
rest will be given between sets. This stimulation protocol recruits all motor units of the
hindlimb. The maximal force production of the plantar ﬂexors (gastrocnemius, soleus, and
plantaris) are greater than the dorsiﬂexors (TA and EDL) (306, 307), which results in net
plantar ﬂexion of the ankle (90). Therefore, the dorsiﬂexors undergo lengthening eccentric
muscle contractions against the shortening concentric plantar ﬂexors. Each session lasts
~20 min in duration. Following each stimulation procedure, mice will be given an
intraperitoneal injection of warm saline and returned to cages upon complete recovery.
Mice will be killed 3h after the last set of stimulation procedure. Mice will be fasted since
2h before HFES until sacrifice, but had free access to water ad libitum.
Protein Synthesis Measurement: see Aim 1.
Protein collection and western blot: see Aim1.
Statistical Analysis:
All statistical analysis will be conducted by Prism Software. In experiment 3.1-3.4,
two-way ANOVA will be used to determine the main effects of IL-6/LIF, main effects of
mechanical stretch and their interactions. In experiment 3.5 and 3.6, two way repeated
measures (RM-ANOVA) will be conducted to measure the main effects of IL-6, main
effects of eccentric contractions and their interactions. If possible, post-hoc analysis will
be conducted using Student-Newman-Kelus (SNK) method. p < 0.05 will be considered as
significant.
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Limitations and Pitfalls
IL-6 or LIF administration on myotubes:
Administration of IL-6 and LIF on myotubes will be conducted in serum-free
environment, which will exclude the combined effects of IL-6/LIF with other cytokines. It
has been reposted that IL-6 can cooperate with other cytokines to induce muscle wasting.
Serum starvation regulates insulin sensitivity in cultured myotubes (308), which may
influence mTOR signaling and protein synthesis. Therefore, serum starvation effects is a
pontential confounder of experiments in Aim 1 and 2. The in vitro myotube culture
experiment also excludes the systematic effects of IL-6 and LIF, including the potential
global metabolic and immune effects of IL-6 and LIF (204, 309, 310).
RNA interference:
RNA interference can not fully block the target protein. It is possible that the results of
mechanistic studies using siRNA (gp130 and AMPK) is influenced by residual targeted
signaling pathways in siRNA transfected cells.
In vivo IL-6 infusion and IL-6 overexpression:
It is difficult to control serum level of IL-6 in IL-6 injected or IL-6 overexpressing
mice, and it is possible that plasma IL-6 level in animal models of this proposal is different
from those under certain physiological or pathological conditions. It has been reported the
mice injected with IL-6 showed higher plasma IL-6 level compared with IL-6 level post
resistance exercise (301, 311).

It is possible that plasma IL-6 levels in IL-6

overexpressing mice are different from those in animal models of muscle wasting diseases,
such as cancer cachexia (125).
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In vitro cell stretch:
Cell stretch is a different mechanical stimuli model from in vivo eccentric contractions.
Myotubes are passively stretched and no myotubes contractions will be induced in cell
stretch experiment, which is different from in vivo muscle eccentric contractions. The
neuron-muscular interactions in in vivo muscle eccentric contractions is also absent in
myotube stretch model. Furthermore, the IL-6 added in cell culture media during stretch
dose not fully mimic the micro-environment of muscle fibers during exercise or overload.
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APPENDIX C
RAW DATA
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Table C.1: Fig. 3.1B raw data (Puromycin, different doses of IL-6)
Signal

-bg
64.011
69.350
63.581
113.659
125.626
88.068
125.933
148.885
118.016
180.859
178.589
160.914
198.227
178.589
160.914

Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

Normalized
59.83575
65.17494
59.40616
109.4841
121.4512
83.89279
121.7581
144.7105
113.8414
176.6842
174.4135
156.739
194.0519
174.4135
156.739

0.975
1.062
0.968
1.784
1.979
1.367
1.984
2.358
1.855
2.879
2.842
2.554
3.162
2.842
2.554

Table C.2: Fig. 3.1B raw data (Puromycin, different doses of LIF)
Signal
Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

-bg

Normalized

63.533

59.83575

0.975

68.872

65.17494

1.062

63.103

59.40616

0.968

106.799

103.1016

1.68

95.875

92.17774

1.502

109.315

105.6178

1.721

131.162

127.4655

2.077

120.484

116.7871

1.903

122.080

118.3827

1.929

265.624

261.9272

4.268

283.237

279.5404

4.555

268.079

264.382

4.308

154.851

151.1543

2.463

164.425

160.728

2.619

140.368

136.671

2.227

153.869

150.1724

2.447

161.479

157.7823

2.571

128.278

124.5811

2.03
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Table C.3: Fig. 3.1B raw data (Puromycin, different doses of TNF - α)
Signal
Control

5ng/ml

10ng/ml

20ng/ml

-bg

Normalized

81.576

78.7917

1.135

68.316

65.53248

0.944

66.164

63.38046

0.913

62.416

59.63178

0.859

57.973

55.1889

0.795

85.602

82.81806

1.193

83.797

81.01314

1.167

63.527

60.7425

0.875

66.164

63.38046

0.913

49.920

47.13618

0.679

32.773

29.98944

0.432

57.487

54.70296

0.788

Table C.4: Fig. 3.1C raw data (p-NFκB, different doses of TNF-α)

Signal
Control

5ng/ml

10ng/ml

20ng/ml

-bg

Normalized

64.079

62.70887

0.735

69.402

68.03192

0.797

118.911

117.5407

1.377

96.632

95.26176

1.116

82.803

81.43344

0.954

88.608

87.23792

1.022

311.910

310.5397

3.638

273.242

271.8716

3.185

245.756

244.3857

2.863

298.167

296.7967

3.477

330.774

329.4042

3.859

255.487

254.1167

2.977

344.005

342.635

4.014

279.388

278.0175

3.257

255.231

253.8606

2.974
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Table C.5: Fig. 3.1D raw data (p-p70S6K, different doses of IL-6)

Signal
Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

-bg

Normalized

82.863

81.97332

1.124

64.995

64.10547

0.879

73.674

72.78414

0.998

203.927

203.0371

2.784

232.662

231.7715

3.178

173.588

172.6982

2.368

165.128

164.2384

2.252

291.078

290.1885

3.979

202.833

201.9432

2.769

283.785

282.8955

3.879

186.278

185.3881

2.542

239.298

238.4082

3.269

85.635

84.74466

1.162

76.883

75.99306

1.042

114.223

113.3332

1.554

Table C.6: Fig. 3.1D raw data (p-p70S6K, different doses of LIF)

Signal
Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

-bg

Normalized

82.863

81.97332

1.124

64.995

64.10547

0.879

73.674

72.78414

0.998

339.358

338.4681

4.641

405.141

404.251

5.543

432.125

431.2351

5.913

243.747

242.8569

3.330

257.312

256.4219

3.516

143.541

142.6511

1.956

133.987

133.0973

1.825

74.185

73.29465

1.005

78.123

77.23287

1.059

47.565

46.6752

0.640

9.496

8.60574

0.118

35.678

34.78761

0.477
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Table C.7: Fig. 3.1D raw data (p-4EBP1 different doses of IL-6)

Signal
Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

-bg

Normalized

89.712

88.82176

1.024

94.309

93.41898

1.077

79.043

78.15274

0.901

78.436

77.54556

0.894

129.786

128.8956

1.486

111.657

110.767

1.277

99.340

98.4499

1.135

76.007

75.11684

0.866

110.356

109.4659

1.262

70.109

69.21852

0.798

98.559

97.66924

1.126

102.202

101.3123

1.168

91.013

90.12286

1.039

80.517

79.62732

0.918

104.891

104.0013

1.199

Table C.8: (Fig. 3.1D raw data, p-4EBP1, different doses of IL-6)

Signal
Control

5ng/ml

10ng/ml

20ng/ml

100ng/ml

-bg

Normalized

81.576

78.7917

1.135

68.316

65.53248

0.944

66.164

63.38046

0.913

89.351

86.56674

1.247

92.266

89.48238

1.289

56.099

53.31456

0.768

82.409

79.62474

1.147

85.394

82.6098

1.19

87.060

84.27588

1.214

89.351

86.56674

1.247

92.266

89.48238

1.289

56.029

53.24514

0.767

65.811

63.02699

1.027

63.356

60.57219

0.987

70.659

67.87522

1.106
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Table C.9: Fig. 3.2A raw data (gp130 protein level, Control/gp130 siRNA + IL-6)

Control siRNA

Control siRNA + IL-6

gp130 siRNA

gp130 siRNA + IL-6

52.975

51.94938

1.074

46.591

45.56454

0.942

48.622

47.59608

0.984

44.414

43.38789

0.897

58.441

57.41519

1.187

46.107

45.08084

0.932

11.377

10.35118

0.214

10.652

9.62563

0.199

14.134

13.10827

0.271

14.521

13.49523

0.279

10.652

9.62563

0.199

15.247

14.22078

0.294

Table C.10: Fig. 3.2A raw data (gp130 protein level, Control/gp130 siRNA + LIF)

Signal
Control siRNA

Control siRNA + LIF

gp130 siRNA

gp130 siRNA + LIF

-bg

Normalized

54.681

51.69615

0.935

57.888

54.90297

0.993

63.251

60.2661

1.09

67.730

64.74459

1.171

54.571

51.58557

0.933

57.556

54.57123

0.987

19.683

16.69758

0.302

18.687

15.70236

0.284

14.098

11.11329

0.201

19.683

16.69758

0.302

18.687

15.70236

0.284

14.098

11.11329

0.201
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Table C.11: Fig. 3.2B raw data (Puromycin, Control/gp130 siRNA + IL-6/LIF)

Signal
Control siRNA

Control siRNA + IL-6

gp130 siRNA

gp130 siRNA + IL-6

-bg

Normalized

66.195

63.031

1.140

53.588

50.424

55.745

52.581

135.473

132.309

2.393

193.472

190.308

3.442

129.170

126.006

52.649

49.485

59.173

56.009

43.747

40.583

65.365

62.201

1.125

63.541

60.377

1.092

57.238

54.074

0.978

Signal

-bg

Normalized

55.275

52.378

1.059

0.912

50.923

48.026

0.971

0.951

51.566

48.669

0.984

152.415

149.518

3.023

185.602

182.705

3.694

2.279

104.735

101.838

2.059

0.895

45.878

42.981

0.869

1.013

47.559

44.662

0.903

0.734

46.669

43.772

0.885

54.434

51.537

1.042

50.824

47.927

0.969

58.836

55.939

1.131

Control siRNA

Control siRNA + LIF

gp130 siRNA

gp130 siRNA + LIF

Table C.12: Fig. 3.2C raw data (p-p70S6K, Control/gp130 siRNA + IL-6/LIF)

Signal
Control siRNA

Control siRNA + IL-6

gp130 siRNA

gp130 siRNA + IL-6

-bg

Normalized

49.819

46.92179

1.109

30.229

27.33226

0.646

55.573

52.67595

1.245

87.305

84.40845

1.995

Signal
Control siRNA

Control siRNA + IL-6

-bg

Normalized

48.524

46.24483

1.093

35.535

33.25566

0.786

50.724

48.44495

1.145

92.611

90.33185

2.135

97.375

94.47823

2.233

139.110

136.8305

3.234

106.810

103.91336

2.456

127.347

125.0684

2.956

17.790

14.89312

0.352

17.172

14.89312

0.352

37.168

34.2711

0.810

36.508

34.22879

0.809

36.068

33.17104

0.784

35.450

33.17104

0.784

42.372

39.47523

0.933

39.216

36.93663

0.873

67.039

64.14196

1.516

57.959

55.67996

1.316

51.807

48.91036

1.156

55.420

53.14136

1.256

gp130 siRNA

gp130 siRNA + IL-6
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Table C.13: Fig. 3 raw data (p-STAT3, different duration of IL-6/LIF treatment)

IL-6
Control

30min

1h

2h

4h

Signal

-bg

Normalized

38.57626

35.59626

1.134

31.76463

28.78463

32.76911

29.78911

216.3692

213.38922

6.798

244.4319

241.45188

7.692

203.2168

200.23681

202.2123

199.23233

159.5533

156.57332

153.1812

150.20115

127.8494

124.86942

3.978

93.91683

90.93683

2.897

158.8941

155.91413

4.967

58.8542

55.8742

1.780

43.53588

40.55588

1.292

27.58976

24.60976

0.784

LIF

Signal

-bg

Normalized

28.36514

25.23514

0.922

0.917

30.19893

27.06893

0.989

0.949

33.04541

29.91541

1.093

182.07506

178.9451

6.538

161.41071

158.2807

5.783

6.379

195.04844

191.9184

7.012

6.347

176.57369

173.4437

6.337

4.988

139.1589

136.0289

4.970

4.785

164.3393

161.2093

5.890

39.8058

36.6758

1.340

29.9526

26.8226

0.980

36.7951

33.6651

1.230

40.29846

37.16846

1.358

24.99863

21.86863

0.799

25.87447

22.74447

0.831

Control

30min

1h

2h

4h

Table C.14: Fig. 3 raw data (p-ERK1/2, different duration of IL-6/LIF treatment)

IL-6
Control

30min

1h

2h

4h

Signal

-bg

Normalized

32.39569

30.26569

1.027

30.30332

28.17332

0.956

32.24834

30.11834

1.022

35.81421

33.68421

1.143

39.82213

37.69213

29.15399

27.02399

50.31345

48.18345

1.635

42.47443

40.34443

1.369

34.39965

32.26965

1.095

41.0304

38.9004

1.320

22.1696

20.0396

30.1265

27.9965

24.8219

22.6919

0.770

43.0933

40.9633

1.390

32.1894

30.0594

1.020

LIF
Control

Signal

-bg

Normalized

20.58432

18.03432

0.922

21.89484

19.34484

0.989

23.92908

21.37908

1.093

149.85636

147.3064

7.531

1.279

127.22544

124.6754

6.374

0.917

139.0788

136.5288

6.980

25.2396

22.6896

1.160

19.5672

17.0172

0.870

27.7824

25.2324

1.290

24.4572

21.9072

1.120

0.680

17.8068

15.2568

0.780

0.950

19.176

16.626

0.850

15.6552

13.1052

0.670

29.7384

27.1884

1.390

24.4572

21.9072

1.120

30min

1h

2h

4h
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Table C.15: Fig. 3 raw data (p-Akt, different duration of IL-6/LIF treatment)

IL-6
Control

30min

1h

2h

4h

Signal

-bg

Normalized

35.766

33.116

1.098

34.288

31.638

28.950

26.300

47.468

44.818

1.486

38.782

36.132

1.198

47.407

44.757

1.484

74.310

71.660

2.376

93.552

90.902

3.014

58.868

56.218

1.864

107.788

105.138

3.486

85.892

83.242

2.760

115.147

112.497

92.527

89.877

123.592

120.942

98.257

95.607

LIF

Signal

-bg

Normalized

25.908

22.898

0.947

1.049

30.551

27.541

1.139

0.872

25.328

22.318

0.923

44.696

41.686

1.724

31.736

28.726

1.188

53.014

50.004

2.068

105.485

102.475

4.238

111.699

108.689

4.495

96.248

93.238

3.856

125.458

122.448

5.064

120.912

117.902

4.876

3.730

117.502

114.492

4.735

2.980

144.802

141.792

5.864

4.010

129.689

126.679

5.239

3.170

152.346

149.336

6.176

Control

30min

1h

2h

4h

Table C.16: Fig. 3.4A raw data (p-Akt, Wortmanin + IL-6/LIF)
IL-6
Control

IL-6

Wortmanin

Wortmanin+IL-6

Signal

-bg

Normalized

31.260

28.610

1.174

23.803

21.153

0.868

25.996

23.346

56.240

53.590

50.878

48.228

97.571

94.921

24.973

22.323

0.916

28.044

25.394

1.042

30.212

27.562

24.510

21.860

33.941

31.291

30.773

28.123

LIF

Signal

-bg

25.878

22.748

1.016

29.080

25.950

1.159

0.958

22.139

19.009

0.849

2.199

63.090

59.960

2.678

1.979

73.345

70.215

3.136

3.895

80.868

77.738

3.472

30.356

27.226

1.216

19.743

16.613

0.742

1.131

26.438

23.308

1.041

0.897

34.252

31.122

1.390

1.284

23.975

20.845

0.931

1.154

19.116

15.986

0.714

Control

LIF

Wortmanin

Wortmanin+LIF
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Normalized

Table C.17: Fig. 3.4B raw data (p-p70S6K, Wortmanin + IL-6/LIF)

IL-6
Control

IL-6

Wortmanin

Wortmanin+IL-6

Signal

-bg

35.752

33.482

Normalized
0.938

35.752

33.482

81.527

79.257

81.527

79.257

2.779

89.798

87.528

1.742

LIF

Signal

-bg

27.849

24.829

0.938

1.174

34.096

31.076

1.174

0.895

26.711

23.691

0.895

91.165

88.145

3.330

77.560

74.540

2.816

Control

LIF

Normalized

89.798

87.528

3.069

65.383

62.363

2.356

N.D

N.D

0.000

N.D

N.D

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

N.D

N.D

0.000

N.D

N.D

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

N.D

N.D

0.000

N.D

N.D

0.000

N.D

N.D

0.000

N.D

N.D

0.000

Wortmanin

Wortmanin+LIF

Table C.18: Fig. 3.4C raw data (Puromycin, Wortmanin + IL-6/LIF)

IL-6
Control

IL-6

Wortmanin

Wortmanin+IL-6

Signal

-bg

Normalized

42.566

40.296

1.048

44.911

42.641

36.683

34.413

107.508

105.238

2.737

79.708

77.438

2.014

57.523

55.253

8.960

6.690

10.921

8.651

9.576

7.306

12.805

10.535

0.274

10.806

8.536

0.222

11.267

8.997

0.234

LIF

Signal

-bg

Normalized

27.813

24.633

0.785

1.109

39.141

35.961

1.146

0.895

37.196

34.016

1.084

101.525

98.345

3.134

86.463

83.283

2.654

1.437

81.253

78.073

2.488

0.174

8.640

5.460

0.174

0.225

10.241

7.061

0.225

0.190

9.142

5.962

0.190

10.523

7.343

0.234

9.644

6.464

0.206

9.425

6.245

0.199
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Control

LIF

Wortmanin

Wortmanin+LIF

Table C.19: Fig. 3.4D raw data, (p-p70S6K, Rapamycin + IL-6/LIF)

IL-6
Control

IL-6

Rapamycin

Rapamycin +IL-6

Signal

-bg

Normalized

68.528

66.178

1.174

55.225

52.875

52.801

50.451

159.002

156.652

2.779

202.013

199.663

3.542

LIF

Signal

-bg

Normalized

59.778

55.518

1.174

0.938

48.618

44.358

0.938

0.895

46.585

42.325

0.895

209.026

204.766

4.330

170.532

166.272

3.516

130.141

127.791

2.267

N.D.

N.D.

0.000

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

Control

LIF

144.049

139.789

2.956

N.D.

N.D.

0.000

0.000

N.D.

N.D.

0.000

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

N.D.

N.D.

0.000

Rapamycin

Rapamycin +LIF

Table C.20 Fig. 3.4E raw data (Puromycin, Rapamycin + IL-6/LIF)

IL-6
Control

IL-6

Rapamycin

Rapamycin+IL-6

Signal

-bg

Normalized

86.216

82.476

1.054

91.145

87.405

72.991

69.251

217.910

214.170

2.737

161.336

157.596

2.014

116.185

112.445

17.356

13.616

21.346

17.606

18.608

14.868

40.048

36.308

0.464

44.587

40.847

0.522

41.613

37.873

0.484

LIF

Signal

-bg

Normalized

65.883

62.933

0.785

1.117

94.825

91.875

1.146

0.885

89.854

86.904

1.084

199.687

196.737

2.454

174.995

172.045

2.146

1.437

242.498

239.548

2.988

0.174

16.900

13.950

0.174

0.225

20.988

18.038

0.225

0.190

18.182

15.232

0.190

77.989

75.039

0.936

63.398

60.448

0.754

53.858

50.908

0.635

Control

LIF

Rapamycin

Rapamycin+LIF
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Table C.21: Fig. 3.5A, B raw data (p-STAT3, LLL12 + IL-6/LIF)

IL-6

Signal

Control

IL-6

LLL12

LLL12+IL-6

-bg

Normalized

Signal

-bg

50.846

48.706

1.074

1.128

49.213

47.073

1.038

0.875

42.728

40.588

0.895

40.098

37.958

0.837

60.415

58.275

1.285

4.349

45.086

42.946

0.947

0.135

8.262

6.122

0.135

0.221

12.162

10.022

0.221

0.114

7.310

5.170

0.114

10.938

8.798

0.194

2.140

0.000

0.000

3.591

1.451

0.032

54.334

50.954

1.014

60.062

56.682

47.349

43.969

163.075

159.695

3.178

175.537

172.157

3.426

221.917

218.537

10.164

6.784

14.485

11.105

9.109

5.729

11.872

8.492

0.169

11.169

7.789

0.155

8.204

4.824

0.096

LIF
Control

LIF

LLL12

LLL12+LIF

Normalized

Table C.22: Fig. 3.5C, Puromycin (LLL12 + IL-6/LIF)

Signal
Control

IL-6

LIF

LLL12

LLL12+IL-6

LLL12+LIF

-bg

Normalized

59.245

56.875

0.957

64.058

61.688

1.038

63.226

60.856

1.024

179.947

177.577

2.988

108.512

106.142

1.786

144.705

142.335

2.395

220.954

218.584

3.678

248.172

245.802

4.136

208.711

206.341

3.472

15.147

12.777

0.215

19.426

17.056

0.287

14.613

12.243

0.206

37.850

35.480

0.597

48.963

46.593

0.784

33.392

31.022

0.522

49.260

46.89027

0.789

45.813

43.44333

0.731

57.996

55.62648

0.936
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Table C.23: Fig. 3.5D raw data (p-p70S6K, LLL12 + IL-6/LIF)

Signal
Control

IL-6

LIF

LLL12

LLL12+IL-6

LLL12+LIF

-bg

Normalized

47.755

45.165

1.045

47.409

44.819

1.037

42.439

39.849

0.922

73.341

70.751

1.637

93.957

91.367

2.114

190.078

187.488

4.338

103.898

101.308

2.344

138.560

135.970

3.146

131.731

129.141

2.988

2.590

0.000

0.000

2.590

0.000

0.000

2.590

0.000

0.000

13.827

11.237

0.260

12.012

9.422

0.218

7.128

4.538

0.105

10.975

8.38468

0.194

10.672

8.08214

0.187

11.882

9.2923

0.215

Table C.24: Fig. 3.6A raw data (p-ERK1/2, PD98059 + LIF, 30min exposure)

Signal
Control

LIF

PD98059+LIF

-bg

Normalized

36.241

33.451

1.035

33.720

30.930

0.957

35.724

32.934

1.019

210.672

207.882

6.432

208.798

206.008

6.374

196.225

193.435

5.985

11.646

8.856

0.274

8.252

5.462

0.169

6.442

3.652

0.113

291

Table C.25: Fig. 3.6B raw data (p-ERK1/2, PD98059 + LIF, 2h exposure)

Signal
Control

LIF

PD98059

PD98059+LIF

-bg

Normalized

38.662

36.635

1.034

35.508

33.481

0.945

38.449

36.422

1.028

41.106

39.079

1.103

35.544

33.517

0.946

38.839

36.812

1.039

15.278

13.251

0.374

16.022

13.995

0.395

16.305

14.278

0.403

15.809

13.782

0.389

15.384

13.357

0.377

14.144

12.117

0.342

Table C.26: Fig. 3.6B raw data (Puromycin, PD98059 + LIF, 2h exposure)

Signal
Control

LIF

PD98059

PD98059+LIF

-bg

Normalized

58.663

55.293

0.941

58.781

55.411

0.943

70.121

66.751

1.136

222.839

219.469

3.735

220.136

216.766

3.689

190.462

187.092

3.184

239.233

235.863

4.014

217.080

213.710

3.637

212.673

209.303

3.562

231.065

227.695

3.875

207.208

203.838

3.469

195.574

192.204

3.271

292

Table C.27: Fig. 3.7A raw data (SOCS3 mRNA expression, different duration of IL-6/LIF
exposure)

Control

IL-6 30min

IL-6 1h

IL-6 2h

IL-6 4h

LIF 30min

LIF 1h

LIF 2h

LIF 4h

GAPDH Ct

SOCS3 Ct

ΔCt

ΔΔCt

Fold Change

17.040

24.115

-7.075

0.023

1.016

16.805

23.690

-6.885

0.213

1.159

16.480

23.815

-7.335

-0.237

0.849

16.750

22.530

-5.780

1.318

2.494

16.140

22.222

-6.082

1.016

2.023

16.355

21.915

-5.560

1.539

2.905

16.850

21.620

-4.770

2.328

5.022

16.435

21.207

-4.772

2.326

5.015

16.770

21.428

-4.658

2.441

5.429

16.370

22.870

-6.500

0.598

1.514

16.265

22.520

-6.255

0.843

1.794

16.925

23.450

-6.525

0.573

1.488

16.745

22.360

-5.615

1.483

2.796

16.970

22.640

-5.670

1.428

2.691

17.305

22.892

-5.587

1.511

2.851

16.875

22.712

-5.837

1.261

2.397

16.970

22.472

-5.502

1.596

3.023

17.235

22.909

-5.674

1.424

2.684

17.045

21.444

-4.399

2.699

6.495

16.890

21.152

-4.262

2.836

7.142

16.925

21.479

-4.554

2.544

5.833

16.495

22.285

-5.790

1.308

2.476

16.550

22.672

-6.122

0.976

1.967

16.630

22.083

-5.453

1.646

3.129

16.725

22.727

-6.002

1.096

2.138

17.015

22.708

-5.693

1.405

2.649

16.930

22.992

-6.062

1.036

2.051
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Table C.28: Fig. 3.7B, Puromycin (different duration of IL-6/LIF exposure)

IL-6

Signal

Control

1h

2h

4h

-bg

Normalized

LIF

Signal

-bg

Normalized

42.441

39.321

0.754

39.605

37.225

0.754

61.997

58.877

1.129

58.119

55.739

1.129

61.424

58.304

1.118

57.576

55.196

1.118

74.722

71.602

1.373

85.322

82.942

1.680

58.868

55.748

1.069

76.534

74.154

1.502

44.684

41.564

0.797

87.346

84.966

1.721

271.067

267.947

5.138

213.091

210.711

4.268

219.855

216.735

4.156

227.260

224.880

4.555

201.864

198.744

3.811

215.066

212.686

4.308

142.778

139.658

2.678

123.978

121.598

2.463

96.260

93.140

1.786

131.680

129.300

2.619

77.903

74.783

1.434

132.075

129.695

2.627

Control

1h

2h

4h

Table C.29: Fig. 3.7C raw data (SOCS3 mRNA expression, SOCS3 siRNA + IL-6/LIF)

Control siRNA

Control siRNA + IL-6

Control siRNA + LIF

SOCS3 siRNA

SOCS3 siRNA + IL-6

SOCS3 siRNA + LIF

GAPDH Ct

SOCS3 Ct

ΔCt

ΔΔCt

Fold Change

18.440

24.115

-5.675

0.097

0.940

18.155

23.690

-5.535

0.237

1.140

17.710

23.815

-6.105

-0.333

0.921

17.866

21.088

-3.222

2.549

5.854

17.680

20.616

-2.936

2.836

7.138

17.631

21.119

-3.488

2.284

4.869

18.204

21.094

-2.890

2.882

7.372

17.665

20.872

-3.207

2.564

5.915

17.935

21.406

-3.471

2.301

4.927

17.605

24.649

-7.044

-1.272

0.414

17.695

24.767

-7.072

-1.301

0.406

18.030

25.205

-7.175

-1.404

0.378

17.680

22.506

-4.826

0.946

1.926

17.965

22.363

-4.398

1.374

2.591

18.320

22.921

-4.601

1.171

2.251

17.915

22.425

-4.510

1.261

2.397

18.250

23.005

-4.755

1.016

2.023

18.580

23.600

-5.020

0.752

1.684
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Table C.30: Fig. 3.7D raw data (Puromycin, SOCS3 siRNA + IL-6/LIF)

IL-6

Signal

Control siRNA

Control siRNA + IL-6

Control siRNA + LIF

SOCS3 siRNA

SOCS3 siRNA + IL-6

SOCS3 siRNA + LIF

-bg

Normalized

57.145

53.475

0.967

58.362

54.692

0.989

61.459

57.789

1.045

107.136

103.466

1.871

97.348

93.678

1.694

99.837

96.167

1.739

122.233

118.563

2.144

106.694

103.024

1.863

110.344

106.674

1.929

82.473

78.803

1.425

79.929

76.259

1.379

91.652

87.982

1.591

118.473

114.803

2.076

161.773

158.103

2.859

170.344

166.674

3.014

188.483

184.8126

3.342

121.957

118.2867

2.139

140.095

136.4251

2.467

Table C.31: Fig. 4.1A raw data (Puromycin, 24h IL-6/LIF treatment)

Signal
Control

20ng/ml IL-6

100g/ml IL-6

20ng/ml LIF

100g/ml LIF

-bg

Normalized

70.089

66.199

0.943

67.772

63.882

0.910

84.409

80.519

1.147

48.467

44.577

0.635

44.115

40.225

0.573

55.978

52.088

0.742

20.668

16.778

0.239

26.003

22.113

0.315

30.496

26.606

0.379

27.688

23.798

0.339

21.931

18.041

0.257

32.883

28.993

0.413

22.423

18.533

0.264

30.145

26.255

0.374

22.072

18.182

0.259
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Table C.32: Fig. 4.1B raw data (p-p70S6K p-4EBP1, 24h IL-6/LIF treatment)

p-p70S6K
Control

20ng/ml IL-6

100g/ml IL-6

20ng/ml LIF

100g/ml LIF

Signal

-bg

Normalized

Signal

-bg

69.178

66.798

0.923

0.905

76.849

74.469

1.029

1.022

78.224

75.844

1.048

36.177

33.797

0.467

44.282

41.902

0.579

0.429

27.348

24.968

0.345

0.389

18.229

15.849

0.219

15.262

12.882

0.178

23.874

21.494

0.297

49.203

46.823

0.647

53.401

51.021

0.705

98.459

95.479

1.074

83.435

80.455

93.836

90.856

33.473

30.493

0.343

37.118

34.138

0.384

41.118

38.138

37.562

34.582

p-4EBP1
Control

20ng/ml IL-6

100g/ml IL-6

Normalized

44.496

41.516

0.467

49.564

46.584

0.524

104.948

101.968

1.147

71.878

68.898

0.775

103.615

100.635

1.132

45.223

42.843

0.592

34.362

31.382

0.353

27.492

25.112

0.347

17.505

15.125

0.209

17.795

15.415

0.213

39.607

36.627

0.412

28.317

25.337

0.285

20ng/ml LIF

100g/ml LIF

Table C.33: Fig. 4.2A raw data (p-STAT3 p-ERK1/2, 24h IL-6/LIF treatment)
p-STAT3
Control

20ng/ml IL-6

100g/ml IL-6

20ng/ml LIF

100g/ml LIF

Signal

-bg

Normalized

31.996

29.016

1.004

34.337

31.357

29.337

26.357

129.504

126.524

4.378

137.481

134.501

4.654

123.753

120.773

4.179

216.118

213.138

7.375

p-ERK1/2

Signal

-bg

Normalized

22.846

20.656

0.963

1.085

24.262

22.072

1.029

0.912

23.812

21.622

1.008

87.432

85.242

3.974

90.929

88.739

4.137

89.899

87.709

4.089

112.550

110.360

5.145

108.925

106.735

4.976

110.169

107.979

5.034

30.332

28.142

1.312

33.786

31.596

1.473

Control

20ng/ml IL-6

100g/ml IL-6

233.689

230.709

7.983

223.314

220.334

7.624

33.441

30.461

1.054

31.707

28.727

0.994

33.123

30.143

1.043

31.062

28.872

1.346

30.840

27.860

0.964

30.011

27.821

1.297

32.971

30.781

1.435

29.560

27.370

1.276

31.678

28.698

0.993

33.238

30.258

1.047

20ng/ml LIF

100g/ml LIF
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Table C.34: Fig. 4.2A raw data (p-Akt, 24h IL-6/LIF treatment)

p-Akt
Control

20ng/ml IL-6

100g/ml IL-6

20ng/ml LIF

100g/ml LIF

Signal

-bg

Normalized

40.149

37.569

1.135

34.819

32.239

0.974

32.105

29.525

0.892

28.233

25.653

0.775

24.856

22.276

0.673

20.255

17.675

0.534

11.649

9.069

0.274

13.669

11.089

0.335

14.066

11.486

0.347

20.355

17.775

0.537

18.104

15.524

0.469

18.236

15.656

0.473

9.829

7.249

0.219

6.982

4.402

0.133

9.101

6.521

0.197

Table C.35: Fig. 4.2B raw data (SOCS3 mRNA expression, 24h IL-6/LIF treatment)

Control

20ng/ml IL-6

100ng/ml IL-6

20ng/ml LIF

100ng/ml LIF

GAPDH Ct

SOCS3 Ct

ΔCt

ΔΔCt

Fold Change

15.760

22.971

-7.211

-0.089

0.940

15.605

22.589

-6.984

0.138

1.100

14.840

22.019

-7.179

-0.057

0.961

15.816

22.225

-6.409

0.713

1.639

15.060

22.214

-7.154

-0.032

0.978

14.621

21.628

-7.007

0.115

1.083

15.734

22.663

-6.929

0.193

1.143

15.385

22.428

-7.043

0.079

1.056

15.585

22.411

-6.826

0.296

1.228

14.895

21.189

-6.294

0.828

1.775

15.145

21.321

-6.176

0.946

1.927

15.870

21.947

-6.077

1.045

2.063

15.380

21.934

-6.554

0.568

1.482

15.575

21.829

-6.254

0.868

1.825

15.880

22.013

-6.133

0.989

1.985
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Table C.36: Fig. 4.2C raw data (p-AMPK, 24h IL-6/LIF treatment)

Signal
Control

20ng/ml IL-6

100g/ml IL-6

20ng/ml LIF

100g/ml LIF

-bg

Normalized

45.487

42.707

1.065

38.228

35.448

0.884

44.965

42.185

1.052

182.147

179.367

4.473

140.403

137.623

3.432

162.097

159.317

3.973

158.168

155.388

3.875

141.646

138.866

3.463

142.007

139.227

3.472

122.438

119.658

2.984

113.697

110.917

2.766

128.093

125.313

3.125

160.934

158.154

3.944

181.947

179.167

4.468

170.077

167.297

4.172

Table C.37: Fig. 4.3B raw data (p-STAT3, C-188-9 + 24h IL-6/LIF treatment)

Signal
Control

IL-6

C-188-9

C-188-9 + IL-6

-bg

Normalized

Signal

-bg

Normalized

56.577

54.317

1.021

49.678

47.488

0.923

53.758

51.498

0.968

50.502

48.312

0.939

56.098

53.838

1.012

60.740

58.550

1.138

186.811

184.551

3.469

60.534

58.344

1.134

47.620

45.430

0.883

55.132

52.942

1.029

19.529

17.339

0.337

24.416

22.226

0.432

Control

LIF

229.637

227.377

4.274

222.136

219.876

4.133

25.774

23.514

0.442

22.529

20.269

0.381

23.806

21.546

0.405

20.403

18.213

0.354

27.211

24.951

0.469

24.159

21.969

0.427

27.966

25.776

0.501

18.345

16.155

0.314

23.912

21.652

0.407

28.062

25.802

0.485
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C-188-9

C-188-9 + LIF

Table C.38: Fig. 4.3C raw data (p-p70S6K, C-188-9 + 24h IL-6/LIF treatment)

Signal
Control

IL-6

LIF

C-188-9

C-188-9 + IL-6

C-188-9 + LIF

-bg

Normalized

49.078

47.098

1.091

44.071

42.091

0.975

42.301

40.321

0.934

29.997

28.017

0.649

32.717

30.737

0.712

30.386

28.406

0.658

13.506

11.526

0.267

14.456

12.476

0.289

12.082

10.102

0.234

10.528

8.548

0.198

11.607

9.627

0.223

10.355

8.375

0.194

13.550

11.570

0.268

12.211

10.231

0.237

12.945

10.965

0.254

12.729

10.74933

0.249

14.197

12.21711

0.283

13.506

11.52639

0.267

Table C.39: Fig. 4.3D raw data (Puromycin, C-188-9 + 24h IL-6/LIF treatment)
Signal
Control

IL-6

LIF

C-188-9

C-188-9 + IL-6

C-188-9 + LIF

-bg

Normalized

83.989

79.709

0.947

99.560

95.280

1.132

81.716

77.436

0.920

48.974

44.694

0.531

55.540

51.260

0.609

44.092

39.812

0.473

36.685

32.405

0.385

41.567

37.287

0.443

35.170

30.890

0.367

23.723

19.443

0.231

26.922

22.642

0.269

20.104

15.824

0.188

22.292

18.012

0.214

18.336

14.056

0.167

20.188

15.908

0.189

23.387

19.10659

0.227

20.525

16.24481

0.193

21.535

17.25485

0.205
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Table C.40: Fig. 4.3E raw data (p-STAT3, STAT3 siRNA + 24h IL-6/LIF treatment)
Signal
Control siRNA

Control siRNA + IL-6

STAT3 siRNA

STAT3 siRNA + IL-6

Normalized

Signal

-bg

77.271

-bg
72.621

1.025

67.518

63.148

0.987

77.767

73.117

1.032

62.080

57.710

0.902

71.462

66.812

0.943

75.452

71.082

1.111

243.769

239.119

3.375

77.371

73.001

1.141

155.986

151.336

2.136

73.788

69.418

1.085

202.109

197.459

2.787

64.127

59.757

0.934

60.409

55.759

0.787

56.130

51.760

0.809

53.123

48.753

0.762

50.692

46.322

0.724

54.210

49.840

0.779

51.907

47.537

0.743

48.964

44.594

0.697

56.654

52.004

0.734

60.976

56.326

0.795

57.221

52.571

0.742

57.008

52.358

0.739

61.401

56.751

0.801

Control siRNA

Control siRNA + LIF

STAT3 siRNA

STAT3 siRNA + LIF

Normalized

Table C.41: Fig. 4.3E raw data (total STAT3, STAT3 siRNA + 24h IL-6/LIF treatment)

Control siRNA

Control siRNA + IL-6

STAT3 siRNA

STAT3 siRNA + IL-6

Signal

-bg

Normalized

Signal

-bg

72.364

68.714

1.051

66.872

63.222

0.967

60.832

55.942

0.941

63.210

58.320

0.981

67.919

64.269

71.907

68.257

0.983

69.096

64.206

1.080

1.044

65.767

60.877

1.024

62.140

57.250

0.963

61.070

56.180

0.945

36.815

31.925

0.537

28.432

23.542

0.396

Control siRNA

Control siRNA + LIF

Normalized

67.199

63.549

0.972

67.984

64.334

0.984

34.575

30.925

0.473

38.432

34.782

0.532

39.674

36.024

0.551

29.443

24.553

0.413

40.851

37.201

0.569

29.086

24.196

0.407

29.562

24.672

0.415

33.307

28.417

0.478

37.844

34.194

0.523

36.209

32.559

0.498

STAT3 siRNA

STAT3 siRNA + LIF
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Table C.42: Fig. 4.3F raw data (Puromycin, STAT3 siRNA + 24h IL-6/LIF treatment)

Control siRNA

Control siRNA + IL-6

STAT3 siRNA

STAT3 siRNA + IL-6

Signal

-bg

Normalized

Signal

-bg

86.178

82.108

1.122

70.444

66.374

0.907

93.508

88.618

1.088

79.091

74.201

0.911

75.128

71.058

49.808

45.738

0.971

86.421

81.531

1.001

0.625

46.674

41.784

0.513

53.108

48.218

0.592

48.792

43.902

0.539

34.538

29.648

0.364

29.977

25.087

0.308

Control siRNA

Control siRNA + LIF

Normalized

47.466

43.396

0.593

54.345

50.275

0.687

30.708

26.638

0.364

26.609

22.539

0.308

31.513

27.443

0.375

35.434

30.544

0.375

32.171

28.101

0.384

36.574

31.684

0.389

37.551

32.661

0.401

21.587

16.697

0.205

24.341

20.271

0.277

31.805

27.735

0.379

STAT3 siRNA

STAT3 siRNA + LIF

Table C.43: Fig. 4.4B raw data (p-AMPK, 24h IL-6/LIF treatment + Compound C)
Signal
Control

IL-6

LIF

Compound C

Compound C + IL-6

Compound C + LIF

-bg

Normalized

96.511

94.441

1.03

90.001

87.931

0.959

94.860

92.790

1.012

237.897

235.827

2.572

193.060

190.990

2.083

253.209

251.139

2.739

217.266

215.196

2.347

200.946

198.876

2.169

229.736

227.666

2.483

41.955

39.885

0.435

37.462

35.392

0.386

38.012

35.942

0.392

63.777

61.707

0.673

55.709

53.639

0.585

41.222

39.152

0.427

25.543

23.47264

0.256

33.061

30.99122

0.338

29.760

27.69038

0.302

301

Table C.44: Fig. 4.4C raw data (p-p70S6K, 24h IL-6/LIF treatment + Compound C)

Signal
Control

IL-6

LIF

Compound C

Compound C + IL-6

Compound C + LIF

-bg

Normalized

57.468

54.078

1.118

48.422

45.032

0.931

49.390

46.000

0.951

26.656

23.266

0.481

22.351

18.961

0.392

24.915

21.525

0.445

21.335

17.945

0.371

24.141

20.751

0.429

22.641

19.251

0.398

85.087

81.697

1.689

109.949

106.559

2.203

87.264

83.874

1.734

116.914

113.524

2.347

98.002

94.612

1.956

118.269

114.879

2.375

96.454

93.06388

1.924

106.128

102.73788

2.124

95.148

91.75789

1.897

Table C.45: Fig. 4.4D raw data (Puromycin, 24h IL-6/LIF treatment + Compound C)
Signal
Control

IL-6

LIF

Compound C

Compound C + IL-6

Compound C + LIF

-bg

Normalized

28.541

24.761

0.976

32.017

28.237

1.113

26.867

23.087

0.910

17.531

13.751

0.542

20.753

16.973

0.669

20.981

17.201

0.678

16.034

12.254

0.483

17.404

13.624

0.537

19.890

16.110

0.635

225.412

221.632

8.736

193.116

189.336

7.463

209.074

205.294

8.092

215.239

211.459

8.335

205.269

201.489

7.942

210.140

206.360

8.134

222.546

218.76551

8.623

203.569

199.78875

7.875

162.013

158.23269

6.237

302

Table C.46: Fig. 4.4E raw data (p-AMPK, AMPK siRNA + 24h IL-6/LIF treatment)
Signal
Control siRNA

Control siRNA+IL-6

Control siRNA+LIF

AMPK siRNA

AMPK siRNA+IL-6

AMPK siRNA+LIF

-bg

Normalized

34.037

30.257

0.963

39.159

35.379

1.126

32.372

28.592

0.910

81.482

77.702

2.473

93.767

89.987

2.864

98.574

94.794

3.017

103.224

99.444

3.165

102.250

98.470

3.134

100.491

96.711

3.078

25.114

21.334

0.679

22.412

18.632

0.593

24.580

20.800

0.662

26.937

23.157

0.737

30.079

26.299

0.837

32.529

28.749

0.915

27.753

23.97346

0.763

30.676

26.89552

0.856

32.466

28.68646

0.913

Table C.47: Fig. 4.4E raw data (total AMPK, AMPK siRNA + 24h IL-6/LIF treatment)
Signal
Control siRNA

Control siRNA+IL-6

Control siRNA+LIF

AMPK siRNA

AMPK siRNA+IL-6

AMPK siRNA+LIF

-bg

Normalized

59.791

57.101

1.003

65.655

62.965

1.106

53.415

50.725

0.891

63.890

61.200

1.075

66.736

64.046

1.125

63.207

60.517

1.063

62.637

59.947

1.053

62.410

59.720

1.049

65.996

63.306

1.112

27.568

24.878

0.437

28.593

25.903

0.455

29.447

26.757

0.470

31.667

28.977

0.509

26.714

24.024

0.422

26.202

23.512

0.413

28.081

25.39078

0.446

27.682

24.99227

0.439

30.301

27.61105

0.485
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Table C.48: Fig. 4.4F raw data (Puromycin, AMPK siRNA + 24h IL-6/LIF treatment)

Signal
Control siRNA

Control siRNA+IL-6

Control siRNA+LIF

AMPK siRNA

AMPK siRNA+IL-6

AMPK siRNA+LIF

-bg

Normalized

77.287

74.597

0.942

90.274

87.584

1.106

78.000

75.310

0.951

60.578

57.888

0.731

55.985

53.295

0.673

54.639

51.949

0.656

62.320

59.630

0.753

63.825

61.135

0.772

57.727

55.037

0.695

36.900

34.210

0.432

43.631

40.941

0.517

39.513

36.823

0.465

37.771

35.081

0.443

39.988

37.298

0.471

37.454

34.764

0.439

36.108

33.41818

0.422

33.178

30.48815

0.385

42.047

39.35743

0.497

Table C.49: Table 4.1 raw data (Plasma IL-6 in IL-6 overexpression mice)

Group

Standard Curve

D-0 (pg/ul)

D-4 (pg/ul)

D-5 (Sac) (pg/ul)

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

Standard Sample (pg/ul)

Readout

0

0.16

16

0.392

N.D.

N.D.

N.D.

31

0.465

N.D.

N.D.

N.D.

Control

63

0.581

N.D.

N.D.

N.D.

125

0.831

N.D.

N.D.

N.D.

250

1.353

N.D.

N.D.

N.D.

500

2.121

N.D.

213.5

257.7

1000

3.488

N.D.

134.4

467.0

N.D.

105.1

524.0

N.D.

106.5

414.0

N.D.

136.9

542.0

N.D.

95.2

537.0

N.D.

98.1

225.0

N.D.

193.2

425.0

IL-6
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Table C.50: Table 4.1 raw data (Body weight and muscle weight of IL-6 overexpressing
mice)

Group

Control

IL-6

Body Weight (g)

Solues (mg)

Plantaris (mg)

Gastroc (mg)

EDL (mg)

T.A.(mg)

Tibia Length (mm)

23.7

9

18

121

6

42

17.10

25.6

6

15

130

9

39

17.25

26.3

7

17

118

10

48

16.90

22.9

6

19

135

8

42

17.20

25.8

8

16

121

9

41

17.15

26.4

9

17

116

7

45

16.95

27.0

6

19

129

8

48

17.00

26.2

8

18

118

10

42

16.95

24.8

7

15

115

9

50

16.90

25.3

6

16

109

7

39

17.15

23.9

6

19

127

6

43

17.20

24.1

9

14

130

8

44

16.85

26.2

6

17

125

9

47

17.00

25.8

7

19

122

7

45

17.05

23.2

6

18

119

9

48

16.95

Table C.51: Fig. 4.5A raw data (p-STAT3, IL-6 overexpression cage control)

Control

IL-6

Signal

-bg

Normalized

29.730

26.541

1.047

26.739

23.550

0.929

31.226

28.037

1.106

37.285

34.096

1.345

21.999

18.810

0.742

24.204

21.015

0.829

29.629

26.440

1.043

111.864

108.675

4.287

149.940

146.751

5.789

122.131

118.942

4.692

155.644

152.455

6.014

98.049

94.860

3.742

151.563

148.374

5.853

105.578

102.389

4.039

150.168

146.979

5.798
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Table C.52: Fig. 4.5B raw data (p-p70S6K, IL-6 overexpression cage control)

Control

IL-6

Signal

-bg

Normalized

48.152

44.717

0.793

57.851

54.416

0.965

73.471

70.036

1.242

72.738

69.303

1.229

54.299

50.864

0.902

49.280

45.845

0.813

63.152

59.717

1.059

52.100

48.665

0.863

39.637

36.202

0.642

28.190

24.755

0.439

16.236

12.801

0.227

23.510

20.075

0.356

52.438

49.003

0.869

43.697

40.262

0.714

48.885

45.450

0.806

Table C.53: Fig. 4.5C raw data (Puromycin, IL-6 overexpression cage control)

Control

IL-6

Signal

-bg

Normalized

131.844

128.409

1.245

126.068

122.633

1.189

129.060

125.625

1.218

90.382

86.947

0.843

92.857

89.422

0.867

80.274

76.839

0.745

97.499

94.064

0.912

89.969

86.534

0.839

92.342

88.907

0.862

95.952

92.517

0.897

78.108

74.673

0.724

76.149

72.714

0.705

103.275

99.840

0.968

90.279

86.844

0.842

82.647

79.212

0.768
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Table C.54: Fig. 5.1B raw data (Puromycin, Short term IL-6/LIF with Stretch)

Signal
Control

Control+Stretch

IL-6

IL-6+Stretch

-bg

Normalized

66.773

64.083

0.913

81.022

78.332

1.116

70.774

68.084

0.970

175.638

172.948

2.464

Signal
Control

Control+Stretch

-bg

Normalized

84.561

80.891

1.038

80.197

76.527

0.982

80.041

76.371

0.980

184.857

181.187

2.325

165.998

162.328

2.083

156.725

153.055

1.964

196.079

192.409

2.469

230.836

227.166

2.915

180.481

177.791

2.533

208.768

206.078

2.936

142.158

139.468

1.987

152.546

149.856

2.135

159.986

157.296

2.241

238.863

235.193

3.018

103.974

101.284

1.443

99.914

96.244

1.235

85.263

81.593

1.047

93.445

89.775

1.152

97.868

95.178

1.356

106.010

103.320

1.472

LIF

LIF+Stretch

Table C.55: Fig. 5.1C raw data (p-p70S6K, Short term IL-6/LIF with Stretch)

Signal
Control

Control+Stretch

IL-6

IL-6+Stretch

-bg

Normalized

50.026

47.336

0.972

52.169

49.479

51.926

49.236

187.068

184.378

3.786

215.704

213.014

4.374

157.459

154.769

142.118

139.428

Signal

-bg

Normalized

56.654

52.984

1.129

1.016

51.163

47.493

1.012

1.011

44.405

40.735

0.868

176.044

172.374

3.673

137.327

133.657

2.848

3.178

167.596

163.926

3.493

2.863

72.047

68.377

1.457

91.382

87.712

1.869

99.079

95.409

2.033

60.737

57.067

1.216

68.199

64.529

1.375

71.108

67.438

1.437

126.242

123.552

2.537

151.420

148.730

3.054

67.899

65.209

1.339

49.588

46.898

0.963

57.478

54.788

1.125

Control

Control+Stretch

LIF

LIF+Stretch
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Table C.56: Fig. 5.2A raw data (Puromycin, Long term IL-6/LIF with Stretch)

Signal

Normalized

71.316

68.626

0.872

74.858

72.168

0.917

97.996

95.306

1.211

161.113

158.423

2.013

Control

Control+Stretch

-bg

Signal
Control

Control+Stretch

-bg

Normalized

71.541

68.871

1.029

62.714

60.044

0.897

74.553

71.883

1.074

134.924

132.254

1.976

118.994

116.324

1.738

110.628

107.958

1.613

33.324

30.654

0.458

22.615

19.945

0.298

149.308

146.618

1.863

147.262

144.572

1.837

49.753

47.063

0.598

47.706

45.016

0.572

43.063

40.373

0.513

44.970

42.300

0.632

50.854

48.164

0.612

34.194

31.524

0.471

29.844

27.174

0.406

26.832

24.162

0.361

IL-6

IL-6+Stretch

49.438

46.748

0.594

46.605

43.915

0.558

LIF

LIF+Stretch

Table C.57: Fig. 5.2B raw data (p-p70S6K, Long term IL-6/LIF with Stretch)
Signal
Control

Control+Stretch

IL-6

IL-6+Stretch

LIF

LIF+Stretch

-bg

Normalized

72.776

70.086

0.932

71.874

69.184

0.920

88.944

86.254

1.147

154.068

151.378

2.013

142.788

140.098

1.863

140.832

138.142

1.837

47.660

44.970

0.598

45.704

43.014

0.572

41.268

38.578

0.513

48.712

46.022

0.612

47.359

44.669

0.594

44.652

41.962

0.558

32.093

29.403

0.391

19.685

16.995

0.226

14.872

12.182

0.162

19.309

16.6192

0.221

25.400

22.7104

0.302

14.872

12.1824

0.162
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Table C.58: Fig. 5.3A raw data (Plasma IL-6, IL-6 overexpression + HFES)

Group

Standard Curve

D-0 (pg/ul)

D-4 (pg/ul)

D-5 (Sac) (pg/ul)

N.D.

N.D.

151.4

N.D.

N.D.

43.0

Standard Sample (pg/ul)

Readout

0

0.157

16

0.384

N.D.

N.D.

266.0

31

0.469

N.D.

N.D.

109.7

N.D.

218.5

337.7

N.D.

194.3

592.0

Control

63

0.573

125

0.84

250

1.329

N.D.

105.1

1344.0

500

2.137

N.D.

76.5

914.0

1000

3.359

IL-6

Table C.59: Fig. 5.3B raw data (p-STAT3, IL-6 overexpression + HFES)

Signal
Control

HEFS

IL-6

IL-6+HEFS

-bg

Normalized

29.780

27.090

1.075

31.342

28.652

1.137

22.749

20.059

0.796

56.946

54.256

2.153

71.864

69.174

2.745

75.694

73.004

2.897

90.361

87.671

3.479

129.295

126.605

5.024

80.256

77.566

3.078

107.925

105.235

4.176

118.333

115.643

4.589

101.902

99.212

3.937
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Table C.60: Fig. 5.3C raw data (p-p70S6K, IL-6 overexpression + HFES)

Signal
Control

HEFS

IL-6

IL-6+HEFS

-bg

Normalized

40.192

37.502

1.202

29.054

26.364

0.845

32.424

29.734

0.953

215.256

212.566

6.813

109.488

106.798

3.423

134.884

132.194

4.237

25.435

22.745

0.729

30.115

27.425

0.879

28.992

26.302

0.843

279.590

276.900

8.875

234.693

232.003

7.436

154.915

152.225

4.879

Table C.61: Fig. 5.3D raw data (Puromycin, IL-6 overexpression + HFES)

Signal

-bg

Control

HEFS

IL-6

IL-6+HEFS

40.365

36.235

59.537

55.407

55.541

51.411

89.208

85.078

72.721

68.591

68.108

63.978

63.285

59.155

31.517

27.387

56.263

52.133

102.705

98.575

61.274

57.144

69.008

64.878
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